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 Anxiety disorders are one of the most common mental illnesses in children. Multiple 
pharmacotherapies for treating anxiety exist; selective serotonin reuptake inhibitors (SSRIs) are the 
recommended first-line pharmacotherapy for pediatric anxiety. SSRI adherence is important to consider 
during care and parent adherence may help predict child SSRI adherence. The burden of serious events 
following an anxiety diagnosis has not been well characterized in children. 
In children with anxiety, we aimed to: 1) describe the initial anti-anxiety medication prescribed 
and psychotherapy utilization, 2) estimate SSRI adherence and determine if parental medication 
adherence predicts child SSRI adherence, and 3) estimate the incidence of emergency room (ER) visits, 
mental health related hospitalizations, and treated self-harm events after a new anxiety diagnosis. 
 The research was completed in a large commercial claims database (2004-2014) in children (3-17 
years) with diagnosed anxiety (ICD-9-CM code). We estimated the proportion of children initiating each 
medication class and factors independently associated with non-SSRI initiation. For adherence we 
measured the 6-month proportion of days covered; parent SSRI, statin, and antihypertensive adherence 
was evaluated prior to child SSRI initiation. We estimated the cumulative incidence of each event 
following the new anxiety diagnosis. 
Among children initiating anti-anxiety medication (n=84,500), 70% initiated an SSRI followed 
by benzodiazepines (8%) and non-SSRI antidepressants (7%). Anxiety disorder, age, provider type, and 
co-morbid diagnoses were associated with the initial medication; less than a third had psychotherapy 
claims before medication initiation. In children initiating an SSRI, parent high adherence (risk ratio=1.16) 
independently predicted high child adherence compared to parents with low adherence. One-year after a 
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new anxiety diagnosis, 2.0% of children had a mental health related hospitalization, 8 per 10,000 an 
inpatient, treated self-harm event, and 1.4% an anxiety-related ER visit, with higher incidence in older 
children with co-morbid depression. 
SSRIs are the most commonly used first-line medication for pediatric anxiety; yet, a third 
initiated a medication with limited evidence of effectiveness for pediatric anxiety. Parental adherence may 
help predict child SSRI adherence. Following a new anxiety diagnosis, a significant proportion of 
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CHAPTER 1: STATEMENT OF SPECIFIC AIMS 
Anxiety disorders are one of the most common mental illnesses in children and adolescents with 
estimates of current worldwide prevalence from 2%1 to 7%2 and lifetime prevalence estimates in the 
United States (US) of pediatric anxiety ranging from 15-20%.3 Anxiety disorders are associated with 
symptoms causing impairment and poor functioning, resulting in high disability-adjusted life years,4 and 
are predictive of future depression and substance use.5-9 Anxiety disorders typically begin during 
childhood,10,11 making this an important age to consider.  
Effective early treatment of anxiety may reduce its negative impact and reduce its persistence into 
young adulthood and beyond.5 Selective serotonin reuptake inhibitors (SSRIs) are recommended as the 
first line medication treatment for children with functionally impairing anxiety disorders,5 based on 
randomized controlled trial (RCT) evidence.5,12-16 There are a variety of other prescription medications 
that can be used to treat anxiety and it is unclear what medication is typically first prescribed to children. 
The combination of cognitive behavioral therapy (CBT) and SSRIs has been shown to offer an advantage 
over SSRI and CBT mono-therapies in treating children with moderate to severe anxiety;17,18 however, 
psychotherapy is often not received with medication treatment.19,20  
Antidepressant non-adherence is common outside trial settings in children,21,22 with limited 
information specifically on SSRI adherence in pediatric anxiety; determining ways to improve medication 
adherence remains a research priority.23-25 Finally, describing the risk of serious, impactful events in 
children newly diagnosed with an anxiety disorder can help inform the patient and caregiver and 
contribute to the larger discussion on the importance of managing symptoms. 
The overall goals of this dissertation were to, in a population of commercially insured children 
with anxiety, describe the initial anti-anxiety medication prescribed to children and psychotherapy claims 
surrounding medication initiation, estimate SSRI adherence and evaluate whether parent adherence can 
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serve as a predictor for child adherence, and estimate the incidence of treated self-harm, mental health 
related hospitalizations, and ER visits after a new anxiety diagnosis. To address the three aims, we 
utilized Truven Health Analytic’s Marketscan Commercial Claims and Encounters database (2004-2014), 
which provides longitudinal data, adequate sample size, and a linkage to parent claims. The cohort varied 
for each aim, but each includes commercially insured children (3-17 years) with an anxiety disorder 
diagnosis (ICD-9-CM codes). The three dissertations aims are: 
AIM 1. In children diagnosed with anxiety beginning prescription anti-anxiety medication: a) 
describe the initial medication class received and b) describe psychotherapy claims in the months 
surrounding medication initiation. This aim evaluated whether the initial pharmacotherapy prescribed 
(based on records of dispensed prescriptions) in a general population is concordant with recommendations 
and evidence and whether psychotherapy was used surrounding medication initiation. The duration of 
medication use and factors associated with non-SSRI initiation were also estimated. 
AIM 2. In a population of commercially insured children with anxiety: a) estimate SSRI 
adherence after initiation and b) determine if prior parental medication adherence was predictive of child 
SSRI adherence. Multiple aspects of child SSRI adherence were considered. Parent adherence to statins, 
antihypertensives, and SSRIs was identified and evaluated in the year before child SSRI initiation.  
AIM 3. In children newly diagnosed with anxiety in an office setting: a) estimate the risk of 
mental health related hospitalizations, inpatient treated self-harm, and ER visits overall and by age and 
psychiatric co-morbidities and b) estimate the incidence of events in a similar population of children 
without diagnosed anxiety. 
Findings from the specific aims add to the understanding of current prescribing practices and 
treatment utilization in pediatric anxiety, determine if parent adherence can be used as a baseline predictor 
of child adherence, and expand the current understanding on the burden of anxiety disorders. Together 




CHAPTER 2: REVIEW OF THE LITERATURE 
2.1. EPIDEMIOLOGY OF PEDIATRIC ANXIETY DISORDERS  
 2.1.1 Anxiety disorders include disorders with features of excessive fear and anxiety. 
Symptoms of anxiety may include feelings of overwhelming panic and fear, painful memories, recurring 
nightmares, and physical symptoms.26 This dissertation focuses on anxiety disorders in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).27 These include separation anxiety 
disorder (SAD), selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, 
generalized anxiety disorder (GAD), anxiety disorder due to another medical condition, other specified 
anxiety disorder, and unspecified anxiety disorder. Additionally posttraumatic stress disorder (PTSD), 
which is under ‘Trauma- and Stressor-Related Disorders’ in the DSM-5, and obsessive-compulsive 
disorder (OCD) under ‘Obsessive-Compulsive Disorders’ are included as they were previously under 
‘Anxiety Disorders’ in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). 
The diagnostic criteria for anxiety disorders consider a patient’s presence and severity of symptoms, 
functional impairment, length of symptoms, and other co-morbid conditions.  
 2.1.2 Anxiety disorders are highly prevalent in children with the causes of anxiety disorders 
largely unknown.26 The current thought is that mental illnesses, including anxiety, are likely caused by 
genetic, environmental, psychological, and developmental factors; ongoing research aims to learn more 
about what makes the brain create excessive fear and anxiety.28 Anxiety disorders are one of the most 
common mental illnesses in children; estimates of the lifetime prevalence of pediatric anxiety range from 
15-20%.3,28 A meta-analysis estimating the global prevalence of any anxiety disorder based on data from 
1980-2009, estimated the adjusted current global prevalence in children (3-17 years) to be 7% (95% CI: 
5%-11%).2 The adjusted prevalence estimates for all ages varied by country’s economic status 
(developing: 5%, emerging: 9%, developed: 8%) and culture (range: 10% in Western Europe/North 
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America/Australia to 5% in Indonesia/Asia and Africa).2 The Global Burden of Disease 2013 Study 
estimated that globally 2.2% of children 0-19 years have an anxiety disorder, also with variation by 
developed (3.4%) countries vs. non-developed (2.1%)1   
 In the United States (US) anxiety disorders have a predicted lifetime prevalence of 32% by age 
75.11 Prevalence estimates for current anxiety vary depending on age and diagnostic criteria. From a large 
review, an estimated 4.6% of children have an anxiety disorder.1 Three percent of surveyed parents 
reported current diagnosed anxiety in their child (3-17 years).29 In older children (13-18 years), who were 
interviewed and given DSM-IV diagnoses, 32% met the criteria for an anxiety disorder, 8% of whom had 
severe anxiety.10 The National Comorbidity Survey Replication-Adolescent Supplement 2001-2004, 
looked at one specific anxiety disorder, GAD, and found 3% of adolescents (13-18 years) met the DSM-
IV/5 criteria for GAD.30 There is a lot of variation in prevalence by specific anxiety disorder, exemplified 
in the Early Developmental Stages of Psychopathology study in children and young adults (14-24 years) 
in Germany, prevalence estimates varying from 1.6% for panic disorder to 16.2% for specific phobia.8 
When adolescents and adults with anxiety were retrospectively interviewed, the median age of 
onset for anxiety disorder symptoms was reported to be 610 and 1111 years, making childhood an 
important age to consider treatment utilization and impactful events.  
 2.1.3. Anxiety disorders are associated with current and future impairment, including social, 
family, and academic impairments; children with anxiety disorders are at risk for developing additional 
anxiety disorders along with future depression and substance use.6-9,31 Pediatric anxiety disorders are 
likely to occur in association with somatic symptoms that can include headache, nausea, trouble sleeping, 
dizziness, and stomachache.32 Mental and substance use disorders overall account for 7% of all global 
disability-adjusted life years (DALYs) and 23% of the years lived with disability (YLDs).33 Anxiety 
disorders constituted 15% of those mental health related DALYS and YLDs, with anxiety related DALYs 
rising through childhood and adolescence.33 In the US, anxiety was the 5th leading contributor to YLD in 
2010 behind low back pain, major depressive disorder, other musculoskeletal disorders, and neck pain.34 
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The Global Burden of Diseases, Injuries, and Risk Factors 2015 Study, specifically for children and 
adolescents, anxiety disorders ranked 23rd in global disability-adjusted life years (DALYs)4 
A meta-analysis of 29 studies (the vast majority in adult populations) found mortality to be higher 
in persons with anxiety (RR: 1.43, 95% CI: 1.24, 1.64) compared to the general population with no details 
on heterogeneity by age,35 demonstrating the impairment and poorer health often present in the population 
with an anxiety disorder. Anxiety disorders in adults have been found to be predictive of chronic 
conditions, such as incident hypertension36 and the escalation of symptoms of social phobia in childhood 
have been linked to adolescent alcohol use.37 Retrospectively, 35% of adults treated for anxiety reported 
their worries and feelings related to anxiety as children had caused them to stay home from school for an 
extended period of time,38 demonstrating the impact anxiety can have on daily childhood life.  
Despite the impairment associated with anxiety, not all patients seek treatment. In a survey of 
children with a current clinical level anxiety disorder (n=32), 31% of children ever received medication or 
counseling compared to 40% of children with depression and 79% of children with attention-
deficit/hyperactivity disorder (ADHD).39 In a more general population (Medical Expenditure Panel 
Survey, MEPS) of children (6-17 years) with more severe mental health impairment (all diagnoses, not 
restricted to anxiety) only 44% had used any outpatient mental health service (outpatient visit with a 
mental disorder diagnosis, use of psychotherapy, or use of psychotropic medications) in 2010-2012 up 
from 36% in 2003-2005.40  
  2.1.4. Effective early treatment of anxiety may reduce its negative impact and reduce its 
persistence into young adulthood and beyond.5 As written by Katzman et al. “because anxiety is highly 
prevalent and associated with chronic morbidity and comorbidities, effective treatment is essential to help 
patients manage their symptoms and improve their quality of life.”41 There is a need for studies focused 




Summary: Given that anxiety disorders are prevalent in children, can cause impairing symptoms, 
and appropriate treatment can lessen the impact, there is a heightened importance to learn more 
about treatment and impact of anxiety disorders during childhood. 
2.2. PSYCHOTHERAPY FOR ANXIETY DISORDERS 
 2.2.1. Psychotherapy, particularly cognitive behavioral therapy (CBT), is an effective 
treatment for pediatric anxiety.43,44 The American Academy of Child and Adolescent Psychiatry 
(AACAP) recommends that psychotherapy be considered as part of the treatment for children with 
anxiety.5,45 AACAP guidelines for PTSD and for anxiety disorders state that treatment should, until more 
evidence from comparative trials is available, begin with psychotherapy for conditions of mild severity 
with pharmacotherapy added when there is a need for acute reduction of moderate/severe symptoms, 
comorbid conditions requiring treatment, and partial or unsatisfactory response to psychotherapy with 
possibility of improved outcome with combined treatment.5,45 
CBT for the treatment of pediatric anxiety disorders often involves the following steps as 
described by James et al.: “(1) recognize anxious feelings and bodily or somatic reactions to anxiety, (2) 
clarify thoughts or cognitions in anxiety-provoking situations (e.g. unrealistic or negative attributions and 
expectations), (3) develop coping skills (e.g. modifying anxious self-talk into coping self-talk) and (4) 
evaluate outcomes.”43 A recent literature review surmised that approximately two-thirds of children with 
anxiety responded favorably to CBT.46 A Cochrane Collaboration that reviewed CBT for anxiety 
disorders in children (5-18 years) found that CBT was more likely to result in remission of anxiety 
diagnosis (ITT analysis, 59% CBT vs. 18% waitlist, OR=0.1, 26 studies).43 Of importance, given the 
nature of the therapy, there was no blinding of treatment for the patient or clinician, for the majority of 
studies it was unclear if bias was present in the randomization process, and it was unclear when the 
outcome was evaluated in each arm.43  
 2.2.2. The combination of medication and psychotherapy was shown to offer increased 
benefits for children with anxiety.17,18 The Child/Adolescent Anxiety Multimodal Study (CAMS) 
randomized 488 children, 7-17 years with moderate to severe anxiety to CBT (14 sessions), sertraline (an 
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SSRI), combination therapy (CBT+sertraline), or placebo for 12 weeks.17 The proportion of children very 
improved or much improved at 12 weeks was 81% (95% CI: 73-86) combination therapy, 60% (95% CI: 
51-68%) CBT mono-therapy, 55% (95% CI: 46-63%) sertraline mono-therapy, and 24% (95% CI: 16-
35%) placebo group. CBT demonstrated superior improvement to placebo and a similar response to 
sertraline17 with combination therapy offering an advantage over CBT and sertraline mono-therapies up to 
9 months after treatment initiation.17,18 Similar results were found in the Treatment for Adolescents with 
Depression Study (TADS) and the Pediatric OCD Treatment Study (POTS);47-49 with the exception that in 
TADS, SSRI (fluoxetine) mono-therapy was more similar to combination therapy and superior to CBT 
mono-therapy.49 Further, in a naturalistic study of children (7-18 years) with separation anxiety disorder 
(SAD) who were referred to a hospital and treated with an SSRI, patients also receiving psychotherapy 
were more likely to respond to treatment than those receiving medication only (73% vs. 51%).50 
Additional randomized controlled trials (RCTs) have also considered the efficacy of combination therapy 
compared to mono-therapy or mono-therapies in adults with major depressive disorder,51 PTSD,52 and 
panic disorder.53 
 2.2.3. Despite recommendations, adequate psychotherapy is often not implemented in the 
treatment of mental health disorders.19,20,54-57 There are difficulties accessing psychotherapy (i.e. shortage 
of pediatric mental health specialists, convenience) that may result in underutilization.57 The choice on the 
use of psychotherapy and medication can be influenced by preference and views of the family.58 Based on 
the 2007 MEPS, 9% of children and adults treated for an anxiety disorder received psychotherapy alone 
(down from 20% in 1998), 35% psychotherapy and medication (down from 42% in 1998), and 56% 
medication alone (up from 38% in 1998).54 While the estimate combined children and adults, it suggests 
that psychotherapy mono-therapy may be becoming a less common treatment choice.  
Appendix 2 contains more information on estimates of psychotherapy use. Even if psychotherapy is 
initiated, it may not be continued sufficiently long enough. Many studies/surveys have defined 
psychotherapy use as 1 visit, often during a year period. A study in children with depression defined 
‘minimally adequate psychotherapy’ as at least 4 visits within a 12 week period following a depressive 
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episode, of which approximately two-thirds of children received this amount of psychotherapy.56 The 
Cochrane review of CBT for pediatric anxiety was limited to RCTs with 9+ CBT sessions (mean 13). 
Summary: In children with anxiety, psychotherapy, specifically CBT, is an effective treatment; 
however, it is often underutilized in children, the extent of underutilization surrounding medication 
initiation is unknown. 
2.3. PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS  
 2.3.1. There are many potential pharmacotherapies for anxiety; SSRIs are the 
recommended first-line prescription medication for treating anxiety in children. The National 
Institute of Mental Health (NIMH) lists antidepressants (SSRIs, serotonin norepinephrine reuptake 
inhibitors, SNRIs, tricyclic antidepressants, TCAs, monoamine oxidase inhibitors, MAOIs), anti-anxiety 
medications (benzodiazepines, buspirone), and beta-blockers among the most common medications for 
anxiety.59 Atypical antipsychotics, anticonvulsants, antihistamines, and other medications have also been 
suggested as alternative treatments for anxiety.59-65 However, SSRIs are considered the first line 
pharmacotherapy. This recommendation is based on RCT evidence in children with anxiety where SSRIs 
had increased treatment efficacy over placebo and were well tolerated.5,12-16 In a meta-analysis of RCTs in 
children with non-OCD anxiety (6 studies: 4 SSRIs, 2 SNRIs) the risk difference of treatment efficacy 
was 37 per 100 (95% CI: 23-52) and 20 per 100 (95% CI: 13-27) in children with OCD, higher than in 
children with major depressive disorder (11, 7-15).16 The AACAP practice parameter for pediatric 
anxiety, which was published in 2007 following the black-box warning, recommends SSRIs be prescribed 
when moderate/severe symptoms of anxiety are present, if the condition makes it difficult for the child to 
participate in psychotherapy, or in cases of partial treatment response with psychotherapy.5 SSRIs are 
often preferred over other medications because they are generally well-tolerated, have a mild side effect 
profile compared to other treatments, do not have the concern for dependency compared to 
benzodiazepines, and there is little or no clinical trial evidence to support the use of other medications to 
treat anxiety in children.12,15,66-70 Most of the medications lack evidence because no trials have been done 
in a pediatric anxiety population.  
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The non-SSRI medications that can be prescribed for anxiety are listed in Table 3.1. Appendix 1 
contains specific details on the evidence and reasoning behind the inclusion of each pharmacotherapy (ex. 
non-SSRI antidepressants, benzodiazepines, buspirone, anticonvulsants, antipsychotics, hydroxyzine).  
 2.3.2. It is unknown what proportion of children initiating pharmacotherapy for anxiety 
initiate on SSRIs. To date no SSRI has been approved by the US Food and Drug Administration (FDA) 
to treat non-OCD anxiety in children,13 possibly resulting in treatment ambiguity as the first line 
pharmacotherapy for pediatric anxiety is not FDA approved for non-OCD anxiety in children. There is 
evidence that some SNRI antidepressants are effective in treating pediatric anxiety and duloxetine, a 
SNRI, was recently approved for pediatric generalized anxiety disorder.71 However, SNRIs are not 
recommended as first-line anti-anxiety medication. There is limited evidence for the long-term efficacy 
and safety of pharmacotherapy for children with anxiety and there are concerns over the potential harms 
of routine pharmacological treatment.12,72,73 Trial results for pharmacotherapies in adults with anxiety may 
not be equivalent to children, as evidence has suggested a difference between children and adults in the 
absorption, distribution, metabolism, and safety of some medications.74,75  
Additionally, as of October 2004 SSRIs carry a black-box warning for an increased risk in 
suicidality in children (<18 years), a potentially lethal side effect.74 This decision was based on a meta-
analysis of RCTs in children that found children randomized to antidepressants had twice the rate of 
suicidal ideation and behavior when compared to placebo.74,76,77 Through 2006 there were 6 placebo 
controlled RCTs with newer antidepressants in children (<19 years) with non-OCD anxiety; suicide 
ideation or suicide attempt/preparatory actions in the group treated with antidepressants (6/573) vs. 
placebo (1/582) resulted in a risk difference of 1 (-0 to 2) per 100 children.16 Because of the black-box 
warning, non-antidepressant medications may be preferred by caregivers or providers when prescribing 
pharmacotherapy for pediatric anxiety. This was highlighted in a chart-review of children offered a trial 
of antidepressants, the percentage of caregivers refusing antidepressant treatment in children (4-12 years) 
with anxiety was 8% (n=5) prior to the black-box warning and increased to 33% (n=17) after the black-
box warning, higher than the change in refusal for children with depression (11% to 25%). There were 
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also high changes in refusal for older children (13-17 years) with anxiety (14% to 44%) and with 
depression (4% to 25%) following the black-box warning. 78 
There is evidence that children are commonly treated with antidepressants and other psychotropics 
for anxiety and other mental illnesses: Among children 0-19 years who filled an antidepressant 
prescription in 2010, 49% had an anxiety diagnosis;79 the percentage of antipsychotic medication 
prescriptions at outpatient psychiatrist visits (based on mostly adults in the National Ambulatory Medical 
Care Survey, NAMCS) for anxiety disorders doubled from 1996-1999 (11%) to 2004-2007 (21%);80 the 
prevalence of antidepressant use from 2007-2010 was 3% of commercially insured children and 4% of 
children insured under Medicaid;81 in Medicaid 9% of enrolled children (6-17 years) receiving 
antipsychotics had an anxiety or depression diagnosis.82 Prior studies have shown that, following concerns 
of the risk of suicidality associated with antidepressants and the subsequent black-box warning, 
antidepressant use decreased in youth.83-88 Aim 1 determines which pharmacotherapies are prescribed to 
treatment naïve children. Children as young as 3 years old are included in the study as anxiety symptoms 
present early in childhood10,11 and prior literature has shown that young, preschool aged children do 
receive psychotropic medications for mental illnesses.89,90 There is limited evidence for the long-term 
efficacy and safety of pharmacotherapy for children with anxiety.5,12,72 Therefore, it is unclear how long 
children remain on these medications when used in standard care. 
Summary: SSRIs are effective in treating pediatric anxiety and are considered the recommended 
first-line treatment. It is unknown how often other pharmacotherapies are used as the initial 
treatment in pediatric anxiety. 
2.4. SSRI ADHERENCE AND PARENT ADHERENCE AS A PREDICTOR  
 2.4.1. Adherence to SSRIs in children with anxiety is unclear. Adherence can be defined as 
the process by which patients take medications as prescribed.91 Antidepressant non-adherence is common 
among children21,22 and among adults with anxiety disorders.92-94 Sertraline adherence in CAMS was 
based on the extra pills returned during visits; sertraline adherence among patients without missing 
adherence data was over 90% at 12 weeks.70 However, adherence in RCTs is usually much higher than 
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the general population.25 This is likely due to the selection of participants (e.g., able to consent and 
willing to be randomized) and effort research investigators put into sample maintenance that is not part of 
real world clinical care. Our observational study is able to examine SSRI adherence in a general 
population of children. 
In some scenarios medication discontinuation may be appropriate (i.e. medication is ineffective, 
side effects). However, it is important to optimize adherence early in treatment to determine if SSRIs are 
effective and to maintain adherence if the child responds to treatment. When poor adherence is the reason 
for lack of medication effectiveness (non-response), poor adherence will likely remain a problem with the 
new medication.95 Given that recommendations suggest that if a child does not respond to SSRI treatment 
it is recommended the provider try another SSRI agent before switching to another medication class,13 
adherence is important to evaluate as the cause for SSRI non-response before dose alterations and 
changing medications.  
 2.4.2. A variety of factors influence adherence and parents play an important role in child 
adherence.25 In addition to medication related factors that may affect adherence, there are also factors 
related to the patient, such as remembering to take a medication each day or whether they value the 
medication, and there are factors related to the larger healthcare system, such as copayment or pharmacy 
access.25,96 In child adherence, there is an additional factor related to parents and caregivers. As stated by 
Osterberg and Blaschke, “Achieving full adherence in pediatric patients requires not only the child’s 
cooperation but also a devoted, persistent, and adherent parent or caregiver.”25 Especially for young 
children when parents are responsible for storing the child’s psychotropic medication and have 
responsibility for monitoring medication adherence, benefits, and side effects.97 Parent behaviors and 
views have been shown to influence child adherence; in Australia lack of parental involvement in 
medication routines and monitoring was associated with poor psychotropic adherence in children 
(n=84).98 There was higher adherence in children with ADHD (n=33) when they had parents reporting 
higher perceived psychosocial benefits of the medication.99 In children with ADHD in Sweden (n=79), 
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negative parent views on stimulant medication was related to the child’s willingness to discontinue 
medication.100 
 2.4.3. Parent adherence may serve as a predictor for child SSRI adherence. It remains a 
research priority to identify ways to assist patients in adhering to medications.23-25 In adults with 
depression, past medication adherence to non-psychiatric chronic medications predicted future 
antidepressant adherence,101 demonstrating the consistent influence of adherence related behaviors across 
medication classes. Parent adherence may also be associated with their child’s medication adherence. 
Determining if parent prior adherence is predictive of child adherence could help target intervention 
efforts before SSRI initiation and during SSRI treatment, help the provider determine an appropriate 
treatment plan, and encourage conversations on a family’s barriers to adherence.  
Summary: SSRI adherence in pediatric anxiety has not been well described and parent adherence 
may represent a way to predict future child SSRI adherence. 
2.5. SERIOUS EVENTS IN PEDIATRIC ANXIETY  
 2.5.1. The burden of serious events children newly diagnosed with anxiety is unknown. 
Serious events include hospitalizations and events that are life threatening or incapacitating.17 Adults with 
anxiety disorders have high rates of health care service use,32,102-104 but findings are less definitive for 
children as there have been few studies conducted in that population.32 Events evaluated include treated 
self-harm events, mental health related hospitalizations, and emergency room (ER) visits. These events 
place a significant burden on the patient, caregivers, and the healthcare system.105-107 The incidence of 
these events in children with newly diagnosed anxiety is unknown and whether the incidence varies by 
age and by co-morbid depression. There are few longitudinal studies describing the risk following a new 
diagnosis, a time especially useful to inform the patient and caregiver. 
 2.5.2. Mental health related hospitalizations. In 2011 the rate of mental health related inpatient 
hospitalizations in children was 26/10,000 (37% admitted through the ER) with anxiety disorders 
accounting for 2.7% of the inpatient hospitalizations.108 The mean cost of each mental health related 
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hospitalization in children was $5,805 with a mean length of stay of 7 days.108 Mental health related 
hospitalizations occurred in 7% of Medicaid enrolled children with a mental health diagnosis.106 
 2.5.3. Treated self-harm events. In 2010, suicide was the 4th leading cause of death in children 
5-14 years (n=274 deaths) and the 3rd leading cause of death in children 15-24 years (n=4,600 deaths) 
based on death certificate data published by the National Center for Health Statistics.109 Suicide attempts 
are associated with future death by suicide; suicide risk in adults following self-poisoning was strikingly 
increased relative to persons without a prior self-poisoning episode (hazard ratio=42).110 Suicide attempts 
and suicide ideations are common. In the 2011 Youth Risk Behavior Survey of students in grades 9-12, 
16% reported they had seriously considered suicide, which was down from 19% in 2001, and 8% reported 
they had attempted suicide one or more times during the prior year.29,111 In a 7-19 year follow-up study of 
a small sample of children (n=66) treated with CBT for anxiety, 9% had made at least 1 suicide attempt 
and 27% reported experiencing suicidal ideation, treatment responders were less likely to report lifetime 
suicide ideation than non-responders.112 A review of the literature by Hill et al. on the relationship 
between anxiety disorders and suicide related behaviors concluded: “It is clear that anxiety is a risk 
marker for suicide-related behaviors in children and adolescents. Even so, there is not yet sufficient 
evidence to confirm anxiety as a causal risk factor for suicide-related behaviors in this age group.”113 
While the causal association between anxiety and suicide may not be clear, children with anxiety are 
often at an increased risk.  
 2.5.4. Emergency room visits. In 2012, 18% of children had an ER visit109 and in 2011, 10.5% 
of treat-and-release ER visits for mental health conditions in children were due to anxiety disorders.108 In 
the US from 2009-2011, there were an estimated 1,498 annual ER visits due to an adverse event from 
antidepressants in children 0-10 years and 8,250 in children 11-18 years.114 Injury (including adverse 
effects) was the reason for 21% of ER visits for children (<18 years) from 2009-2010 in the US.111 
Anxiety disorders have been found to be predictive of unintentional burns, poisonings, and head 
injuries,107 events that often result in an ER visit. Patients (16+ years) in Denmark with PTSD had a 
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higher baseline prevalence of traumatic events, including accidents and injuries from external causes, than 
did members of the comparison cohort.115 
Summary: The burden of events (treated self-harm events, mental health related hospitalizations, 
and ER visits) following a new anxiety disorder diagnosis has not been characterized in children. 
2.6. DATASOURCE  
 To address the study aims, we utilized a secondary datasource that provided adequate 
sample size, longitudinal data, a general population, and parent linkage. The aims all center on 
having a general population of children to see how medications are prescribed and utilized in standard 
care. Aim 1 examines how anti-anxiety medications are prescribed in children as it is unclear how often 
medication treatment recommendations are followed. Aim 2 assesses adherence patterns in children 
initiating SSRI treatment. The ability to link parents with children in Aim 2 and collect parent adherence 
details was another major benefit of the datasource. The large sample size of the datasource allows for 
stratification of results by anxiety disorder and other clinically relevant characteristics and allows 
incidence estimates for events with a low event rate. The datasource also provides longitudinal follow-up 
to evaluate medication adherence and events. The datasource has been previously used to evaluate 
healthcare utilization, antidepressant and psychotropic use, medication adherence, and self-harm related 
behaviors in adults and children.116-124
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CHAPTER 3: TREATING PEDIATRIC ANXIETY: INITIAL USE OF SSRIS AND OTHER 
ANTI-ANXIETY PRESCRIPTION MEDICATIONS AND PSYCHOTHERAPY UTILIZATION1   
3.1. INTRODUCTION 
 Anxiety disorders are one of the most common mental illnesses in children in the United States 
(US),10 with lifetime prevalence of pediatric anxiety around 15-20%.3 Children with anxiety have an 
increased risk of developing additional anxiety disorders, depression, and substance abuse and experience 
academic impairments.7,8,31,37,38 Pediatric anxiety disorders are likely to occur in association with somatic 
symptoms, including headaches, nausea, and trouble sleeping.32 In 2010, anxiety disorders were the fifth 
leading contributor to years lived with disability in the US,34 demonstrating the sustained impact of 
unmanaged anxiety. Early diagnosis and treatment of anxiety can reduce the negative impact and 
persistence of anxiety into young adulthood and beyond5 and is essential to manage symptoms and 
improve quality of life.41 
The American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters 
recommend psychotherapy as the first-line treatment for anxiety of mild severity.5,45,125 AACAP 
recommends pharmacological treatment when moderate to severe symptoms or comorbid psychiatric 
disorders are present, or when children are unable/unwilling to participate in or have a partial response to 
psychotherapy.5,45,125 While there are a variety of pharmacological approaches to treat anxiety, selective 
serotonin reuptake inhibitors (SSRIs) are considered the first-line pharmacotherapy for pediatric 
anxiety.5,45,125 Randomized controlled trials (RCTs) showed efficacy of SSRIs over placebo in children 
with anxiety.16,126 SSRIs are generally well tolerated and have a mild side effect profile compared to other 
drugs, and there is minimal empirical evidence to support use of other medications to treat pediatric 
anxiety.5,12,45,125,127,128 However, since 2004, antidepressants, including SSRIs, carry a black-box warning 
for an increased risk of suicidality in children74 and, while select SSRIs are approved by the US Food and 
                                                     
1 Parts of this chapter were accepted to appear as an article in the Journal of Clinical Psychiatry 
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Drug Administration (FDA) to treat obsessive-compulsive disorder (OCD), SSRIs are not approved for 
pediatric non-OCD anxiety. These factors may lead caregivers or providers to prefer non-SSRI 
medications for children beginning pharmacotherapy for anxiety.  
Evidence on long-term efficacy and safety of anti-anxiety medications for children is limited, 
raising concern over the potential harms of routine pharmacological anxiety treatment.12,73 The 2007 
AACAP guidelines caution that while RCTs have established the safety and efficacy of short-term SSRI 
treatment for pediatric anxiety, the benefits and risks of long-term SSRI use have not been studied.5 Post-
trial follow-up data have provided important evidence of continued SSRI response up to 36 weeks.18,129 
Benzodiazepines, another common anti-anxiety medication, are usually recommended for only short-term 
treatment given dependency concerns.12 
Psychotherapy is a recommended part of treatment for pediatric anxiety.130 However, in the US 
there is an increasing trend for mental illness to be treated with medication alone, rather than 
psychotherapy alone or the combination of psychotherapy and medication.54 Further, adequate treatment 
is often not received for children with anxiety including underutilization of cognitive behavioral therapy 
(CBT).57  
There is little understanding of how often SSRIs and other pharmacotherapies are used and their 
duration of use when treating pediatric anxiety and how often psychotherapy is used surrounding 
medication initiation. Understanding treatment utilization can detail what, if any, changes in clinical 
practice are needed to improve treatment for pediatric anxiety. Therefore, this study sought to estimate the 
initial medication class received by children diagnosed with anxiety beginning anti-anxiety medication, 
determine whether this varied across the study period and by patient characteristics, estimate treatment 
continuation of the initial anti-anxiety medication, and describe psychotherapy utilization in the months 
before and after anti-anxiety medication initiation.   
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3.2 METHODS  
We used Truven Health Analytics’ MarketScan Commercial Claims and Encounters database, 
containing individuals covered by employer-sponsored private health insurance across the US, with over-
representation of large employers. We utilized data from enrollment files, inpatient and outpatient 
services, and outpatient drug claims for reimbursed, dispensed prescriptions. The outpatient drug claims 
contains records on mail and retail reimbursed, dispensed prescriptions; providing the days covered by the 
prescription, number of units dispensed, the National Drug Code (NDC) Classification, and the 
therapeutic class.131,132 The NDC, a system of classification by the FDA, provides specific details of the 
dispensed medication including the brand name.132  
We included children 3-17 years with an anxiety diagnosis who initiated an anti-anxiety 
medication between 2004 and 2014. An anxiety diagnosis was defined as an inpatient or outpatient ICD-
9-CM code (293.84, 300.0x-300.3x, 309.21, 309.81, 313.23). These codes roughly correspond to the 
Diagnostic and Statistical Manual of Mental Disorders, DSM-5 anxiety disorders27 and additionally post-
traumatic stress disorder (PTSD) and OCD were included, as they share similar treatment 
recommendations and were previously classified under anxiety disorders.133   
To identify initiators of anti-anxiety medications we selected the initial anti-anxiety prescription 
based on records of dispensed prescriptions, defined as having no anti-anxiety prescription in the prior 
year (Figure 3.1). Children were required to have continuous insurance enrollment with prescription and 
mental health services coverage the year before medication initiation. We defined anti-anxiety 
medications as medications with trial evidence of effectiveness in treating anxiety in adult or pediatric 
populations and also medications suggested as potential effective treatments for anxiety (Table 3.1, 
grouped into medication classes).127,128,134,135 A detailed reasoning for the inclusion of each medication is 
provided in Appendix 1. Children could have initiated anti-anxiety pharmacotherapy with two medication 
classes (e.g. SSRI+benzodiazepine); children initiating with >2 classes were excluded (0.3%). As these 
therapies have multiple indications, we required ≥1 anxiety diagnosis within 30 days prior to or on the 
date of the initial anti-anxiety prescription (Supplementary eFigure 1). When evaluating psychotherapy 
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utilization we also required continuous insurance enrollment with mental health services coverage in the 3 
months after medication initiation.  
Each initial anti-anxiety prescription was grouped into one of twelve medication classes but 
children were also broadly classified as initiating 1) SSRI with no other anti-anxiety medication (SSRI 
alone), 2) SSRI+another anti-anxiety medication, and 3) non-SSRI anti-anxiety medication. These 
mutually exclusive categories represented three treatment strategies. 
Following initiation, treatment length per initial medication class was evaluated. A child was 
considered to have discontinued treatment in that medication class when there was no record of a 
dispensed prescription 30 days after the previous prescription’s days supply ran out. Switching agents 
within a medication class was regarded as continuing that medication class. The primary measures for 
treatment continuation were 1) refilling a prescription in the initial medication class before 
discontinuation and 2) remaining on treatment for 6 months.  
We examined psychotherapy claims (CPT codes in Appendix 4) billed through insurance in 
inpatient or outpatient medical settings in the three months before and in the three months after a child 
initiated an anti-anxiety medication. Children with at least 2 recorded psychotherapy claims in that three-
month period were considered psychotherapy “users.”  
Patient characteristics were collected in the year prior to and on the date of medication initiation 
to describe the study cohort and identify factors associated with initial medication choice. Characteristics 
included age, sex, anxiety diagnosis details, anxiety-related symptoms, psychiatric co-morbidities, non-
psychiatric co-morbidities, healthcare utilization, region, and year of medication initiation. The anxiety 
diagnosis most prior to or on the date of anti-anxiety medication initiation (index diagnosis) was grouped 
into mutually exclusive categories. Patients with an unspecified and a specific anxiety diagnosis were 
assigned to the specific diagnosis; patients with ≥1 specific diagnosis were grouped under ‘multiple’. The 
provider type of the index diagnosis was categorized as psychiatry, family practice, pediatrics, 
psychologist/therapist, all other types, and unknown/multiple providers. For common psychiatric co-
morbidities (depression, adjustment disorder, attention-deficit/hyperactivity disorder [ADHD]) we created 
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indicators for a recent diagnosis (within 30 days) or only a prior diagnosis (31-365 days prior). Any recent 
psychiatric diagnosis was defined as an ICD-9-CM code=290-319 (excluding anxiety diagnoses). 
Appendix 5 contains detailed definitions for the included covariates. 
3.2.1. Statistical analyses 
We determined the number and proportion of children initiating each anti-anxiety medication 
class overall and stratified by anxiety disorder and by year of initiation and age. As the proportion of 
children diagnosed with co-morbid depression and co-morbid ADHD increased across the study period, 
trends identified were examined in children without depression and without ADHD. We used 
multivariable Poisson regression with robust variance estimation to estimate fully adjusted risk ratios 
(RR) with 95% confidence intervals (CI) to identify factors independently associated with initiating 1) 
SSRI+another anti-anxiety medication vs. SSRI alone, 2) non-SSRI anti-anxiety medication vs. SSRI 
alone, and 3) SSRI+another anti-anxiety medication vs. non-SSRI anti-anxiety medication. We used 
Kaplan-Meier (KM) estimator to examine treatment continuation for each initial medication class up to 2 
years, with censoring at insurance disenrollment and end of data (12/31/2014). The proportion of children 
refilling their initial medication class was evaluated in children with ≥60 days of insurance enrollment 
after medication initiation. In an exploratory analysis, we estimated the proportion of children initiating 
with a non-SSRI anti-anxiety medication who subsequently filled an SSRI prescription within three 
months. This was restricted to children with ≥3 months of insurance enrollment.  
  Additional sensitivity analyses were completed. Given the multiple indications for anti-anxiety 
medications, we examined the proportion of children initiating each medication class in restricted cohorts: 
1) children initiating anti-anxiety medication the same day as an anxiety diagnosis and 2) children with ≥2 
anxiety diagnoses and no recent co-morbid psychiatric diagnosis. We considered an interaction term 
between anxiety disorder and provider type in our multivariable model. When examining treatment 
continuation, analyses were repeated using 15-and 60-day grace periods to define discontinuation and 
stratified by 1 vs. ≥2 prior anxiety diagnoses.  
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Based on recorded psychotherapy claims, we estimated the proportion of children who were 
psychotherapy users before and after medication initiation. Among children who did not have 
psychotherapy claims before medication initiation, we estimated how had psychotherapy claims after 
medication initiation by the provider specialty recording the anxiety diagnosis most prior to anti-anxiety 
medication initiation. This was further stratified by year of medication initiation and internally 
standardized by age group, sex, and region. In a sensitivity analysis, we examined psychotherapy claims 
in children without any co-morbid psychiatric diagnosis in the prior year. 
3.3. RESULTS 
We identified 84,500 children with diagnoses for anxiety who initiated anti-anxiety 
pharmacotherapy. The cohort had more girls (58%), few children aged 3-5 years (2%), with the majority 
14-17 years (58%), and 50% had an index anxiety diagnosis of unspecified anxiety (Table 3.2). 
Approximately 24% were diagnosed with anxiety by a psychiatrist and 25% by a pediatrician. Fifty-seven 
percent of children had an anxiety diagnosis on the day of medication initiation, resulting in a median 
number of days between the index anxiety diagnosis and anti-anxiety medication initiation of 0 
(interquartile range, IQR=0-3). 
Overall, 63% of children initiated with an SSRI alone and an additional 7% initiated an 
SSRI+another anti-anxiety medication (Table 3.3). Benzodiazepines were the most commonly used non-
SSRI medication (8%=benzodiazepine alone, 3%=SSRI+benzodiazepine), with the majority of use in 
children 14-17 years. Eight-percent initiated with a non-SSRI antidepressant and a small proportion 
initiated with an atypical antipsychotic, hydroxyzine, or clonidine/guanfacine. In sensitivity analyses with 
restricted cohorts, there was a slightly higher use of SSRIs alone, but overall findings were consistent 
(Table 3.3).  
Across the study period initiation with an SSRI remained fairly stable in children 3-13 years but 
increased in children 14-17 years (2004=55%, 2014=66%, Figure 3.2). The proportion of children 14-17 
years initiating with a benzodiazepine decreased across the study period (2004=20%, 2014=10%) and 
approached the low levels of use in younger children (Figure 3.3). This trend remained in children 
 
 21 
without a recent co-morbid depression diagnosis. While few children 3-5 years with anxiety initiated an 
anti-anxiety medication (n=1,449), the proportion that did so on guanfacine or clonidine increased, from 
11% in 2007 to 18% in 2009 and further to 27% by 2014. The increase remained but stabilized 
(2007=10%, 2009=15%, 2014=18%) when restricted to children without a co-morbid ADHD diagnosis. 
The initial medication prescribed varied by anxiety disorder (Figure 3.4). Children with OCD 
(77%) and selective mutism (78%) were most likely to initiate with an SSRI alone and children with 
panic disorder (46%), other/specific phobia (46%), and PTSD (48%) were least likely. In children with 
panic disorder 24% initiated with a benzodiazepine alone and 8% with an SSRI+benzodiazepine (full 
cohort=8% and 3%, respectively). In children with PTSD, 9% initiated with an atypical antipsychotic 
alone (19%, n=66 in those with a recent co-morbid conduct or oppositional defiant disorder diagnosis vs. 
8%, n=268 without this diagnosis) and 5% with an SSRI+atypical antipsychotic (full cohort=3% and 1%, 
respectively).   
The initial anti-anxiety medication also varied by age, provider type, co-morbid psychiatric 
diagnoses, and other patient factors (Table 3.2). Children with a recent depression diagnosis were less 
likely (RR:0.57, 95% CI:0.55-0.59) and children with a recent ADHD diagnosis were more likely 
(RR:1.53, 95% CI:1.48-1.59) to initiate a non-SSRI medication than SSRI alone. Children 3-13 years 
were less likely to initiate with an SSRI+another anti-anxiety medication vs. SSRI alone, as were children 
diagnosed with anxiety by a pediatrician (RR:0.53, 95% CI:0.48-0.59) compared to a psychiatrist. 
Inferences were limited for the interaction between anxiety disorder and provider type given sample size. 
However, the primary variation was with social phobia where family practice providers were more likely 
to prescribe an SSRI+another anti-anxiety medication and panic disorder where pediatrics and family 
practice more likely to prescribe a non-SSRI than psychiatry.  
SSRI prescriptions were most likely to be refilled (81%), followed by atypical antipsychotics 
(71%) and bupropion (69%) (Table 3.4). Over half (55%) of children initiating with an SSRI continued 
SSRI treatment for 6 months, 34% for 1 year, and 17% for 2 years. Benzodiazepine and hydroxyzine 
initiators were least likely to refill (25% and 19%, respectively) and continue treatment for 6 months (5% 
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and 3%, respectively). Children initiating a benzodiazepine or hydroxyzine were more likely to receive a 
shorter days supply: 54% of initial benzodiazepine prescriptions and 42% of hydroxyzine prescriptions 
were for ≤10 days compared with only 6% of initial SSRI prescriptions with a days supply <30 days. We 
observed similar patterns when varying the grace period to define treatment continuation and when 
stratified by ≥2 prior anxiety diagnoses, with higher continuation in children with ≥2 diagnoses (Tables 
3.4 and 3.5).  
Eighteen percent (n=4,121) of children initiating with a non-SSRI anti-anxiety medication 
subsequently filled an SSRI prescription within 3 months. This varied by medication class including 24% 
of benzodiazepine initiators and 20% of atypical antipsychotic initiators later filling an SSRI prescription 
(Table 3.6). 
Of the 75,024 children with 3 months of follow-up, 50% (n=37,480) had at least one 
psychotherapy claim in the year prior to medication initiation. A third (35%, n=26,085) of children were 
psychotherapy users before initiating an anti-anxiety medication (2+ claims in prior 3 months), with a 
median of 4 psychotherapy claims (IQR=3-7) during those 3 months. This proportion of children who 
were psychotherapy users before anti-anxiety medication initiation remained relatively stable across the 
study period (2004-2014, range: 31-37%). An additional 10% of children had just one psychotherapy 
claim in the three months before medication initiation. The majority of children who were psychotherapy 
users before medication initiation remained psychotherapy users after anti-anxiety medication initiation 
(80%, n=20,881/26,085).  
Among children who did not have psychotherapy claims before medication initiation, 30% 
(n=14,688/48,939) became psychotherapy users after medication initiation (median claims=4, IQR=3-6). 
An additional 9% of children had only one recorded psychotherapy claim in the three months after 
medication initiation. In children diagnosed by a psychiatrist before medication initiation 44% became 
psychotherapy users after medication initiation and 21% of children diagnosed by a pediatrician (Figure 
3.5). Within each provider, there was no increase in the proportion of children becoming psychotherapy 
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users after medication initiation from 2004 to 2014. Overall 54% of children were psychotherapy users 
before or after medication initiation based on recorded psychotherapy claims. 
When restricted to children without any recorded co-morbid psychiatric diagnosis in the year 
before anti-anxiety medication initiation (n=32,309), results were fairly consistent with slightly lower 
psychotherapy use. Twenty-percent were psychotherapy users before medication start (20%, n=6,562) 
and 79% remained psychotherapy users after medication initiation. In those without psychotherapy claims 
prior to medication start, 24% became psychotherapy users after starting a medication. 
3.4. DISCUSSION 
Concordant with the majority of evidence and recommendations, SSRIs were the most commonly 
used first-line anti-anxiety medication in children with anxiety diagnoses. By 2007 there was convincing 
evidence that SSRIs were effective in treating pediatric anxiety, summarized in a meta-analysis of RCTs16 
with findings upheld in an updated meta-analysis.126 There are appropriate reasons for a child to initiate 
with a non-SSRI medication; however, those reasons likely do not account for the third of children who 
began pharmacotherapy with an anti-anxiety medication with limited evidence of effectiveness, or no trial 
evidence. Additionally, our findings based on recorded psychotherapy claims, suggest that psychotherapy 
utilization can be improved surrounding anti-anxiety medication initiation in children with anxiety. 
There is evidence demonstrating efficacy of SNRIs for some anxiety disorders,16 and duloxetine 
was recently approved for pediatric generalized anxiety disorder.71 SNRIs are not recommended first-line 
therapy and were rarely used as the initial anti-anxiety medication in our study. Benzodiazepines, while 
used much less frequently than SSRIs, were the second most commonly used initial anti-anxiety 
medication. Conversely, in US adults with anxiety, where benzodiazepines are approved for several 
anxiety disorders, SSRIs and benzodiazepines are used at more comparable frequencies.136,137 While the 
proportion of children initiating with an atypical antipsychotic remained low across the study period, 
given the potential harms of antipsychotics, they should not be considered as first-line treatment for 
anxiety.138 Our finding that 18% of non-SSRI initiators filled an SSRI prescription in the following 
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months highlights that some children could have avoided being exposed to potential side effects from 
medications lacking evidence of effectiveness. 
In adult guidelines for panic disorder, SSRIs, SNRIs, tricyclic antidepressants, and 
benzodiazepines are said to be roughly comparable in efficacy,139 possibly explaining the higher observed 
benzodiazepine use in children with panic disorder. Relatedly, while SSRIs are approved to treat PTSD in 
adults,45 there is less evidence supporting SSRIs for pediatric PTSD, likely explaining the lower 
proportion of children with PTSD initiating with an SSRI alone.45,135 The variation observed in initial 
medication class by co-morbid psychiatric diagnoses was expected and potentially appropriate as 
medication selection should consider co-morbidities.5 Still, 31% of children with no recent co-morbid 
psychiatric diagnosis initiated with a non-SSRI anti-anxiety medication. Variation in initial medication 
class by provider type is likely influenced by familiarity with treatment guidelines and clinical experience 
or potentially due to unmeasured differences in anxiety and co-morbidity severity between providers.  
The large increase in the proportion of young children initiating anti-anxiety pharmacotherapy 
with guanfacine or clonidine occurred following the medications’ FDA approval for pediatric ADHD. In 
the US, guanfacine and clonidine use increased from 11% of children receiving any psychotropic 
medication in 2009 to 14% in 2011, with the majority of use for ADHD.140 The trend we observed with 
guanfacine and clonidine could be related to caregiver preferences for selecting treatment with pediatric 
FDA approval.141 Relatedly, caregivers may prefer initiating a child on a non-antidepressant given the 
antidepressant black-box warning. In a small chart-review of children with anxiety who were offered a 
trial of antidepressants, the percentage of caregivers refusing antidepressant treatment increased after the 
black-box warning.78 
AACAP practice parameters state that prescribers should have a clear rationale for prescribing 
medication combinations.97 In our cohort 7% initiated with an SSRI+another anti-anxiety medication. 
Half of those children initiated an SSRI+benzodiazepine, which is sometimes done to achieve rapid 
reduction in severe anxiety symptoms.5 The practice of concurrent anti-anxiety medication initiation was 
less common in younger children and children diagnosed by a provider outside psychiatry, but occurred 
 
 25 
across provider types, similar to findings from broader psychotropic polypharmacy in children.142 Despite 
some exceptions, beginning pharmacotherapy with an SSRI+another anti-anxiety medication raises 
concern given limited data on psychotropic polypharmacy in regards to effectiveness and possible 
increased adverse event burden, especially for treatment naïve children.143 
Pediatric OCD guidelines state that treatment should typically be continued for 6-12 months then 
gradually withdrawn.125 For non-OCD anxiety a medication free period has been recommended in 
children who experienced anxiety symptom reduction for a year,144 but there are no formal guidelines on 
recommended SSRI treatment length.5,45 In our study just over half of commercially insured children with 
anxiety continued SSRI treatment for 6 months. This was similar to 6-month SSRI estimates in children 
with major depressive disorder (46%),101 where guidelines are more specific, recommending ≥6 months 
of continued medication.31 
The previously described gap between the amount of provider contact required by evidence-based 
treatments and the amount received in children with anxiety145 could influence early medication 
discontinuation. Medication discontinuation may be appropriate, including if the child responded to 
concurrent cognitive behavioral therapy. As such, we cannot discern whether medication was 
discontinued due to nonresponse, side effects, or other reasons, and whether a clinician advised 
discontinuation. In certain instances the initial anti-anxiety medication was likely intended for short-term 
use (i.e. benzodiazepine and hydroxyzine with short initial days supply values). It is reassuring that the 
recommended medication class with the most evidence of efficacy for pediatric anxiety had the highest 
continuation and that benzodiazepines were used primarily for short-term treatment.12  
Only a third of children had psychotherapy claims in the months before starting an anti-anxiety 
medication. In Medicaid enrolled children aged 0-20 years only half received a psychosocial service in 
the three months before antipsychotic initiation, demonstrating that psychotherapy and behavioral 
interventions are not consistently used as a first-line treatment option.146 In many areas the need for 
qualified practitioners to deliver quality, evidence-based psychotherapy, often makes medication the 
default treatment.57,130,146 For pediatric anxiety specifically, the benefits of treating children with an SSRI 
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and CBT compared to an SSRI alone have been described,17 highlighting the public health importance of 
having access to psychotherapy. The advent of online and electronic sources of therapy147-149 may increase 
access to psychotherapy for children unable to access traditional office-based face-to-face therapy. 
Additionally, therapy delivered in primary care settings such as brief behavioral therapy for pediatric 
anxiety and depression may provide another means to increase access.150,151 
 Around 44% of children with severe mental health impairment receive outpatient mental health 
services40 and 31% of children with anxiety report receiving treatment, 9% treated with medication.39 
These estimates highlight that our findings apply to a subset of children with anxiety, children who were 
diagnosed and initiated an anti-anxiety pharmacotherapy. With our additional requirements of continuous 
private insurance coverage, our results are likely not generalizable to all US children. Given prior reports 
of treatment differences by insurance type,152 future research could explore whether the initial 
prescription anti-anxiety medication differs in children covered by Medicaid.  
Almost half of children in our population had an unspecified anxiety diagnosis given most prior 
to, or on, the data of anti-anxiety medication initiation. The use of unspecified anxiety diagnoses has 
increased, rising from 45% (1999-2002) to 58% (2007-2010) of all anxiety diagnoses in ambulatory 
settings.153 Children classified as having an unspecified anxiety diagnosis prior to medication initiation 
likely include children with a specific anxiety disorder who were not evaluated or the diagnosis was not 
recorded, resulting in misclassification. However, in some cases, children with an unspecified anxiety 
diagnosis may represent those with sub-threshold anxiety that does not meet the criteria for a specific 
anxiety disorder. These factors limit our ability to interpret the associations between unspecified anxiety 
and treatment choice. 
Additional limitations should be considered. While we aimed to describe anti-anxiety medication 
utilization in children with anxiety, including children with co-morbid conditions, we cannot be certain 
that medications were initiated to treat anxiety. It is possible that when an anxiety diagnosis was recorded 
on the same day as medication initiation the two events were unrelated. Additionally, little is known about 
the validity of ICD-9-CM anxiety diagnostic codes for children in administrative data and ICD-9 codes 
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for anxiety disorders do not perfectly correspond with DSM diagnoses. Selected symptoms that may 
guide anti-anxiety medication selection are not available in our datasource. The study design excluded 
children with baseline anti-anxiety medication use and, given the multiple indications of these 
medications, we thereby excluded children with an array of previously treated conditions. We do not have 
information on if and when dispensed medications were taken, including if medications filled the same 
day were taken concurrently, and whether adequate dosing was achieved. Additionally, we lack details on 
whether anti-anxiety medications were intended for short-term or prn (as-needed) use. Treatment length 
estimates rely on correct days supply values for dispensed prescriptions. The datasource lacks information 
on prescriptions provided in-hospital or obtained outside insurance (i.e. paid out-of-pocket, free samples), 
possibly resulting in misclassification of anti-anxiety medication initiation or continuation.  
Regarding psychotherapy utilization, we are only able to evaluate psychotherapy that is billed 
through insurance claims and cannot identify therapy obtained outside of insurance; therefore, we may 
underestimate the use of psychotherapy. We may also be more likely to underestimate psychotherapy use 
in children diagnosed with anxiety outside mental health providers. In 1999, an estimated 34% of 
outpatient psychotherapy visits for anxiety disorders were reported to be self-paid.154 In 2005-2006, 72% 
of psychiatrists accepted private non-capitated insurance, which decreased to 55% in 2009-2010.155 
However, it is unclear how often psychotherapy is paid for out-of-pocket and not entered through 
insurance in privately insured children with anxiety. The varying patterns of psychotherapy claims 
surrounding medication initiation observed in our study may all be appropriate depending on the clinical 
situation; we cannot know whether a child would have benefited from using psychotherapy prior to or 
after anti-anxiety medication initiation. Relatedly, we sought to describe psychotherapy utilization and did 
not attempt to account for differences in anxiety severity and psychiatric co-morbidities, which likely 
influence the provider type seen and psychotherapy use. 
While the majority of children with anxiety initiated anti-anxiety pharmacotherapy with an SSRI, 
as recommended by current guidelines, a third of children initiated with a non-SSRI anti-anxiety 
medication and a notable proportion of children initiated with two anti-anxiety medication classes. By 
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describing the initial anti-anxiety pharmacotherapy and psychotherapy claims surrounding medication 
initiation in children with anxiety, our study provides insight into existing practices and can inform future 





Table 3.1. Anti-anxiety medications included grouped by medication class 
Medication class Generic names included  
Selective serotonin 
reuptake inhibitors 





Desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine 
Tricyclic 
antidepressants 
Amitriptyline, clomipramine, desipramine, doxepin, imipramine, 
maprotiline, nortriptyline, protriptyline, trimipramine, amoxapine*  
Bupropion  - 
Other antidepressants Atomoxetine, isocarboxazid, mirtazapine, nefazodone, phenelzine, 
selegiline transdermal, tranylcypromine, trazodone, vortioxetine 
Benzodiazepines Alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, 
diazepam, halazepam, lorazepam, oxazepam, prazepam 
Buspirone - 
Anticonvulsants Carbamazepine, gabapentin, lamotrigine, levetiracetam, pregabalin, 
tiagabine, topiramate, valporic acid 
Atypical antipsychotics  Aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone 
Hydroxyzine -  
Beta-blockers Acebutolol, atenolol, atenolol/chlorthalidone, bendroflumethiazide/nadolol, 
betaxolol, bisoprolol fumarate, carteolol, carvedilol, esmolol, metoprolol 
succinate, metoprolol tartrate, propranolol, timolol maleate, nadolol, 
nebivolol, penbutolol sulfate, pindolol, sotalol  
Other Clonidine, D-cycloserine, guanfacine, memantine, prazosin, riluzole 

















Initial anti-anxiety treatment group  



















RR (95% CI) 
No. (%) 
Vs. SSRI alone 
Multivariable 
RR (95% CI) 
Female 49,255 (58) 31,688 (60) 3,771 (64) REF 13,796 (54) REF REF 
Male 35,245 (42) 21,321 (40) 2,092 (36) 1.0 (0.9-1.0) 11,832 (46) 1.1 (1.1-1.1) 0.9 (0.8-0.9) 
Age, median (IQR) 14 (11, 16) 14 (11, 16) 15 (13, 16)  14 (10, 16)   
     3-5 years 1,449 (2) 696 (1) 25 (<1) 0.4 (0.2-0.5) 728 (3) 1.4 (1.3-1.5) 0.2 (0.2-0.3) 
     6-9 years 12,377 (15) 7,782 (15) 332 (6) 0.4 (0.4-0.5) 4,263 (17) 1.0 (1.0-1.1) 0.5 (0.4-0.5) 
     10-13 years 21,997 (26) 14,525 (27) 1,269 (22) 0.8 (0.7-0.8) 6,203 (24) 0.9 (0.9-1.0) 0.9 (0.8-0.9) 
     14-17 years 48,677 (58) 30,006 (57) 4,237 (72) REF 14,434 (56) REF REF 
Anxiety disorder, index diagnosis 




     Unspecified 42,652 (50) 26,037 (49) 2,417 (41) REF 14,198 (55) REF REF 
     Generalized anxiety disorder 20,508 (24) 13,812 (26) 1,417 (24) 1.1 (1.0-1.2) 5,279 (21) 0.8 (0.8-0.8) 1.4 (1.3-1.5) 
     OCD 6,194 (7) 4,773 (9) 353 (6) 0.9 (0.8-1.0) 1,068 (4) 0.5 (0.5-0.6) 1.8 (1.7-2.0) 
     Panic disorder 4,294 (5) 1,967 (4) 507 (9) 2.0 (1.9-2.2) 1,820 (7) 1.3 (1.3-1.4) 1.3 (1.2-1.4) 
     PTSD 3,531 (4) 1,683 (3) 492 (8) 1.5 (1.4-1.7) 1,356 (5) 1.2 (1.1-1.2) 1.3 (1.2-1.4) 
     Social phobia 1,972 (2) 1,465 (3) 156 (3) 1.0 (0.9-1.2) 351 (1) 0.6 (0.6-0.7) 1.7 (1.5-1.9) 
     Otherc 3,530 (4) 1,993 (4) 279 (5) 1.6 (1.4-1.7) 1,258 (5) 1.1 (1.0-1.1) 1.3 (1.2-1.5) 
     Multiple  1,819 (2) 1,279 (2) 242 (4) 1.6 (1.5-1.9) 298 (1) 0.6 (0.6-0.7) 2.1 (1.9-2.3) 
Provider type, index anxiety diagnosis 




    Psychiatry 20,514 (24) 14,114 (27) 1,674 (29) REF 4,726 (18) REF REF 
    Psychologist; Therapist 10,124 (12) 5,761 (11) 444 (8) 0.7 (0.7-0.8) 3,919 (15) 1.6 (1.6-1.7) 0.5 (0.4-0.5) 
    Family practice 11,136 (13) 7,004 (13) 788 (13) 0.9 (0.8-0.9) 3,344 (13) 1.0 (1.0-1.1) 0.9 (0.8-0.9) 
    Pediatrics 13,565 (16) 9,574 (18) 502 (9) 0.5 (0.5-0.6) 3,489 (14) 0.9 (0.8-0.9) 0.7 (0.7-0.8) 
    Other 20,980 (25) 12,109 (23) 1,768 (30) 1.0 (0.9-1.0) 7,103 (28) 1.3 (1.2-1.3) 0.8 (0.7-0.8) 
    Unknown 8,181 (10) 4,447 (8) 687 (12) 1.0 (0.9-1.1) 3,047 (12) 1.3 (1.3-1.4) 0.7 (0.7-0.8) 
Anxiety diagnosis details 











     Prior anxiety diagnosis  27,639 (33) 17,809 (34) 1,454 (25) 0.8 (0.8-0.9) 8,376 (33) 1.0 (1.0-1.0) 0.8 (0.8-0.9) 
     Acute reaction to stress diagnosis 861 (1) 474 (1) 79 (1) 1.1 (0.9-1.3) 308 (1) 1.1 (1.0-1.2) 1.0 (0.8-1.2) 
    Anxiety-related symptoms, prior 3 
monthsd 15,688 (19) 8,651 (16) 1,248 (21) 1.1 (1.1-1.2) 5,789 (23) 1.2 (1.2-1.2) 
0.9 (0.8-0.9) 
Psychiatric co-morbidity detailsf 




    Depression diagnosisb 




        No recorded diagnosis 62,350 (74) 37,829 (71) 3,431 (59) REF 21,090 (82) REF REF 
        Recent diagnosis 18,875 (22) 13,163 (25) 2,231 (38) 1.1 (1.0-1.2) 3,481 (14) 0.6 (0.6-0.6) 1.9 (1.8-2.1) 
        Prior diagnosis, no recent diagnosis 3,275 (4) 2,017 (4) 201 (3) 0.9 (0.8-1.1) 1,057 (4) 0.9 (0.9-1.0) 1.0 (0.9-1.2) 
    Self-harm related behaviore 438 (1) 284 (1) 69 (1) 0.8 (0.6-1.0) 85 (<1) 0.8 (0.6-0.9) 1.1 (0.9-1.3) 
    Adjustment disorder (any)b 




        No recorded diagnosis 71,515 (85) 44,232 (83) 4,921 (84) REF 22,362 (87) REF REF 
        Recent diagnosis 6,826 (8) 4,729 (9) 561 (10) 1.0 (0.9-1.1) 1,536 (6) 0.9 (0.9-0.9) 1.1 (1.0-1.2) 
        Prior diagnosis, no recent diagnosis 6,159 (7) 4,048 (8) 381 (6) 0.9 (0.8-0.9) 1,730 (7) 1.0 (0.9-1.0) 0.9 (0.8-1.0) 
    Attention deficit disorder (ADD/ADHD)b 




        No recorded diagnosis 69,432 (82) 44,959 (85) 5,199 (89) REF 19,274 (75) REF REF 
        Recent diagnosis  10,191 (12) 5,139 (10) 428 (7) 1.0 (0.9-1.2) 4,624 (18) 1.5 (1.5-1.6) 0.6 (0.5-0.7) 
        Prior diagnosis, no recent diagnosis 4,877 (6) 2,911 (5) 236 (4) 1.1 (0.9-1.2) 1,730 (7) 1.2 (1.1-1.2) 0.9 (0.8-1.0) 
    Disruptive behavior, conduct disorder 5,341 (6) 2,876 (5) 385 (7) 1.1 (1.0-1.2) 2,080 (8) 1.1 (1.1-1.2) 0.9 (0.8-1.0) 
    Other episodic mood disorder 4,073 (5) 2,036 (4) 455 (8) 1.2 (1.1-1.3) 1,582 (6) 1.3 (1.2-1.3) 0.8 (0.8-0.9) 
    Sleep disorder 3,948 (5) 1,918 (4) 400 (7) 1.6 (1.5-1.8) 1,630 (6) 1.3 (1.3-1.4) 1.1 (1.0-1.2) 
    Substance use disorder 2,785 (3) 1,308 (2) 391 (7) 1.3 (1.1-1.4) 1,086 (4) 1.2 (1.2-1.3) 1.0 (0.9-1.0) 
    Autism spectrum, pervasive 
developmental disorder 
2,502 (3) 1,516 (3) 96 (2) 0.9 (0.7-1.1) 890 (3) 1.0 (1.0-1.1) 0.8 (0.7-1.0) 
    Developmental delay, learning disability 2,235 (3) 1,287 (2) 76 (1) 0.8 (0.7-1.0) 872 (3) 1.0 (0.9-1.0) 0.8 (0.7-1.0) 
    Bipolar disorder 1,479 (2) 466 (1) 164 (3) 1.6 (1.4-1.8) 849 (3) 1.8 (1.7-1.9) 0.6 (0.5-0.7) 
    Eating disorder 1,373 (2) 994 (2) 132 (2) 0.9 (0.8-1.1) 247 (1) 0.8 (0.7-0.8) 1.1 (1.0-1.3) 
    Tic 999 (1) 493 (1) 45 (1) 1.2 (0.9-1.6) 461 (2) 1.4 (1.3-1.5) 0.7 (0.6-1.0) 
    Personality disorder 614 (1) 320 (1) 77 (1) 1.1 (0.9-1.4) 217 (1) 1.1 (1.0-1.2) 1.0 (0.9-1.3) 
    Schizophrenia 103 (<1) 28 (<1) * 1.4 (0.8-2.3) 65 (<1) 1.7 (1.5-2.0) 0.5 (0.3-0.9) 
Non-psychiatric co-morbidities 




    Allergic rhinitis 10,608 (13) 6,452 (12) 681 (12) 1.0 (0.9-1.1) 3,475 (14) 1.0 (1.0-1.1) 1.0 (0.9-1.0) 
    Asthma 8,423 (10) 4,915 (9) 627 (11) 1.1 (1.0-1.2) 2,881 (11) 1.1 (1.0-1.1) 1.0 (0.9-1.1) 






    Cardiac disorder 2,373 (3) 1,137 (2) 215 (4) 1.2 (1.0-1.3) 1,021 (4) 1.2 (1.1-1.2) 0.9 (0.8-1.0) 
    Migraine, chronic headache 2,371 (3) 1,144 (2) 182 (3) 1.1 (1.0-1.3) 1,045 (4) 1.3 (1.2-1.3) 0.8 (0.7-0.9) 
    Overweight, obesity 1,792 (2) 1,067 (2) 145 (2) 1.0 (0.9-1.2) 580 (2) 1.0 (1.0-1.1) 0.9 (0.8-1.1) 
    Visual disturbance/loss 1,495 (2) 806 (2) 88 (2) 1.0 (0.8-1.2) 601 (2) 1.1 (1.0-1.2) 0.8 (0.7-1.0) 
    Convulsions 1,123 (1) 451 (1) 68 (1) 1.3 (1.0-1.6) 604 (2) 1.2 (1.1-1.3) 0.8 (0.6-1.0) 
    Urinary incontinence, encopresis, enuresis 1,032 (1) 599 (1) 40 (1) 0.9 (0.7-1.2) 393 (2) 1.1 (1.0-1.2) 0.8 (0.6-1.1) 
    Diabetes 591 (1) 356 (1) 47 (1) 1.0 (0.7-1.3) 188 (1) 1.0 (0.9-1.1) 1.0 (0.8-1.2) 
    Epilepsy, recurrent seizers 550 (1) 205 (<1) 23 (<1) 0.9 (0.6-1.3) 322 (1) 1.2 (1.1-1.3) 0.6 (0.4-0.8) 
    Hypertension 546 (1) 271 (1) 47 (1) 1.0 (0.8-1.4) 228 (1) 1.1 (1.0-1.2) 1.0 (0.7-1.2) 
    Cancer, any diagnosis 328 (<1) 135 (<1) 27 (<1) 1.5 (1.1-2.1) 166 (1) 1.2 (1.1-1.3) 0.9 (0.7-1.3) 
Injury events 




    Fracture, dislocation, sprain (non-skull) 12,776 (15) 7,568 (14) 980 (17) 1.1 (1.0-1.1) 4,228 (16) 1.1 (1.0-1.1) 1.0 (0.9-1.0) 
    Head/brain injury, concussion, skull 
fracture  3,047 (4) 1,728 (3) 221 (4) 0.9 (0.8-1.1) 1,098 (4) 1.0 (1.0-1.1) 
0.9 (0.8-1.0) 
    Poisoning from drug, biologic  1,211 (1) 713 (1) 176 (3) 0.9 (0.7-1.0) 322 (1) 0.9 (0.8-1.0) 1.1 (0.9-1.2) 
    Other injury, burn 17,618 (21) 10,318 (19) 1,353 (23) 1.0 (1.0-1.1) 5,947 (23) 1.0 (1.0-1.1)  1.0 (0.9-1.0) 
Family difficultiesg 1,551 (2) 958 (2) 153 (3) 0.9 (0.8-1.1) 440 (2) 1.0 (0.9-1.0) 1.0 (0.9-1.1) 
Child trauma, neglecth 654 (1) 332 (1) 106 (2) 1.0 (0.8-1.2) 216 (1) 1.0 (0.9-1.1) 1.0 (0.9-1.2) 
Healthcare utilization 




    Preventative, well visit 45,235 (54) 29,208 (55) 2,890 (49) 0.9 (0.9-1.0) 13,137 (51) 1.0 (0.9-1.0) 1.0 (1.0-1.1) 
    Outpatient problem-oriented visits, 
median (IQR) 4 (2, 6) 4 (2, 6) 3 (2, 6)  4 (2, 6)  
 
         0-1 15,976 (19) 10,107 (19) 1,320 (23) REF 4,549 (18) REF REF 
         2-5 43,041 (51) 27,556 (52) 2,849 (49) 0.9 (0.9-1.0) 12,636 (49) 0.9 (0.9-1.0) 1.0 (0.9-1.0) 
         6+ 25,483 (30) 15,346 (29) 1,694 (29) 0.9 (0.8-1.0) 8,443 (33) 0.9 (0.9-1.0) 1.0 (0.9-1.1) 
    Non-psychiatric inpatient admissioni 1,801 (2) 825 (2) 158 (3) 1.1 (1.0-1.3) 818 (3) 1.1 (1.1-1.2) 0.9 (0.8-1.0) 
    Psychotherapy, recentb 




         No recorded sessions 49,619 (59) 29,980 (57) 3,627 (62) REF 16,012 (62) REF REF 
         1-2 22,520 (27) 14,725 (28) 1,353 (23) 0.8 (0.8-0.9) 6,442 (25) 0.9 (0.9-0.9) 1.0 (0.9-1.0) 
         3+ 12,361 (15) 8,304 (16) 883 (15) 0.9 (0.9-1.0) 3,174 (12) 0.9 (0.8-0.9) 1.1 (1.0-1.2) 
    Mental health diagnostic/evaluation visit 45,051 (53) 29,917 (56) 3,294 (56) 1.1 (1.0-1.1) 11,840 (46) 0.8 (0.8-0.8) 1.4 (1.3-1.4) 
Medication utilization 




    Prescriptions by therapeutic group, 
median (IQR) j 2 (1, 3) 2 (1, 3) 2 (1, 4)  2 (1, 4)  
 






        2-5 42,639 (50) 26,568 (50) 2,863 (49) 1.0 (0.9-1.0) 13,208 (52) 1.0 (1.0-1.0) 1.0 (0.9-1.1) 
        6+ 6,830 (8) 3,787 (7) 545 (9) 1.1 (1.0-1.2) 2,498 (10) 1.0 (1.0-1.1) 1.0 (0.9-1.1) 
    ADHD medication dispensed  11,703 (14) 6,506 (12) 441 (8) 0.7 (0.6-0.8) 4,756 (19) 1.1 (1.0-1.1) 0.7 (0.6-0.7) 
    Opioid medication dispensed 10,769 (13) 6,032 (11) 901 (15) 1.1 (1.0-1.2) 3,836 (15) 1.1 (1.0-1.1) 1.0 (0.9-1.0) 
Region 




    Northeast 14,682 (17) 9,309 (18) 1,007 (17) 0.9 (0.9-1.0) 4,366 (17) 1.0 (1.0-1.0) 0.9 (0.9-1.0) 
    North Central 26,131 (31) 17,345 (33) 1,674 (29) 0.8 (0.8-0.9) 7,112 (28) 0.9 (0.8-0.9) 0.9 (0.9-1.0) 
    South 27,238 (32) 16,496 (31) 2,019 (34) REF 8,723 (34) REF REF 
    West 15,649 (19) 9,331 (18) 1,122 (19) 0.9 (0.9-1.0) 5,196 (20) 1.1 (1.0-1.1) 0.9 (0.8-0.9) 
    Unknown 800 (1) 528 (1) 41 (1) 0.8 (0.6-1.1) 231 (1) 0.9 (0.8-1.0) 0.8 (0.6-1.1) 
Year of treatment initiation 




    2004-2006 7,539 (9) 4,390 (8) 460 (8) 1.0 (0.9-1.1) 2,689 (10) 1.3 (1.2-1.3) 0.7 (0.7-0.8) 
    2007-2009 14,892 (18) 8,968 (17) 1,023 (17) 1.1 (1.0-1.2) 4,901 (19) 1.2 (1.1-1.2) 0.9 (0.8-0.9) 
    2010-2012 32,334 (38) 20,213 (38) 2,310 (39) 1.1 (1.0-1.1) 9,811 (38) 1.1 (1.0-1.1) 1.0 (0.9-1.0) 
    2013-2014 29,735 (35) 19,438 (37) 2,070 (35) REF 8,227 (32) REF REF 
IQR: Interquartile range, REF: Referent category 
*Number not displayed due to small sample 
aAll variables were used to calculate multivariable RRs; ‘Any recent non-anxiety psychiatric diagnosis’ was not entered into the full multivariable model as specific 
indicators for psychiatric disorders were used instead  
bRecent=0-30 days before anti-anxiety medication initiation, prior=31-365 days before anti-anxiety medication initiation  
cAnxiety disorders with <1000 children: other anxiety, separation anxiety, selective mutism, anxiety due to medical condition, agoraphobia, other/specific phobia 
dAny diagnostic code for abdominal pain, unspecified chest pain, headache, hyperventilation, malaise/fatigue, nausea, palpations, or weight loss in the prior 3 
months 
eSelf-harm event, ICD-9-CM=E950-E959 
fICD-9-CM codes used to define co-morbidities: acute stress (308.x); adjustment disorder (309.0x, 309.3x, 309.4x, 309.9x, 309.22, 309.23, 309.24, 309.28, 309.29, 
309.82, 309.83, 309.89); attention deficit disorder (314.0x); autism spectrum, pervasive developmental disorder (299.x); bipolar disorder, cyclothymic (296.0x, 
296.4x, 296.5x, 296.6x, 296.7x, 296.8x, 301.13); disturbance of conduct, oppositional defiant disorder (312.x, 313.81); depression (296.2x, 296.3x, 300.4x, 309.1x, 
311.x); developmental delay, learning disability (315.x, 784.61, V40.0x); eating disorder (307.1x, 307.5x); other episodic mood disorder (296.9x); personality 
disorder (301.x); schizophrenia (295.x); sleep disorders (327.x, 347.x, 307.4x, 780.5x); substance use disorder (291.x, 292.x, 303.x, 304.x, 305.x); tics (307.2x) 
gFamily difficulties, ICD-9-CM=V61.0x, V61.20, V61.23-V61.29, V61.4x, V61.8, V61.9 
hChild neglect/trauma, ICD-9-CM=V15.4x, V61.21, V71.81, 995.5x, 995.80-995.85, E967.x 
iNon-psychiatric inpatient admissions excludes inpatients admissions with an ICD-9-CM code=290-319 as the primary or secondary diagnosis; separate for 
psychiatric hospitalizations not included due to high correlation with inpatient index anxiety diagnosis  




Table 3.3. Initial anti-anxiety medication class in children with diagnosed anxiety beginning anti-anxiety 
pharmacotherapy  
 
Primary analysis: Full 
cohort 
Anxiety diagnosis 
same day as initial 
anti-anxiety 
prescription 
2+ Anxiety diagnoses, 
no recent comorbid 
psychiatric diagnosisa 
 
No. % (95% CI) No. % (95% CI) No. % (95% CI) 
SSRI alone 53,009 63% (62-63) 32,044 67% (66-67) 13,492 67% (66-67) 
SSRI+another anti-anxiety 
medicationb 
5,863 7% (7-7) 3,664 8% (7-8) 1,147 6% (5-6) 
    SSRI+benzodiazepine 2,528 3% 1,890 4% 652 3% 
    SSRI+other antidepressant 926 1% 475 1% 113 1% 
    SSRI+atypical antipsychotic 894 1% 299 1% 104 1% 
    SSRI+hydroxyzine 761 1% 511 1% 132 1% 
Non-SSRI anti-anxiety medication 25,628 30% (30-31) 12,265 26% (25-26) 5,610 28% (27-28) 
    Benzodiazepine 7,125 8% 4,038 8% 1,735 9% 
    Hydroxyzine 3,244 4% 1,937 4% 750 4% 
    Other antidepressant  2,987 4% 1,051 2% 658 3% 
    Other anti-anxietyc 2,967 4% 1,090 2% 519 3% 
    Atypical antipsychotic 2,264 3% 732 2% 343 2% 
    Bupropion 1,251 1% 592 1% 211 1% 
    Buspirone 1,226 1% 876 2% 253 1% 
    TCA 1,157 1% 497 1% 382 2% 
    Anticonvulsant 988 1% 289 1% 294 1% 
    SNRI 761 1% 345 1% 165 1% 
    Beta-blocker 705 1% 391 1% 176 1% 
    Non-SSRI + Non-SSRI 953 1% 427 1% 124 1% 
 84,500 100% 47,973 100% 20,249 100% 
aAt least two anxiety diagnoses in the prior year and no comorbid psychiatric diagnosis in the 30 days before anti-
anxiety medication initiation 
bPrimary analysis: SSRI+other anxiety (n=355), SSRI+buspirone (n=133), SSRI+beta-blocker (n=110), 
SSRI+anticonvulsant (n=83), SSRI+TCA (n=55), SSRI+bupropion (n=17), SSRI+SNRI (not reported due to small 
sample) 
c98% of prescriptions were clonidine or guanfacine  
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Table 3.4. The proportion of children refilling their initial anti-anxiety medication class and continuing 





% (95% CI) 
Continued medication for 
6 months 
% (95% CI) Initial medication classa 
   SSRI 58,872 81 (80-81) 55 (55-56) 
   Benzodiazepine 10,005 25 (24-26) 5 (4-7) 
   Hydroxyzine 4,165 19 (18-20) 3 (1-7) 
   Other antidepressant 4,151 58 (56-59) 28 (26-31) 
   Atypical antipsychotic 3,501 71 (69-72) 41 (38-43) 
   Other anti-anxietyc 3,424 64 (62-66) 38 (35-40) 
   Buspirone 1,474 49 (46-51) 19 (15-23) 
   Bupropion 1,459 69 (66-71) 37 (33-40) 
   TCA 1,279 55 (52-57) 27 (23-32) 
   Anticonvulsant 1,218 64 (61-66) 35 (30-39) 
   Beta-blocker 887 32 (29-35) 14 (9-20) 
   SNRI 881 66 (63-69) 38 (33-43) 
aEach medication class evaluated separately for patients initiating two classes 
bCalculated from the 93% of children with 60 days of continuous insurance in follow-up 




Table 3.5. Treatment continuation sensitivity analysis: Proportion of children who refilled the initial anti-
anxiety medication and continued treatment for 6 months, by anxiety diagnoses in the prior year 
 
Children with at least 2 
anxiety diagnoses in the 






Children with one anxiety 
diagnosis in the prior year 
(n=44,887)a 











6 months Initial medication class 
   SSRI 84% 61%  78% 50% 
   Benzodiazepine 28% 7%  23% 4% 
   Hydroxyzine 22% 4%  17% 3% 
   Other antidepressant 61% 32%  54% 24% 
   Atypical antipsychotic 72% 43%  69% 38% 
   Other anti-anxiety 66% 39%  62% 36% 
   Buspirone 57% 26%  45% 15% 
   Bupropion 68% 40%  69% 33% 
   TCA 58% 30%  52% 25% 
   Anticonvulsant 64% 35%  63% 34% 
   Beta-blocker 38% 21%  28% 10% 
   SNRI 67% 41%  66% 36% 




Table 3.6. Treatment continuation sensitivity analysis: Varying the grace period to define treatment 
discontinuation to 15 and 60 days 
 15 day grace period  60 day grace period 












for 6 months 
   SSRI 75% 41%  83% 67% 
   Benzodiazepine 20% 3%  29% 10% 
   Hydroxyzine 15% 2%  23% 8% 
   Other antidepressant 51% 19%  61% 39% 
   Atypical antipsychotic 64% 28%  74% 54% 
   Other anti-anxiety 57% 28%  68% 49% 
   Buspirone 43% 12%  52% 28% 
   Bupropion 63% 25%  70% 48% 
   TCA 49% 19%  58% 36% 
   Anticonvulsant 57% 25%  67% 46% 
   Beta-blocker 28% 9%  35% 19% 
   SNRI 60% 27%  68% 49% 






Table 3.7. Proportion of children initiating with a non-SSRI anti-anxiety medication with a subsequent 
SSRI fill within 3 months  
Non-SSRI anti-anxiety 







SSRI prescription filled 
within 3 months  
No. No. No. % (95% CI) 
   Benzodiazepine 7,477 6,810 1,649 24 (23-25) 
   Hydroxyzine 3,404 3,006 486 16 (15-18) 
   Other antidepressant 3,225 2,889 459 16 (15-17) 
   Other anti-anxiety 3,069 2,668 349 13 (12-14) 
   Atypical antipsychotic 2,607 2,353 470 20 (18-22) 
   Bupropion 1,442 1,273 227 18 (16-20) 
   Buspirone 1,341 1,191 200 17 (15-19) 
   TCA 1,224 1,092 140 13 (11-15) 
   Anticonvulsants 1,135 987 130 13 (11-15) 
   SNRI 880 789 109 14 (12-16) 
   Beta-blocker 777 676 73 11 (9-13) 
All non-SSRI initiators 25,628 22,884 4,121 18 (18-19) 
Each medication class evaluated separately for patients initiating two classes (4%) 





Figure 3.1. Study design, cohort of children with anxiety initiating anti-anxiety medication 
  
Initial prescription for 
an anti-anxiety 
medication, Time0 Time0 – 1 year 
Treatment length evaluated Continuous insurance enrollment with mental health services 
coverage  
No use of any anti-anxiety related medications 
Baseline covariates collected 






Results standardized internally by US census division (children with unknown division, n=799, excluded); imprecise 
estimates for children 3-5 years (SSRI alone, ex. 2005: 95% CI: 36%-65%, 2014: 37%-51%); widest confidence 
interval range for SSRI alone in children 6-9 years 13%, 10-13 years 9%, 14-17 years 7%) 
aUncommon initiation with an SSRI and another anti-anxiety medication in children 3-5 years, results not displayed 
 
Figure 3.2. Proportion of children with anxiety initiating anti-anxiety medication with an SSRI alone and 









2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Year of medication initiation 
Percent initiating  
with an SSRI alone 
Percent initiating with an 
SSRI + another  
anti-anxiety medication 
14-17 years 





Results standardized internally by US census division (children with unknown division, n=799, excluded); dotted 
lines represent 95% confidence intervals  
aIncludes children initiating with a benzodiazepine alone or with an SSRI+benzodiazepine 
bUncommon benzodiazepine initiation in children 3-5 years, results not displayed  
Figure 3.3. Proportion of children with anxiety initiating anti-anxiety medication with a benzodiazepine 














































aDisplayed by the anxiety disorder with the highest proportion of children initiating with an SSRI alone to the lowest 
proportion of children initiating with an SSRI alone 
Figure 3.4. The proportion of children initiating anti-anxiety pharmacotherapy with SSRI alone, 




Non-SSRI anti-anxiety medication 
  
 



















































































































































































































Index anxiety diagnosis 
78         77         74         70         67         61        60         58         55        53         48         46         46 
18         17         18         16         26         33        34         37         26         40         38        48         42 
aDisplayed by the anxiety disorder with the highest proportion of children initiating with an SSRI alone to the 
lowest proportion of children initiating with an SSRI alone 
Figure 1. The proportion of children initiating anti-anxiety pharmacotherapy with SSRI alone, SSRI+another 




Dotted lines represent 95% confidence intervals  
aRestricted to non-psychotherapy users (<2 sessions in 3 months) before anti-anxiety medication initiation; 
psychotherapy use after medication initiation defined as 2+ sessions in the following 3 months; the majority of 
children with an anxiety diagnosis from a psychologist/therapist were psychotherapy users before anti-anxiety 
medication initiation and therefore were excluded from this figure  
bStandardized internally (reference year=2012) by sex, age group (3-9, 10-13, 14-17 years), and region to account 
for shifts in the population covered across the study period; children with an unknown region or provider specialty 
and prior psychotherapy users were excluded (included n=43,809) 
cPrimary values under ‘other’ provider specialty include acute care hospital, medical doctor-not elsewhere classified, 
multispecialty physician group, internal medicine-not elsewhere classified, nurse practitioner, and mental health 
facilities; the remaining third includes 80+ different values. 
Figure 3.5. Proportion of children becoming psychotherapy users after anti-anxiety medication initiation 
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CHAPTER 4: EXAMINING PARENTAL MEDICATION ADHERENCE AS A PREDICTOR OF 
CHILD SSRI ADHERENCE IN PEDIATRIC ANXIETY  
4.1. INTRODUCTION   
The estimated lifetime prevalence of pediatric anxiety disorders is 15-20%3 and 8% for anxiety 
disorders with severe impairment.10 Selective serotonin reuptake inhibitors (SSRI) are the recommended, 
and most commonly prescribed,(Aim 1) first-line pharmacotherapy for children with anxiety.31,156 
Randomized controlled trials have shown SSRIs to be effective in treating pediatric anxiety over placebo 
with relatively mild side effects.16,31,126 In pooled estimates from randomized controlled trials 
approximately 50-70% of children with anxiety randomized to SSRIs or serotonin–norepinephrine 
reuptake inhibitor (SNRIs) responded to treatment.16  
Poor medication adherence, the process by which patients take medications as prescribed,91 can 
reduce medication effectiveness. Adherence should be encouraged at SSRI initiation and evaluated as a 
reason for non-response before dosing or agent changes. Antidepressant non-adherence is common 
among children and adolescents21,22 and in adults with anxiety.92-94 However, there is limited information 
specifically on SSRI adherence in children and adolescents with anxiety. 
Medication adherence is influenced by many factors, including medication related, patient 
related, and provider and system related factors.25,96 For child adherence, parents and caregivers play an 
important role.25 Parents have responsibility in storing their child’s psychotropic medication and 
monitoring medication adherence, benefits, and side effects97 with psychotropic medication considered a 
more challenging treatment option when there is limited family investment or adult supervision.97 Parent 
attitudes towards and involvement in a child’s treatment have been associated with child psychotropic 
adherence98,157 and children and parents share common barriers to adherence. 
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Identifying ways to assist patients in adhering to medications remains a research priority.23-25 
Determining if parent prior adherence is predictive of child SSRI adherence could target interventions in 
children prior to and after SSRI initiation, help the provider determine an appropriate treatment plan, and 
reduce unnecessary medication switches. To address current research gaps, we sought to estimate SSRI 
adherence immediately after initiation in a large population of commercially insured children and 
adolescents with anxiety and to determine if prior parental medication adherence was predictive of child 
SSRI adherence. 
4.2. METHODS 
4.2.1. Study population 
We identified commercially insured children in the United States from the MarketScan 
Commercial Claims database. We utilized enrollment files, inpatient and outpatient services, and 
outpatient, dispensed prescriptions. We included children (3-17 years) newly initiating an SSRI between 
2005 and 2014. Children were required to have continuous prescription coverage with no record of a 
dispensed SSRI prescription in the year prior to SSRI initiation (Figure 4.1) and a recent anxiety 
diagnosis, at least 30 days prior to, or on, the date of SSRI initiation (index anxiety diagnosis). An anxiety 
diagnosis was defined as an inpatient or outpatient anxiety ICD-9-CM code (293.84, 300.0x-300.3x, 
309.21, 309.81, 313.23) roughly corresponding to anxiety disorders in the Diagnostic and Statistical 
Manual of Mental Disorders, DSM-5,27 and we additionally included post-traumatic stress disorder 
(PTSD) and obsessive compulsive disorder (OCD), which were classified under anxiety disorders in the 
DSM-IV.133 We excluded children with baseline diagnoses of bipolar disorder, personality disorder, 
schizophrenia, or autistic disorder, as anxiety would likely be treated secondary to these conditions. We 
required 6-months of insurance enrollment following SSRI initiation to evaluate 6-month adherence. 
Lastly, we excluded children for which we could not identify at least one parent in the datasource.  
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4.2.2. Parent identification 
The child enrollment identification number was used to identify the primary and secondary 
beneficiary on the child’s insurance plan. We required the primary and secondary beneficiary to have 
enrollment with prescription coverage in the year before his or her child initiated an SSRI (Figure 4.1). 
We considered the primary and/or secondary beneficiary to be a parent if he or she was at least 15 years 
older than the child.  
4.2.3. Child SSRI adherence measures 
The primary measure of child SSRI adherence was the 6-month proportion days covered (PDC). 
The PDC was calculated by summing the days supply for all SSRI prescriptions dispensed in the first 180 
days of SSRI treatment and dividing the sum by 180 days. PDC values were truncated to 1 and, where 
relevant, dichotomized to “low adherence” (PDC <0.80) and “high adherence” (PDC≥0.80).  
We included three secondary measures to capture additional aspects of adherence, continuation 
for 6-months (persistence), modified medication possession ratio (MPR), and gap in medication coverage. 
A child was considered to have discontinued SSRI treatment when there was no record of a dispensed 
prescription 30 days after the previous prescription’s days supply ran out. If the child remained on 
treatment 180 days after initiation, the child was considered to be persistent at 6-months. The MPR 
provides an estimate of days with medication coverage during time on treatment. The MPR was 
calculated by summing all prescriptions’ days supplies between the first and last SSRI prescription in the 
6-month period (excluding the last prescription) and dividing by the number of days between the first and 
last prescription. Children without a second SSRI fill had a missing MPR. Lastly, we included a measure 
for a gap without medication coverage between the first and second SSRI prescription fill, among 
children with a second SSRI fill. We calculated days without medication coverage by subtracting the days 
supply of the first SSRI fill from the number of days between the first and second prescriptions fills 
(dispensing dates). We defined a long gap without medication as 20+ days. We evaluated all SSRIs and 
allowed switching between SSRI agents when calculating adherence measures.  
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4.2.4. Parent medication adherence measures 
We examined parent adherence to 1) SSRIs, 2) statins, and 3) antihypertensives (ACEs, ARBs, 
thiazides) in the year before child SSRI initiation. We selected these medication classes since SSRIs are a 
common psychiatric medication (and the drug being studied in children) and statins and antihypertensives 
are commonly prescribed chronic, often preventative, medications. For parents, the 6-month PDC was 
calculated for each medication class and dichotomized in the same manner as child 6-month. Parents were 
required to have a prescription for a medication of interest at least 6 months before his or her child’s SSRI 
initiation date to calculate a 6-month PDC prior to child SSRI initiation. When two parents per child had 
an available PDC measure for a medication class, their PDCs were averaged; selecting the higher parent 
PDC value was also considered and results were consistent (Table 4.3 footnote). For the parent summary 
adherence measure, PDCs were averaged across medication classes. For a sensitivity analysis, among 
children without a parent statin or antihypertensive PDC measure available we identified parents with a 
statin or antihypertensive prescription 1-3 years prior to child SSRI initiation. As statins and 
antihypertensives are often to be taken chronically, we considered these parents to have discontinued the 
medication and grouped them with low adherence. 
4.2.5. Covariates, baseline predictors 
In the year prior to SSRI initiation we measured the following child-related characteristics: age, 
sex, psychiatric co-morbidities, non-psychiatric co-morbidities, healthcare/medication utilization, region, 
and anxiety diagnosis details. The index anxiety diagnosis was grouped by the specific diagnosis (≥1 
specific diagnosis were grouped under ‘multiple’) and as unspecified anxiety when no specific anxiety 
diagnosis was provided. The provider type of the index diagnosis was identified and categorized: 
psychiatry, psychologist, therapist; pediatrics; family practice; multi-specialty physician group; other 
specialty; unknown, multiple. Healthcare utilization included indicators for outpatient visits (problem-
oriented and well/preventative, defined with CPT procedure codes), psychiatric and non-psychiatric 
related inpatient admissions, and ER visits. Medication included an overall count of therapeutic classes 
prescribed in the prior year, other psychiatric medications that can be prescribed for anxiety, ADHD 
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medications, and opioids. Prior psychotherapy use was identified through recorded psychotherapy CPT 
procedure codes. 
For each child’s parent(s), we created variables for whether either parent had a psychiatric 
diagnosis (anxiety, depression, adjustment disorder, substance abuse, or other), preventative/well 
outpatient visit, benzodiazepine prescription fill, or psychotherapy session in the prior year. We included 
an indicator for one parent being age 50 or older (above third quartile of parent age=49 years), since 
adherence in older adults may be higher.101 
4.2.6. Statistical analysis 
We described the mean 6-month SSRI PDC with 95% confidence intervals (CI) and estimated the 
proportion of children with high adherence overall and stratified by age group, index anxiety diagnosis, 
and recent (≤30 days) co-morbid depression diagnosis. We described child SSRI adherence stratified by 
parent adherence to SSRIs, statins, and antihypertensives. Parents were classified as low adherence, high 
adherence, or non-users for each medication class. This was repeated with the secondary measures of 
child adherence (6-month persistent, MPR, and gaps between fills). We estimated the crude predictive 
risk difference (RD) and risk ratio (RR) with 95% CIs of high child adherence by parent adherence. 
Results were stratified by sex of the parent with an adherence measure and child age. These factors were 
considered potential modifiers of the predictive association between parent adherence and child adherence 
as mothers may have more regular involvement in a child’s anxiety treatment; in a randomized controlled 
trial in pediatric anxiety, 87% of caregiver baseline interviews were completed by mothers.158 Child age 
was considered as parent involvement in medication use likely differs between older and younger 
children. We estimated the multivariable predictive RR of parent adherence with high child SSRI 
adherence in a full model with all child and parent level variables with a prevalence >2% using modified 
Poisson regression.159 For a sensitivity analysis we examined results stratified by whether we identified 1 
parent per child or 2 parents per child. 
To determine if parent-level factors improved the prediction of child adherence over child-level 
predictors, we estimated the change in c-statistic and clinical risk reclassification. For the c-statistic 
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change, we used least absolute shrinkage and selection operator (LASSO) regression methods to 
automatically select predictors that resulted in the minimized cross-validated error (lambda).160 This was 
done in three random training datasets (80% samples) with predictors with a prevalence >2% included as 
possible predictors. In the validation datasets we estimated the c-statistic for the models identified in the 
training datasets with and without considering the parent measures. We additionally evaluated the average 
c-statistic change when allowing for all possible 2-way interactions in the models with and without 
parent-level variables. 
For clinical risk reclassification the predicted probabilities of high child adherence with only 
child-level variables were cross-classified with the predicted probabilities from the model also containing 
child and parent-level variables.161 This was summarized with the net reclassification index (NRI).162  
4.3. RESULTS 
4.3.1. Study population 
The final cohort included 70,979 children with anxiety initiating an SSRI (Figure 4.2). The 
median age of children at SSRI initiation was 14 years (IQR:11-16), 41% of children were male, and a 
quarter of children had a recent depression diagnosis (Table 4.1). The majority of children initiated on 
sertraline (39%) followed by fluoxetine (27%), escitalopram (15%), and citalopram (13%) and 88% had 
an initial SSRI days supply of 30 days with 6% of children initiating with a days supply <30 days. 
4.3.2. Child SSRI adherence 
The mean 6-month SSRI PDC was 0.72 with 42% of children classified as having low adherence 
and 58% high adherence (77% of whom had a PDC≥95%, Table 4.2). The average PDC was higher in 
younger children (3-13 years=0.76) compared to older children (14-17 years=0.70) and similar in children 
with and without a co-morbid depression diagnosis. Children with an index anxiety diagnosis of OCD 
(0.79) or social phobia (0.77) had the highest mean PDC and children with panic disorder (0.68) and 
PTSD (0.65) had the lowest. Results were largely consistent across the secondary adherence measures 
(Table 4.2) with a slightly improved MPR and less with a gap in medication for children with a recent 
depression diagnosis. Persistence at 6-months was highly correlated with binary PDC (Spearman’s 
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correlation coefficient=0.87). Overall, 56% were persistent to SSRI treatment at 6-months with 20% 
(n=14,065) of children discontinuing treatment after the initial fill. 
4.3.3. Prior parent medication adherence 
Overall, two parents were identified in 70% of children. Half (49%) of children 
(n=34,470/70,979) had at least one parent PDC measure in the year before SSRI initiation. There were 
20,268 children (29%) with a parent SSRI PDC (3% had two parent SSRI PDCs), 12,987 children (18%) 
with a parent statin PDC (1% had two parent statin PDCs), and 15,344 children (22%) with a parent 
antihypertensive PDC (2% had two parent antihypertensive PDCs). The mean 6-month PDC parent 
adherence was 0.81 for SSRIs, 0.85 for statins, and 0.88 for antihypertensives. 
4.3.4. Child SSRI adherence by parent adherence 
The mean SSRI PDC was lower in children with parents with low SSRI adherence than in 
children with parents with high adherence (mean PDC=0.70 vs. 0.77). Overall 64% of children had high 
adherence if their parent had high SSRI adherence vs. 53% of children of parents with low SSRI 
adherence, a 12% difference (95% CI:10-13%, RR=1.23, 95% CI:1.19-1.26). Findings were similar, but 
slightly attenuated, for parent statin and parent antihypertensive adherence (Table 4.3). When stratified by 
child age at SSRI initiation and sex of parent with a PDC measure, results were largely consistent (Figure 
4.3). 
The overall predictive relationship between child and parent adherence remained across the 
secondary measures of child SSRI adherence (Table 4.4 and 4.5). In the sensitivity analysis, 3% of 
children without a parent statin adherence measure had a parent with past (1-3 years prior) statin 
discontinuation; 3% also had past antihypertensive discontinuation. Adherence in children with parents 
who discontinued medication was similar to parents with low adherence in the prior year, with no changes 
in the risk differences when grouping past discontinuation with low adherence. Results were also 
consistent when stratifying by whether one or two parents were identified per child (RR=1.21, 1 parent 
vs. RR=1.19, 2 parents).  
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In the full prediction model, parent high adherence independently predicted high child adherence 
for SSRIs (RR:1.17, 95% CI:1.14-1.20), statins (RR:1.11, 95% CI:1.07-1.14), and antihypertensives 
(RR:1.08, 95% CI:1.05-1.13) compared to parent low adherence (Table 4.3). The parent summary 
measure, parent high SSRI, statin, or antihypertensive adherence was associated with a 16% increased 
likelihood of high child adherence. Children with parents with a substance use disorder diagnosis were 
less likely to be adherent (RR=0.86) and children with parents with a well visit were more likely to be 
adherent (RR=1.05) (Figure 4.4). 
4.3.5. Improvement in prediction 
The average increase in the c-statistic when parent-level variables were considered as potential 
predictors in addition to child-level variables was 0.012 (highest c-statistic=0.65). When allowing for 
potential interactions between variables, the average increase in the c-statistic after adding parent-level 
measures was 0.013 (highest c-statistic=0.66). With clinical risk reclassification, 8% with high child 
adherence saw improved reclassification into predicted probability strata (<40%, 40-70%, and >70%) and 
6% had worsened reclassification,(Table 4.6) resulting in an overall positive, but low, NRI of 0.04.  
4.4. DISCUSSION 
In commercially insured children with anxiety beginning an SSRI, around forty-percent were 
classified as having low adherence, some a result of early discontinuation. SSRI adherence was higher in 
children with parents highly adherent to SSRIs, statins, or antihypertensives; overall associations 
remained when considering parent sex and child age. While adherence is difficult to predict at baseline, 
parental adherence offers slight improvement in predicting child SSRI adherence even after accounting 
for available child-level predictors. Parent adherence may help providers distinguish non-responders from 




4.4.1. Child SSRI adherence  
In the Child/Adolescent Anxiety Multimodal Study (CAMS) children randomized to sertraline 
(an SSRI) had high adherence (≥90%) at 12 weeks; however, this estimate was based on pills returned 
during visits, taken over a shorter period of time, and adherence in trials is typically higher than a general 
population.70 To our knowledge, there are limited estimates of SSRI adherence in pediatric anxiety 
outside the trial setting. In Medicaid enrolled children with depression, 21% were adherent over the first 6 
months of antidepressant treatment21 and in adults with anxiety and no depression, 40% were adherent to 
SSRIs or SNRIs at 6 months.94 Both estimates show poorer adherence than we observed, but all 
demonstrate the prevalence of non-adherence. 
We observed the highest adherence in children initiating an SSRI after an OCD diagnosis, with 
social phobia the next highest. This may be related to more specific guidelines on SSRI treatment length 
for children with OCD than non-OCD anxiety disorders.31,125 The lowest adherence was in children 
initiating an SSRI after a PTSD diagnosis, which could be in part because there is less evidence of SSRI 
effectiveness in children with PTSD than there is for other pediatric anxiety disorders.45,163 As such, poor 
adherence may be the result of higher non-response. An important consideration for our study is that we 
cannot disentangle instances when non-adherence led to non-response or when non-response led to non-
adherence.  
If a child does not respond to SSRI treatment it is recommended another SSRI agent be tried 
before switching medication classes.13 When poor adherence is the reason for SSRI non-response, poor 
adherence will likely remain with the new medication.95 Therefore, given the amount of non-adherence to 
SSRIs, as recommended for pediatric ADHD,164 medication adherence should be assessed in children 
before altering dosing or medication. 
4.4.2 Parent adherence predicting child adherence 
Parent adherence to SSRIs, statins, and antihypertensives at baseline was predictive of future 
SSRI adherence in children with anxiety. Family history of SSRI response can be a factor considered in 
SSRI selection for a child.165,166 If family SSRI response is associated with child SSRI response, we may 
 
 53 
expect to see higher child SSRI adherence in parents with higher SSRI adherence. This assumes parents 
with high adherence were more likely to be responders. Additionally high parent SSRI adherence may be 
a sign the parent has more favorable views on SSRIs, which could translate to improved child SSRI 
adherence. However, the parallel associations with parent statin and antihypertensive adherence and child 
SSRI adherence point to other, or additional, explanations for the observed association between parent 
and child adherence.  
Larger unmeasured contextual factors such as pharmacy access, insurance medication coverage 
and co-payments, refill reminders, relationship with provider, or family socio-economic status25,96,167,168 
affecting both parent and child adherence may contribute, at least in part, to our observed link between 
parent and child adherence. Parent views or behaviors that influence their own adherence may directly 
influence their child’s adherence, or indirectly if the child shares a parent’s views or behaviors. These 
could include perceived value/acceptability of medications and their side effects, health literacy, or 
general healthy behaviors. Child views of psychotropic medications has been linked with treatment 
adherence.157 This has also been shown for parent views, with higher ADHD medication adherence in 
children with parents reporting higher perceived psychosocial benefits of medication,99 higher asthma 
medication adherence in children with parents who believe the medication was necessary and outweighed 
medication concerns,169 and negative parent views on stimulant medications related to the child’s 
willingness to discontinue medication.100 There is limited evidence for the association between individual 
health literacy and adherence,170 including in individuals with anxiety disorders.171 However, in children 
with epilepsy, inadequate parent health literacy was associated with more missed medication doses.172 
Statins and antihypertensives are often used as preventative medications and parents initiating and 
adhering to these medications may represent parents more likely to partake in other healthy 
behaviors173,174 that could influence the parent’s care and involvement in his or her child’s treatment. 
Adherent parents may also be accustomed to taking daily medications to manage illness and making 
regular trips to the pharmacy. Since the association between parent and child adherence held across age 
groups, even though adolescents are more in control of their medication as parents are recommended to 
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let the child manage their own medication at this age,157,175 shared family contextual barriers or shared 
parent-child behaviors likely contribute to the observed association.  
4.4.3. Clinical utility of parent adherence as a predictor 
Despite the lack of narrowing in on the specific mechanism that associates parent adherence with 
child SSRI adherence, parent adherence alone can help a provider predict a child’s future SSRI 
adherence. The clinical utility of using parent adherence to predict child adherence is lessened by the fact 
that self-reported adherence is often higher than actual adherence.176 Nevertheless, the results do highlight 
the important role parents have in their child’s care and an important step to addressing adherence could 
be conversing with parents on their barriers to adherence and whether those barriers will translate to 
barriers for their child. In the future electronic health records may incorporate family medication 
utilization, which could help identify children at highest risk for poor adherence. Relatedly, future 
research could examine the potential benefit of synchronizing family prescription refill schedules to 
reduce barriers.  
The no parent adherence category essentially represents missing information on the parent’s 
medication adherence. This group combines parents who started and already discontinued the medication, 
were prescribed but never filled the prescription, do not need the medication, or may need but were never 
prescribed the treatment. Therefore, it is difficult to interpret findings comparing parents with low 
adherence vs. no use of the medication class. Expanding the research to include additional medication 
classes and medication use spanning further in the parent history, as our sensitivity analysis touched on, 
would reduce the number of children without parent adherence information.  
More broadly, parent adherence could potentially be used for adjustment in 
pharmacoepidemiologic studies to proxy for contextual factors and familiar-level behaviors not captured 




Our study has a number of strengths including using objective adherence measures for the parent 
and child as parents have been shown to overestimate adherence in children,164,177 measuring parent 
adherence prior to the child beginning medication treatment, and comprising a large population of 
commercially insured children in standard care. However, some limitations should be considered. We use 
the term ‘parent’ throughout; however, the beneficiary could be a much older sibling or another individual 
on the insurance plan and may not be an individual the child considers a caretaker or an individual with 
involvement in the child’s medication care. In some instances low adherence values are blended with 
discontinuation. The reason for SSRI discontinuation may have been appropriate; the FDA antidepressant 
black-box warning could have been associated with early discontinuation. We evaluated parent adherence 
to three medication classes with multiple indications; the association between parent adherence and child 
SSRI adherence may not hold across other medication classes. Additionally, parent adherence was 
relatively high in our population. This is partially because we did not require parents to be new users of 
medications and thereby include prevalent users who have demonstrated some consistent medication use. 
Parent adherence was the highest to antihypertensives (ACEs, ARBs, thiazides); the PDC measure could 
have been inflated in parents with multiple medications within the antihypertensive class. Our measures 
of child and parent adherence are based on dispensed prescriptions and not on taking the medication; we 
used a PDC at 80% to define high vs. low adherence, which may not be a clinically relevant cut-point for 
all cases.  
Adherence measures relied on correct days supply values of dispensed prescriptions, incorrect 
values could have resulted in over or under-estimation of adherence; however, this would not necessarily 
result in misclassification of binary adherence measures. Incorrect entry of days supply values could be 
pharmacy specific, which would likely be shared by the child and parent. Two-percent of children were 
identified as a potential sibling to another child in the cohort (same insurance plan) who separately met  
inclusion requirements; we assume correlation with high child adherence to remain low given the 
infrequent occurrence of siblings and that adherence is associated with many factors. Our risk 
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reclassification results are sensitive to the predicted probability strata we selected. We are unaware of a 
validation study in MarketScan on the accuracy of enrollment identification variables in linking family 
members.  
4.4.5. Conclusion 
Low SSRI adherence in a large population of commercially insured children with anxiety was 
relatively common. Consequently, adherence should be prioritized and evaluated during follow-up visits. 
High parental adherence to chronic medications at baseline was predictive of high SSRI adherence in 
children with anxiety; the observed predictability could be related to specific parent, or shared child-
parent, views or behaviors or contextual factors that affect adherence in both the parent and child. 
Parental adherence may offer a way to enhance prediction of child SSRI adherence at baseline in children 
with anxiety, with the hope of ultimately improving child SSRI adherence. 
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N=70,979 N=40,982 N=29,997 
Child-level characteristicsa     
Male 29,339 (41.3%) 16,782 (40.9%) 12,557 (41.9%) 
Age, Median (IQR) 14 (11-16) 14 (11-16) 15 (12-16) 
     3-9 years 11,192 (15.8%) 7,113 (17.4%) 4,079 (13.6%) 
     10-13 years 19,070 (26.9%) 11,986 (29.2%) 7,084 (23.6%) 
     14-17 years 40,717 (57.4%) 21,883 (53.4%) 18,834 (62.8%) 
Anxiety disorder, index diagnosis 
       Unspecified anxiety  34,220 (48.2%) 18,985 (46.3%) 15,235 (50.8%) 
    Generalized anxiety disorder 18,094 (25.5%) 10,879 (26.5%) 7,215 (24.1%) 
    OCD 6,251 (8.8%) 4,184 (10.2%) 2,067 (6.9%) 
    Panic disorder  3,221 (4.5%) 1,688 (4.1%) 1,533 (5.1%) 
    PTSD 2,808 (4.0%) 1,267 (3.1%) 1,541 (5.1%) 
    Multiple specific diagnoses 1,742 (2.5%) 1,139 (2.8%) 603 (2.0%) 
    Social phobia 1,743 (2.5%) 1,112 (2.7%) 631 (2.1%) 
    Other specific diagnosisb 2,900 (4.1%) 1,728 (4.2%) 1,172 (3.9%) 
3+ anxiety diagnoses, prior year 25,694 (36.2%) 16,573 (40.4%) 9,121 (30.4%) 
Provider type of index anxiety diagnosis 
       Psychiatry 19,918 (28.1%) 12,544 (30.6%) 7,374 (24.6%) 
    Pediatrics 11,221 (15.8%) 6,408 (15.6%) 4,813 (16.0%) 
    Family practice 9,370 (13.2%) 4,299 (10.5%) 5,071 (16.9%) 
    Psychologist, therapist 7,695 (10.8%) 4,876 (11.9%) 2,819 (9.4%) 
    Multi-specialty 2,325 (3.3%) 1,385 (3.4%) 940 (3.1%) 
    Other type  14,479 (20.4%) 8,052 (19.6%) 6,427 (21.4%) 
    Unknown, multiple 5,971 (8.4%) 3,418 (8.3%) 2,553 (8.5%) 
Anxiety related symptoms, prior 90 daysc 13,360 (18.8%) 7,176 (17.5%) 6,184 (20.6%) 
Psychotherapy use, prior yeard 
       None 33,322 (46.9%) 16,928 (41.3%) 16,394 (54.7%) 
    1-4 claims 17,318 (24.4%) 10,693 (26.1%) 6,625 (22.1%) 
    5+ claims 20,339 (28.7%) 13,361 (32.6%) 6,978 (23.3%) 
Psychiatric co-morbiditiese 
       Any psychiatric diagnosis, recent  33,550 (47.3%) 19,759 (48.2%) 13,791 (46.0%) 
    Depression diagnosis 
           Inpatient diagnosis 3,943 (5.6%) 2,136 (5.2%) 1,807 (6.0%) 
        Specific depression diagnosis 9,586 (13.5%) 5,711 (13.9%) 3,875 (12.9%) 
        General diagnosis 7,496 (10.6%) 4,186 (10.2%) 3,310 (11.0%) 
        No depression diagnosis  49,954 (70.4%) 28,949 (70.6%) 21,005 (70.0%) 
    Adjustment disorder 11,836 (16.7%) 7,352 (17.9%) 4,484 (14.9%) 
    ADHD 14,042 (19.8%) 8,037 (19.6%) 6,005 (20.0%) 
    Disruptive behavior, conduct disorder 4,637 (6.5%) 2,664 (6.5%) 1,973 (6.6%) 
    Other episodic mood disorder 3,653 (5.1%) 2,088 (5.1%) 1,565 (5.2%) 
    Sleep disorder 3,706 (5.2%) 1,987 (4.8%) 1,719 (5.7%) 
    Substance use disorder 2,223 (3.1%) 895 (2.2%) 1,328 (4.4%) 
Medication use in prior year 
       Count of therapeutic prescription groups 3 (2-5) 3 (2-5) 3 (2-5) 
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         0-1 26,090 (36.8%) 15,474 (37.8%) 10,616 (35.4%) 
         2-3 24,136 (34.0%) 14,063 (34.3%) 10,073 (33.6%) 
         4+ 20,753 (29.2%) 11,445 (27.9%) 9,308 (31.0%) 
    Non-SSRI antidepressant 5,558 (7.8%) 3,006 (7.3%) 2,552 (8.5%) 
    Benzodiazepine 7,306 (10.3%) 4,010 (9.8%) 3,296 (11.0%) 
    ADHD medication 13,867 (19.5%) 7,907 (19.3%) 5,960 (19.9%) 
Psychological diagnosis, evaluationf 40,815 (57.5%) 25,671 (62.6%) 15,144 (50.5%) 
Parent-level characteristicsa 
   Male parent 59,609 (84.0%) 34,995 (85.4%) 24,614 (82.1%) 
Female parent 61,002 (85.9%) 35,893 (87.6%) 25,109 (83.7%) 
Parent age, median (IQR) 45 (40-49) 45 (41-49) 44 (40-49) 
    Parent 50+ years 20,130 (28.4%) 11,976 (29.2%) 8,154 (27.2%) 
Psychiatric diagnoses    
    Anxiety 13,391 (18.9%) 7,741 (18.9%) 5,650 (18.8%) 
    Depression 14,943 (21.1%) 8,629 (21.1%) 6,314 (21.0%) 
    Adjustment disorder 6,336 (8.9%) 3,790 (9.2%) 2,546 (8.5%) 
    Substance use disorder 4,147 (5.8%) 1,942 (4.7%) 2,205 (7.4%) 
    Other diagnosis, not above 2,747 (3.9%) 1,631 (4.0%) 1,116 (3.7%) 
Benzodiazepine prescription 17,423 (24.5%) 9,836 (24.0%) 7,587 (25.3%) 
Psychotherapy claim 13,820 (19.5%) 8,374 (20.4%) 5,446 (18.2%) 
Outpatient well/preventative visit 29,724 (41.9%) 18,284 (44.6%) 11,440 (38.1%) 
IQR: interquartile range; OCD: obsessive-compulsive disorder; PTSD: Post-traumatic stress disorder; ‘recent’ 
refers to the 30-day period before SSRI initiation  
aChild and parent level characteristics are defined from inpatient and outpatient diagnoses and procedures and 
outpatient dispensed prescriptions   
bSeparation anxiety disorder (1.2%), agoraphobia (0.9%), other anxiety (0.7%), other/specific phobia (0.5%), 
due to medical condition (0.5%), selective mutism (0.3%) 
cAny diagnostic code for abdominal pain, unspecified chest pain, headache, hyperventilation, malaise/fatigue, 
nausea, palpations, or weight loss in the prior 3 months 
dPsychotherapy CPT codes based on recorded claims: 90804, 90816, 90806, 90818, 90808, 90821, 90810, 
90823, 90812, 90826, 90814, 90828, 90805, 90817, 90807, 90819, 90809, 90822, 90811, 90824, 90813, 90827, 
90815,  90829, 90847, 90849, 90853, 90857, 90832, 90834, 90837, 90833, 90836, 90838, 90853, 90839 
ePsychaitric co-morbidity definitions with ICD-9-CM codes: Any psychiatric diagnosis (290-319.x); specific 
depression diagnosis (296.2x, 296.3x, 300.4x, 309.1x); general depression diagnosis (311.x); Adjustment 
disorder (309.0x, 309.22-309.29, 309.3x, 309.4x, 309.82-309.89, 309.9x,); ADHD (314.x); Disruptive behavior, 
conduct disorder (312.x, 313.81); Other episodic mood disorder (296.9x); Sleep disorder (307.4x, 327.x, 347.x, 
780.5x); Substance use disorder (291-292.x, 303-305.x) 
















Secondary adherence measures 













20+ day gap 
between 1st 
and 2nd filla 
 
No. %  % %  % 
Overall 70,979 0.72 (0.72-0.73) 40,982 58% 56% 61,070 0.86 73% 11.2% 
Age group 
    
     
    3-9 years 11,192 0.76 (0.76-0.77) 7,113 64% 61% 9,785 0.88 77% 11.0% 
   10-13 years 19,070 0.76 (0.76-0.77) 11,986 63% 61% 16,961 0.87 74% 10.6% 
   14-17 years 40,717 0.70 (0.69-0.70) 21,883 54% 51% 34,324 0.86 72% 11.6% 
Anxiety disorder 
    
     
   Unspecified anxiety 34,220 0.71 (0.70-0.71) 18,985 55% 53% 28,958 0.86 72% 11.6% 
   Generalized anxiety disorder 18,094 0.74 (0.74-0.75) 10,879 60% 58% 15,900 0.87 74% 11.0% 
   OCD 6,251 0.79 (0.78-0.79) 4,184 67% 65% 5,623 0.89 78% 9.8% 
   Panic disorder 3,221 0.68 (0.67-0.69) 1,688 52% 50% 2,642 0.86 71% 12.4% 
   PTSD 2,808 0.65 (0.63-0.66) 1,267 45% 43% 2,325 0.84 69% 14.1% 
   Social phobia 1,743 0.77 (0.76-0.78) 1,112 64% 62% 1,577 0.87 75% 9.0% 
   Other anxiety disorderc 4,642 0.75 (0.74-0.76) 2,867 62% 59% 4,045 0.87 75% 10.4% 
Co-morbid recent depressiond 
    
     
    Depression 17,942 0.73 (0.72-0.73) 10,355 58% 55% 15,678 0.87 75% 9.7% 
    No depression  53,037 0.72 (0.72-0.73) 30,627 58% 56% 45,392 0.86 73% 11.7% 
OCD: obsessive-compulsive disorder; PTSD: Post-traumatic stress disorder; PDC: proportion days covered; MPR: modified medication possession ratio; CI: 
confidence interval   
aRestricted to children with a second SSRI fill within 6-months, n=61,070 (86%); 4,156 of those children had a gap of more than 30 days before the 2nd fill 
bPersistence at 6-months is highly correlated with a 6-month PDC≥0.80 
cChildren with multiple specific diagnoses included  














Child high SSRI adherence (PDC≥0.80) 






RR (95% CI) 
Multivariable 
predictionc 
aRR (95% CI) 
Parent SSRI adherence        
     Low 6,585 0.70 (0.69-0.70) 3,463 53% REF REF REF 
     Highc 13,683 0.77 (0.77-0.78) 8,823 64% 12% (10-13) 1.23 (1.19-1.26) 1.17 (1.14-1.20) 
     No SSRI use 50,711 0.72 (0.71-0.72) 28,696 57% 4% (3-5) 1.08 (1.05-1.10) 1.05 (1.02-1.07) 
Parent statin adherence        
     Low  3,323 0.70 (0.69-0.71) 1,817 55% REF REF REF 
     Highc 9,664 0.77 (0.76-0.78) 6,231 64% 10% (8-12) 1.18 (1.14-1.22) 1.11 (1.07-1.14) 
     No statin use 57,992 0.72 (0.72-0.72) 32,964 57% 2% (0-4) 1.04 (1.01-1.07) 1.02 (0.98-1.05) 
Parent antihypertensive adherence        
     Low 2,958 0.69 (0.67-0.70) 1,530 52% REF REF REF 
     Highc 12,386 0.74 (0.73-0.74) 7,424 60% 8% (6-10) 1.16 (1.12-1.20) 1.08 (1.05-1.13) 
     No antihypertensive use 55,635 0.72 (0.72-0.73) 32,028 58% 6% (4-8) 1.11 (1.07-1.15) 1.06 (1.02-1.09) 
Parent adherence (overall)        
     Low 10,312 0.69 (0.69-0.70) 5,429 53% REF REF REF 
     High 24,167 0.76 (0.76-0.76) 15,258 63% 10% (9-12) 1.20 (1.17-1.22) 1.16 (1.13-1.18) 
     No adherence value 36,500 0.71 (0.71-0.71) 20,295 56% 3% (2-4) 1.06 (1.03-1.08) 1.03 (1.01-1.05) 
PDC: proportion days covered; REF: reference; CI: confidence interval   
aParent low adherence: 6-month PDC<0.80, high adherence: PDC≥0.80, no use: neither parent had a prescription in that medication class in the 6 to 
12 months before the child initiated an SSRI (no 6-month PDC able to be calculated)  
bResults for alternative adherence calculation: selected higher parent PDC measure when both parents had available PDC, parent high vs. low 
adherence: parent SSRI adherence: RD=13% (95%CI:11-14), RR=1.24 (95%CI:1.21-1.28); parent statin adherence: RD=10% (95%CI:8-12), 
RR=1.19 (95%CI:1.15-1.23); parent antihypertensive adherence: RD=8% (95%CI:6-11), RR=1.15 (95%CI:1.11-1.20) 










Children persistent at 6-months 





RR (95% CI) 
Parent SSRI adherence      
     Low 6,585 3,372 51% REF REF 
     High 13,683 8,447 62% 11% (9-12) 1.21 (1.17-1.24) 
     No SSRI use 50,711 27,598 54% 3% (2-5) 1.06 (1.04-1.09) 
Parent statin adherence      
     Low  3,323 1,759 53% REF REF 
     High 9,664 5,918 61% 8% (6-10) 1.16 (1.12-1.20) 
     No statin use 57,992 31,740 55% 2% (0-4) 1.03 (1.00-1.07) 
Parent antihypertensive adherence      
     Low 2,958 1,460 49% REF REF 
     High 12,386 7,110 57% 8% (6-10) 1.16 (1.12-1.21) 
     No antihypertensive use 55,635 30,847 55% 6% (4-8) 1.12 (1.08-1.17) 
Parent adherence (overall)      
     Low 10,312 5,266 51% REF REF 
     High 24,167 14,572 60% 9% (8-10) 1.18 (1.16-1.21) 
     No adherence value 36,500 19,579 54% 3% (2-4) 1.05 (1.03-1.07) 
PDC: proportion days covered; REF: reference; CI: confidence interval; RR: risk ratio   
aParent low adherence: 6-month PDC<0.80, high adherence: PDC≥0.80, no use: neither parent had a 
prescription in that medication class in the 6 to 12 months before the child initiated an SSRI (no 6-month 










Table 4.5. Secondary measures of child SSRI adherence among children with 2 SSRI fills stratified by prior parent medication adherencea 
MPR: modified medication possession ratio; REF: reference; CI: confidence interval; RR: risk ratio   
aParent low adherence: 6-month proportion days covered (PDC)<0.80, high adherence: PDC≥0.80, no use: neither parent had a prescription in that medication 









Child high MPR (≥0.80) 
 Children with 20+ day gap between 1st and 2nd 
fill 














RR (95% CI) 
Parent SSRI adherence             
     Low 5,612 0.83 3,750 67% REF REF  797 14% REF REF 
     High 12,293 0.87 9,075 74% 7% (6, 9) 1.10 (1.08-1.12)  1,314 11% -4% (-5, -3) 0.75 (0.69-0.82) 
     No SSRI use 43,165 0.87 31,843 74% 7% (6, 8) 1.10 (1.08-1.13)  4,729 11% -3% (-4, -2) 0.77 (0.72-0.83) 
Parent statin adherence            
     Low  2,819 0.85 1,962 70% REF REF  341 12% REF REF 
     High 8,581 0.88 6,565 77% 7% (5, 9) 1.10 (1.07-1.13)  831 10% -2% (-4, -1) 0.80 (0.71-0.90) 
     No statin use 49,670 0.86 36,141 73% 3% (1, 5) 1.05 (1.02-1.07)  5,668 11% -1% (-2, 1) 0.94 (0.85-1.05) 
Parent antihypertensive 
adherence 
      
 
    
     Low 2,487 0.84 1,688 68% REF REF  311 13% REF REF 
     High 10,742 0.87 7,971 74% 6% (4, 8) 1.09 (1.06-1.13)  1,136 11% -2% (-3, -1) 0.85 (0.75-0.95) 
     No antihypertensive use 47,841 0.86 35,009 73% 5% (3, 7) 1.08 (1.05-1.11)  5,393 11% -1% (-3, 0) 0.90 (0.81-1.00) 
Parent adherence (overall)            
     Low 8,758 0.84 5,963 68% REF REF  1,155 13% REF REF 
     High 21,342 0.87 16,053 75% 7% (6, 8) 1.10 (1.09-1.12)  2,192 10% -3% (-4, -2) 0.78 (0.73-0.83) 
     No adherence value 30,970 0.86 22,652 73% 5% (4, 6) 1.07 (1.06-1.09)  3,493 11% -2% (-3, -1) 0.86 (0.80-0.91) 
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Table 4.6. Clinical risk reclassification of the predicted probabilities of high child SSRI adherence  
Predicted probabilities of high 
child SSRI adherence 
   Model with child + parent variables 
Children with high adherence      <40%      40-70%      >70% 
 Model with child-level variables No. %, row No. %, row No. %, row Total No. 
     <40%  1,380 73%  502  27%  0    0%  1,882 
     40-70%  845 3%  27,262  88%  2,804  9%  30,911  
     >70%  0  0%  1,545 19%  6,644  81%  8,189 
Total No.  2,225  
 
 29,309  
 
 9,448  
 
 40,982  
        Children with low adherence      <40%      40-70%      >70%
 Model with child-level variables No. %, row No. %, row No. %, row Total No. 
     <40%  2,953  84%  571 16%  0   0%  3,524  
     40-70%  1,414  6%  21,104  90%  1,027  4%  23,545  
     >70%  0 0%  703  24%  2,225  76%  2,928 
Total No.  4,367  
 
 22,378  
 
 3,252  
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Figure 4.2. Aim 2 study cohort inclusion criteria  
  
Children with an anxiety diagnosis  
N=96,986 (30%) 
Prior diagnosis of autistic disorder, 
schizophrenia, bipolar disorder, or 
personality disorder (n=4,925, 5%) 
Final study cohort 
N=70,979 
Less than 6 months of follow-up 
(n=20,405, 22%) 
No parent identified (n=6,770, 1%) 






Figure 4.3. Difference in the proportion of children with high SSRI adherence by parent high vs. low 
adherence: Stratified by parent sex, parent medication class, and child agea 
  
Parent statin adherence (high vs. low) 
Parent antihypertensive adherence (high vs. low) 
Child 3-9 years        Female parent       9.0 (5.3-12.7) 
                                 Male parent          8.6 (2.9-14.2) 
Child 10-13 years    Female parent     13.0 (10.0-16.1) 
                                 Male parent         10.0 (5.5-14.5) 
Child 14-17 years    Female parent     12.9 (10.5-15.2) 
                                 Male parent         13.0 (9.5-16.5) 
Child 3-9 years        Female parent       4.4 (-5.7-14.6) 
                                 Male parent          3.9 (-2.4-10.2) 
Child 10-13 years    Female parent     13.3 (6.4-20.3) 
                                 Male parent         11.2 (6.8-15.7) 
Child 14-17 years    Female parent     10.4 (6.2-14.6) 
                                 Male parent         9.7 (6.8-12.7) 
Child 3-9 years        Female parent      10.6 (2.2-19.1) 
                                 Male parent          7.0 (0.0-13.9) 
Child 10-13 years    Female parent     8.7 (2.9-14.4) 
                                 Male parent         8.0 (3.0-13.1) 
Child 14-17 years    Female parent     10.9 (7.3-14.5) 
                                 Male parent         7.2 (3.8-10.6) 
Parent SSRI adherence (high vs. low) 
Risk difference (%) (95% CI) of high child adherence 
Increased high child adherence in 




PDC: proportion days covered; Ref.: reference; RR: risk ratio; dx: diagnosis 
aMultivariable, full model with all child and parent-level variables with >2% prevalence; Variables with less than 
5% change in multivariable RR (i.e. 0.952<RR <1.05) not displayed and include (multivariable RR): female (1.04), 
prior contact with psychiatrist (1.03), ICD-9 codes for potential anxiety-related symptoms (0.97), 3+ anxiety 
diagnoses before SSRI initiation (1.04), adjustment disorder diagnosis (1.00), ADHD diagnosis (0.96), development 
delay/learning disability diagnosis (1.03), disruptive behavior/oppositional defiant disorder diagnosis (0.96), other 
episodic mood disorder diagnosis (1.00), sleep disorder diagnosis (0.97), antidepressant (0.97), benzodiazepine 
(0.99), ADHD medication (0.98), antipsychotic (1.02), hydroxyzine (0.95), opioid (0.97), prescription medication 
use (4+=0.98, 2-3=1.00, 0-1=reference), problem-oriented outpatient visit count (6+=1.04, 2-5=1.02, 0-
Age, 3-9 y                   1.13 (1.10-1.15) 
        10-13 y                   1.12 (1.10-1.14) 
        14-17 y                         Ref. 
Anxiety disorder, GAD         Ref. 
     OCD       1.09 (1.07-1.12) 
     PTSD     0.79 (0.76-0.83) 
     Panic disorder     0.95 (0.92-0.99) 
     Social phobia     1.05 (1.01-1.09) 
     Unspecified     0.99 (0.97-1.00) 
     Other      1.00 (0.97-1.03) 
     Multiple diagnoses    1.08 (1.04-1.12) 
Provider type, psychiatry          Ref. 
     Family practice     0.89 (0.87-0.92) 
     Pediatrics     1.02 (0.99-1.05) 
     Psychologist     0.99 (0.96-1.01) 
     Multi-specialty group    1.00 (0.96-1.04) 
     Other      0.97 (0.95-1.00) 
     Unknown     0.99 (0.96-1.02) 
Psychotherapy, none          Ref. 
    1-4 claims     1.09 (1.07-1.11) 
    5+ claims     1.13 (1.11-1.16) 
Depression, Inpatient dx    1.11 (1.05-1.18) 
    Specific dx     1.01 (0.99-1.03) 
    General dx     1.00 (0.97-1.02) 
     No depression dx          Ref.  
Substance abuse     0.77 (0.73-0.81) 
Region, northeast           Ref. 
    North central     0.98 (0.96-0.99) 
    South      0.90 (0.88-0.91) 
    West      0.95 (0.93-0.97) 
    Unknown     0.99 (0.95-1.04) 
Acne dx      1.07 (1.05-1.09) 
Psychological evaluation    1.10 (1.08-1.12) 
Well visit      1.11 (1.09-1.12) 
ER visit      0.93 (0.91-0.94) 
Parent, SSRI low PDC          Ref.  
    High SSRI PDC     1.17 (1.14-1.20) 
    No SSRI PDC     1.05 (1.02-1.07) 
Parent, statin low PDC           Ref.  
    High statin PDC     1.11 (1.07-1.14) 
    No statin PDC     1.02 (0.98-1.05) 
Parent, antihypertensive PDC         Ref.  
    High antihypertensive PDC   1.08 (1.05-1.13) 
    No antihypertensive PDC    1.06 (1.02-1.09) 
Parent, substance abuse    0.86 (0.83-0.89) 
Parent, well visit     1.05 (1.04-1.06) 
Increased child adherence Decreased child adherence 
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1=reference), psychiatric-related inpatient admission (0.98), non-psychiatric-related inpatient admission (0.99), 
allergic rhinitis (1.02), asthma (0.98), cardiac disorder (1.03), dysthymia (1.00), fainting/dizziness (1.00), 
gastroesophageal reflux disease (1.01), migraine (1.01), scoliosis (1.05), injury: fracture/sprain (0.99), injury: head 
injury (0.95), injury: other (0.98), parent aged 50+ years (1.04), parent anxiety diagnosis (0.99), parent depression 
diagnosis (0.98), parent adjustment disorder diagnosis (0.99), other parent psychiatric diagnosis (1.01), parent 
benzodiazepine prescription (0.97), parent psychotherapy claims (1.00) 
 




CHAPTER 5: INCIDENCE OF MENTAL HEALTH HOSPITALIZATIONS, INPATIENT 
TREATED SELF-HARM, AND EMERGENCY ROOM VISITS FOLLOWING A NEW 
ANXIETY DIAGNOSIS IN CHILDREN AND ADOLESCENTS, UNITED STATES 2005-2014 
5.1. INTRODUCTION      
 Anxiety disorders are one of the most common mental illnesses in children and adolescents with 
estimates of current worldwide prevalence from 2%1 to 7%.2 In the United States (US) estimates of the 
lifetime prevalence of pediatric anxiety range from 15-20%3,28 with a third of individuals having an 
anxiety disorder by age 75.11 Symptoms of anxiety disorders often begin during childhood,10,11 making 
childhood an important age to consider the effects of anxiety. Children with anxiety disorders are at a 
heightened risk for subsequent anxiety disorders, depression, alcohol use, and substance abuse.6-9,31,37  
Anxiety disorders can have a sustained impact on daily life, ranking 23rd in causes of global 
disability-adjusted life years (DALYs) in children4 and individuals with anxiety disorders have 
demonstrated high utilization of healthcare services.32,102-104 In 2013, anxiety disorders were 20th in 
conditions with the largest personal health care spending in the US for children <20 years of age, totaling 
3.4 billion US dollars with 8.3% spent in inpatient settings, 3.8% on pharmaceuticals, and 82.1% in 
ambulatory care.178  
Emergency room (ER) visits, mental health related hospitalizations, and self-harm events are 
serious events that place a significant burden on the patient, caregivers, or healthcare 
system.102,106,107,179,180 In 2010 suicide was the 4th leading cause of death in children 5-14 years, 3rd in 
children 15-24 years.109 While the causal effect of anxiety on suicide in children is not established, 
anxiety has been shown to be a risk factor for suicide related behaviors in children.113 In 2011 the rate of 
inpatient hospitalizations related to mental health in children was 26/10,000 with a mean cost of $5,805 
per hospitalization and mean length of stay of 7 days.108 While relatively uncommon in the overall 
population, mental health related hospitalizations occurred in 7% of Medicaid enrolled children with a 
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mental health diagnosis.106 ER visits are common in children, with 18% of US children having an ER visit 
in a year period,109 injury being a common cause for pediatric ER visits.111 Between 2009 to 2011, around 
1.2 million ER visits for anxiety occurred with 6% of occurring in children under 18 years.103  
Previous important work has described how many serious events are related to anxiety,108 but 
there is less work longitudinally evaluating how many children with anxiety typically experience one of 
these events. Describing the risk of serious, impactful events in children newly diagnosed with an anxiety 
disorder can help inform clinicians, caregivers and patients at a time when information may be 
particularly sought-after. This information can contribute to the clinician’s larger discussion with 
caregivers and patients on the importance of managing symptoms, when to seek additional care, and the 
impact of co-morbid psychiatric conditions. Additionally, comparing the risk of events in children with 
anxiety vs. similar children without anxiety can provide context to further guide expectations and focus 
research efforts.  
Therefore, in a cohort of commercially insured children newly diagnosed with anxiety in an 
office setting we aimed to estimate the risk of mental health related hospitalizations, inpatient treated self-
harm, and ER visits overall and by age and the presence of psychiatric co-morbidities. We also estimated 
the incidence of these events in a similar population of commercially insured children without diagnosed 
anxiety.  
5.2. METHODS 
5.2.1. Datasource & study population  
We used Truven Health Analytics’ MarketScan Commercial Claims and Encounters database. 
We utilized data from January 1, 2004 to December 31, 2014, including inpatient admissions and 
services, outpatient services, outpatient dispensed prescriptions, and health plan enrollment files.  
 We identified a population of children (3-17 years) newly diagnosed with an anxiety disorder 
from 2005-2014. We selected the first anxiety diagnosis recorded in database history (2004-2014). An 
anxiety diagnosis was defined as an ICD-9-CM code (293.84, 300.0x, 300.2x, 300.3x, 309.21, 309.81, 
313.23) corresponding to anxiety disorders in the Diagnostic and Statistical Manual of Mental Disorders, 
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Fourth Edition (DSM-IV)181 which included post-traumatic stress disorder (PTSD) and obsessive 
compulsive disorder (OCD). We required children to have at least one year of continuous insurance 
enrollment (with prescription benefits and mental health services coverage) prior to the first observed 
anxiety diagnosis; this was to increase the likelihood that we identified a new anxiety diagnosis (Figure 
5.1). For example, this requirement removed children with a first anxiety diagnosis in the few months 
after insurance coverage began, since with the limited history we cannot determine if that diagnosis 
represented a new diagnosis. We excluded children with a diagnosis of bipolar disorder (296.0x, 296.4x-
.8x), personality disorder (301.x), schizophrenia (295.x), and autistic disorder (299.00) as it is likely that 
children with these conditions have more complex history and treatment regimens with anxiety a 
secondary diagnosis.  
 We additionally excluded children with anxiety-related treatments in the year before their new 
anxiety diagnosis as we aimed to identify children naïve to anxiety treatment. We excluded children with 
a dispensed SSRI prescription or a recorded psychotherapy session (CPT code) in the year prior to the 
new anxiety diagnosis. We further excluded children with a benzodiazepine, buspirone, other 
antidepressant, hydroxyzine, or antipsychotic prescription in the prior year as these can be used to treat 
anxiety, and antipsychotics are used to treat some of the co-morbid conditions we excluded. We did allow 
other baseline prescription medications that are sometimes used to treat anxiety (ex. beta-blockers, 
anticonvulsants, clonidine/guanfacine) since these medications are rarely used as an initial anti-anxiety 
pharmacotherapy(Chapter 1) and have primary non-anxiety indications.  
 Finally, the cohort was restricted to children with a new anxiety diagnosis in an office setting 
(83%). This restriction was to focus on a more similar, clinically relevant subset of children and exclude 
children diagnosed with anxiety outside an office (i.e. inpatient hospitalization, ER visit, urgent care) who 
likely had a different trajectory leading to their diagnosis.  
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Incident event definitions 
Children were followed beginning the day after their new office-based anxiety diagnosis for up to 
2 years. We identified the first event of interest per child. A mental health related hospitalization was 
defined as an inpatient admission record with a psychiatric diagnosis (ICD-9-CM code=290-319) in any 
placement on the inpatient admission record. For a secondary definition we defined a mental health 
related hospitalization as an inpatient admission record with a psychiatric diagnosis in the primary 
diagnostic position.182 A treated self-harm event was defined as an inpatient record with an ICD-9-CM 
external cause code (E-codes: E950-E958) for intentional suicide and self-inflicted injury.183-185 For 
another secondary outcome we examined recorded suicide ideation (ICD-9 code=V62.84, available late 
2005) to observe how often the code was used, acknowledging very low sensitivity.186  
ER visits were defined as a claim with a category of service designated as an ER.187 Anxiety-
related ER visits were defined as ER visits with a diagnostic code for an anxiety disorder used to define 
anxiety in the patient population or a diagnostic code for adjustment disorder with anxiety (309.24, 
309.28) or acute stress disorder (308.x). Injury-related ER visits (including poisoning) were defined 
broadly as ER visits with an ICD-9-CM diagnostic code 800-999,182 excluding late effects of injuries 
(905-909), or E800-999, excluding late effects (E929, E959, E969, E977, E989, E999) and E849 (place of 
the injury). 
5.2.2. Comparison cohort 
A comparison cohort included children in the same database who matched with a child in the 
anxiety cohort on age, sex, date (defined as a recorded diagnostic code on the date a child was diagnosed 
with anxiety, termed “match date” for the comparison cohort), and region (Figure 5.1). From all possible 
matches (15 million children), the same inclusion requirements used to define the anxiety cohort were 
applied: 1) prior year with prescription and mental health services insurance coverage, 2) no diagnosis of 
anxiety prior to or on the match date, 3) no psychotherapy, SSRI, benzodiazepine, buspirone, other 
antidepressant, antipsychotic, or hydroxyzine use in the prior year, 4) no diagnosis of schizophrenia, 
personality disorder, autistic disorder, and bipolar disorder, and 5) at least one diagnosis on the match 
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date from an office setting. From the remaining possible matches (8 million children) we randomly 
selected up to 10 matches per child with anxiety. A child in the comparison cohort was only allowed to 
match once even if they matched to multiple children. Children in the anxiety cohort were allowed in the 
comparison cohort if they matched to a period before their anxiety diagnosis (3% of the comparison 
cohort were children from the anxiety cohort). We defined and collected covariates and incident events in 
the same manner for the comparison cohort as the anxiety cohort. 
5.2.3. Primary patient covariates 
For each child, age, sex, year of first anxiety diagnosis (or year of match date), and provider of 
first anxiety diagnosis (or provider of diagnoses on match date) were included. For children with anxiety 
we grouped children by the specific anxiety disorder diagnosis. In the year prior to a child’s new anxiety 
diagnosis (or match date), we created indicators for psychiatric and non-psychiatric co-morbidities, 
inpatient and outpatient visits, ER visits, and medication use. A primary variable of interest was 
psychiatric co-morbidity, defined as 1) no psychiatric co-morbidity diagnosis in the prior year, 2) co-
morbid depression diagnosis in the prior year (inpatient or outpatient ICD-9-CM code=296.2x, 296.3x, 
300.4x, 309.1x, or 311.xx), and 3) a non-depression psychiatric co-morbidity (ICD-9-CM: 290-319, 
excluding anxiety and depression diagnoses). As the study cohort is restricted to treatment naïve children, 
a proportion of children previously treated for depression or other psychiatric co-morbidities were, by 
default, excluded. The primary covariates were used to describe the study population, as stratification 
criteria, and to compare the anxiety cohort with the comparison cohort. 
5.2.4. Statistical analysis  
We described the cohort of children newly diagnosed with anxiety and the comparison cohort. 
We used Kaplan Meier estimator to estimate the cumulative incidence and associated 95% confidence 
interval (CI), of each incident event. Children were censored at the occurrence of the first event, insurance 
disenrollment, end of data (12/31/2014), or 2 years after the anxiety diagnosis (or match date). The 
cumulative incidence was reported at 1 month, 6 months, and 1 year after the anxiety diagnosis (or match 
date) and displayed up to 2 years. We stratified results by age group and psychiatric co-morbidity. For the 
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comparison cohort we only present the stratification with no baseline psychiatric co-morbidities, given the 
low prevalence of psychiatric co-morbidities. The analysis for recorded suicide ideation was restricted to 
children diagnosed with anxiety (or match date) from 2006-2014 since the ICD-9 code was not available 
until late 2005. For a sensitivity analysis we examined the incidence in a cohort of children with a second 
anxiety diagnosis in the 3 months after their first diagnosis, as 1 diagnostic code may not represent a true 
diagnosis, i.e. claim was rule-out diagnosis, data entry error, or patient referred to specialist for 
assessment and not subsequently diagnosed.188 
5.3. RESULTS 
From 2005-2014 there were 198,450 children with a new anxiety diagnosis in an office setting 
without prior anxiety treatment. Children had a median age of 12 years (IQR: 8-15 years) and 45% were 
male (Table 5.1). The majority had a new anxiety diagnosis of unspecified anxiety (53%), followed by 
25% diagnosed with generalized anxiety disorder then 5% with OCD and 4% with PTSD. A psychiatrist 
or psychologist/therapist was associated with the anxiety diagnosis in 46% of children followed by 21% 
diagnosed by a pediatrician. Six-percent of children had a baseline depression diagnosis, with 86% of 
them having a depression diagnosis at least 30 days prior to the anxiety diagnosis. The average length of 
follow-up insurance enrollment was 558 days (IQR: 233-1164) in the anxiety cohort and 658 days (IQR: 
337-1213) in the comparison cohort. 
For the comparison cohort, 10 matches were identified for >99% children in the anxiety cohort. 
The comparison cohort had a lower baseline prevalence of psychiatric co-morbidities, medication 
utilization, outpatient visits, and selected non-psychiatric co-morbidities (Table 5.1). Of the top 70% most 
common ICD-9 diagnoses recorded on the match date, 37% had a code related to a vaccination or routine 
visit/exam, 3% were psychiatric diagnoses, 8% were injury/pain related diagnoses, 32% related to general 
acute concerns (ex. fever, ear infection, common cold), 8% were related to conditions likely requiring 
repeat visits but less severe (ex. acne, skin infection, chronic rhinitis), and 11% diagnoses for potentially 
for more chronic, severe conditions (ex. asthma, obesity, unspecified chest pain).   
 
 75 
5.3.1. Cumulative incidence in children with diagnosed anxiety 
Table 5.2 displays the 1-month, 6-month, and 1-year cumulative incidence of each event in 
children with anxiety (Figure 5.2, 5.3). One-year after a new anxiety diagnosis 2.0% of children had a 
mental health related hospitalization. The incidence lowers slightly to 1.7% (95% CI: 1.6-1.8) when 
restricting to hospitalizations with a mental health diagnosis listed in the primary position. Around 6 per 
10,000 (0.06%) children had an inpatient, treated self-harm event 6-months after a new anxiety diagnosis 
and 8 per 10,000 by 1 year. A recorded suicide ideation claim occurred in 1.0% of children in the year 
after an anxiety diagnosis. ER visits were common with 12% of children having an ER visit within 6-
months and 20% within 1 year. Anxiety-related ER visits occurred in 1.4% of children a year after a new 
anxiety diagnosis.  
5.3.2. Cumulative incidence in the comparison cohort 
In the comparison cohort, the cumulative incidence of each outcome was lower than in children 
with anxiety (Table 5.2, Figures 5.2, 5.3). One-year after the match date 0.5% of children had a mental 
health related hospitalization. Around 1 in 10,000 children had an inpatient treated self-harm event by the 
end of one-year. The incidence of an ER visit was 8% at 6-months and 13% at 1-year and injury related 
ER visits at 4% and 7% respectively.  
5.3.3. Age and psychiatric co-morbidity stratification  
The cumulative incidence of each event varied by age at anxiety diagnosis and the presence of 
baseline psychiatric co-morbidities (Table 5.3: 1-year incidence). The incidence of mental health related 
hospitalizations (6-months: 5.1%, 95% CI:4.6-5.6), inpatient treated self-harm events (6-months: 0.43%, 
95% CI:0.30-0.60), and anxiety-related ER visits (6-months: 2.2%, 95% CI:1.9-2.6) following a new 
anxiety diagnosis occurred more frequently in children 14-17 years with co-morbid depression compared 
to other ages and co-morbidity groups (Figure 5.4). In turn, in children 14-17 years without a psychiatric 
co-morbidity diagnosed at baseline, the incidence of mental health related hospitalizations at 6-months 
was 1.6% (95% CI:1.5-1.7), inpatient treated self-harm events 0.07% (95% CI:0.05-0.10), and anxiety-
related ER visits 1.4% (95% CI:1.3-1.5). 
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Restricting the comparison cohort to children without any baseline psychiatric co-morbidity 
(N=1,805,682, 91%), the cumulative incidence of events remained lower than in children with anxiety 
and no psychiatric c-morbidity (Table 5.3). 
5.3.4. Sensitivity analysis 
In children with a second recorded anxiety diagnosis at least 90 days after the first diagnosis 
(n=113,437, 57%), the incidence of ER visits overall and injury related ER visits was similar in children 
without a follow-up anxiety diagnosis within 90 days (n=85,013). There was an increased cumulative 
incidence in inpatient treated self-harm events, mental health related hospitalizations, and anxiety related 
ER visits in children with a second, follow-up anxiety diagnosis (Table 5.4). For example, 2.4% (95% CI: 
2.3-2.5) had a mental health related hospitalization 1 year after a new anxiety diagnosis in the cohort with 
a second anxiety diagnosis compared to 1.3% (95% CI: 1.2-1.4) in children with one anxiety diagnosis.  
5.4. DISCUSSION 
Serious, high healthcare utilizing events were relatively common in the months after children 
were newly diagnosed with anxiety in an office setting. Older children with co-morbid depression had a 
higher incidence of mental health related hospitalizations, anxiety-related ER visits, and inpatient treated 
self-harm events. However, these events still occurred in children with anxiety and no baseline psychiatric 
co-morbidity and at a higher incidence than in a similar population of children without anxiety. Our 
findings add to the literature on pediatric anxiety to inform patients, caregivers, and providers at a time 
when understanding the condition and future risks may be particularly useful.   
5.4.1. Variation by age and psychiatric co-morbidity  
We observed a higher incidence of treated self-harm, mental health related hospitalizations, and 
ER visits in older children. This is consistent with previous findings; the rate of ER visits for anxiety or 
stress disorders in children increased substantially by age with the rate in children 10-14 years 6-fold 
higher than children 5-9 years, and even higher for children 15-17.180 In another example, anxiety-related 
ER visits occurred at a rate of 0.8 per 1,000 children <15 years of age and 5.4 per 1,000 aged 15-19 
years.189 The rate of self-harm injury also increases with age (i.e. 2012-2014 rate: age 5-9 years: 4 per 
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100,000; age 10-14: 154 per 100,000, 15-19: 390 per 100,000).190 To note, we measure age at a new, 
recorded anxiety diagnosis and we do not know the age when symptoms began.  
Children with a baseline depression diagnosis prior to or on the date they received a new anxiety 
diagnosis had a higher risk for the events considered than children without co-morbid depression. This is 
consistent with other research including higher reported medical costs in individuals with anxiety and co-
morbid depression compared to individuals with only anxiety.191 Co-morbid depression is highly 
prevalent in those with anxiety192 with depressive disorders most often developing secondary to pediatric 
anxiety.9 Given our baseline restrictions (no prior antidepressants and psychotherapy) and that we 
examined children with a new anxiety diagnosis, only 6% of children in our cohort had diagnosed 
depression. Depression is especially associated with self-harm events193 and monitoring suicide risk in 
children with anxiety and co-morbid depression is recommended.31 While inpatient treated self-harm 
events were much less common in children without a co-morbid depression diagnosis at baseline, they did 
occur in a small number. The prevalence of depression is expected to increase over time and 
understanding if and when depression symptoms developed in children would further inform the results.  
Further, baseline anxiety severity, which we cannot directly measure, would be another important 
factor to consider in addition to age and psychiatric co-morbidity. We saw a higher incidence of mental 
health related events in children with a follow-up anxiety diagnosis. Children with a recorded follow-up 
anxiety diagnosis may have higher baseline severity. Children without a follow-up anxiety diagnosis 
within 3 months may include children with more mild anxiety, but also children with moderate to severe 
anxiety that do not receive follow-up care.   
5.4.2. Comparison cohort considerations  
Prior studies found serious events to occur more frequently in individuals with anxiety disorders 
compared to individuals without anxiety. For example, adults with anxiety had higher mental-health 
related inpatient admissions, inpatient visits, and ER visits than controls,104,194 including adults with 
anxiety and no co-morbid depression.104 In Denmark, the incidence of death by suicide was 0.61% over 
15 years in adults with PTSD compared to 0.04% in the comparison cohort.115 Not specific to anxiety 
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disorders, 34% of Medicaid enrolled children (0-21 years) with a mental health diagnosis had an ER visit 
in 1999 compared to 20% in other enrolled children.106  
Some of the observed differences in incidence between the anxiety and comparison cohorts could 
be related to baseline differences in co-morbidities, as the anxiety cohort had higher recorded co-
morbidities and prior healthcare utilization. In the literature, selected comorbidities were higher in adults 
with anxiety than control groups104,194 along with a higher Charlson comorbidity index prior to a stress 
disorder diagnosis compared to a control group.115 Relatedly, we do not investigate a causal relationship 
between anxiety and the events considered; the differences in the cumulative incidences between the 
anxiety and comparison cohorts should not be interpreted causally. While we have the date of a new 
anxiety diagnosis, we do not know when anxiety first developed and cannot ensure temporality for 
baseline covariates. For example, somatic symptoms are common in children with anxiety and can 
include chest pain, abdominal pain/stomachaches, and headaches.32,195,196 The baseline differences we see 
in diagnoses for migraines/chronic headaches and cardiac disorders could be diagnoses resulting from the 
anxiety disorder, before anxiety was recognized. The differences in baseline co-morbidities are part of the 
full picture when estimating how often events are experienced in a population with and without an anxiety 
disorder.  
The comparison cohort in our study is also not meant to provide incidence estimates for the 
national, general population, but in a commercially insured cohort with the same baseline exclusions as 
the anxiety cohort (ex. naïve to certain psychiatric treatments/diagnoses). For reference, in the US the 
estimated annual percentage of privately insured children 6-17 years in with an ER visit was 16% in 1997, 
15% in 2010, and 11% in 2012.111 This is fairly similar to our comparison cohort (2005-2014), with 13% 
of children 3-17 years with an ER visit in a year.  
5.4.3. Timing and follow-up of events  
For treated self-harm, mental health related hospitalizations, and anxiety related ER visits we see 
greater separation in the cumulative incidence between the comparison and anxiety cohorts in the first 
months after the anxiety diagnosis. We expect more events following a new anxiety diagnosis, as children 
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with a new anxiety diagnosis are likely experiencing symptoms at a level that resulted in seeking 
advice/care from a medical provider. In contrast, many children in the comparison cohort were matched 
on a diagnosis associated with routine care (vaccination, well visit) and we would not expect to see an 
increase in events following those diagnostic codes. Future research could examine the care received 
leading up to and at an anxiety diagnosis but also the care received during and after each of these serious 
events to determine where improvements are needed. Only 13% of all aged individuals saw a mental 
health specialist during an anxiety-related ER visit.103 In Canada, almost 3% of children with an ER visit 
for anxiety or stress-related returned within 3 days for another mental health related problem and only 
30% of children had a follow-up visit 7 days after discharge.180  
5.4.4. Treated self-harm estimates, part of the picture 
The treated, inpatient self-harm events and recorded suicide ideation we observe represent a small 
fraction of all suicidal ideation and behavior. The results presented may be considerably underestimated 
and should be viewed as a lower limit of the event incidence. This is partially because our definition for 
self-harm required a recorded E-code, which are often incomplete in claims data,197,198 with low 
sensitivity but high specificity in identifying suicide attempts.199 The ICD-9 code for suicide ideation was 
found to be present in only 3% of patients with suicide ideation recorded in health record notes.186 Suicide 
ideation and behavior are self-reported more frequently than our specific event definitions; in high school 
students, 16% reported they had seriously considered suicide and 8% reported they had attempted suicide 
one or more times during the prior year.29,111 In the CAMS 12-week randomized controlled trial of 
children with moderate to severe anxiety 0.8% reported self-harm behavior, 2.3% suicide ideation, and no 
suicide attempts.70 We saw a lower incidence of treated self-harm events than the trial population 
especially considering the trial excluded children with baseline depression; however, this is a component 
of our definition and that we identified children at a new diagnosis and included children with all severity 
levels. In a longitudinal study, children treated with cognitive behavioral therapy for anxiety (n=66) were 
followed for 7-19 years and 9% had made at least 1 suicide attempt and 27% reported experiencing 
 
 80 
suicidal ideation.112 These findings highlight that risk can remain over time and are important to consider 
past the 2 years we evaluated in our study.  
5.4.5. Management of anxiety disorders  
Children and adolescents often do not seek professional help for mental health problems200 
including children and adolescents with anxiety disorders, despite the impairments. Eighteen-percent of 
adolescents with anxiety reported receiving care for their condition, 29% of adolescents with a severe 
anxiety disorder, lower than care in adolescents with depression (38%) and ADHD (60%)201 similar to 
other findings.39 For some children with mild severity, education and support may help manage 
symptoms, but anxiety should be monitored at follow-up visits for changes.32 Typically the course for 
pediatric anxiety disorders is thought to be chronic and persistent;127 the majority of children in the 
Child/Adolescent Anxiety Multi-Modal Extended Long-term Study (CAMELS) experienced relapse or 
chronic anxiety during the 5 years of follow-up.202 The costs of untreated anxiety disorders could 
potentially be reduced with appropriate care.103 While we did not consider treatment or care received 
following a new anxiety diagnosis or know the baseline severity, the incidence of the evaluated events 
hints to the fact that many children with anxiety may need improved care.  
5.4.6. Limitations 
Limitations of the work should be considered. As we mention previously, treated self-harm and 
suicide ideation are underestimated based on our definition and results should be viewed as the lower 
limit of the actual incidence. We cannot be certain we are identifying the date of each child’s first anxiety 
diagnosis. Children may have been previously diagnosed and children with a recorded ICD-9 anxiety 
diagnosis may not meet the clinical criteria for an anxiety disorder. Relatedly, children in the comparison 
cohort could have had undiagnosed anxiety. We miss any outcomes that resulted in death if the patient 
was not first admitted to the hospital; given the age of the study cohort (3-17 years), death does not 
account for substantial loss to follow-up and the competing risk of death would have a minimal influence 
on estimates. Differences in recorded suicide ideation between the anxiety cohort and the comparison 
cohort could be related to reporting opportunities; children subsequently receiving psychotherapy may 
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have more opportunities to report suicidal ideation. Our definition of injury related ER visits is broad and 
allows an injury-related ICD-9 diagnostic code to be in any diagnostic position (ex. not just the 
primary/secondary cause). When considering co-morbid depression, administrative codes for depression 
have shown reasonable concordance with medical records;203 however, undiagnosed, unrecorded 
depression is missed. We additionally exclude children with previously treated depression given 
exclusion criteria. As stated previously, we recognize some treated self-harm behaviors were missed, but 
it is very likely that the outcomes identified were true events. We restricted our analysis to children 
diagnosed with anxiety in an office setting to provide information on a clinically relevant subset of 
children. While outside the scope of this study, children with an anxiety diagnosis first recorded outside 
an office are an important subset to describe further. Our comparison cohort was meant to provide context 
for the incidence of events under the same definitions and in a similar population of children, it is possible 
that due to inclusion requirements we selected a sicker or healthier subset than intended.  
5.4.7. Conclusion 
Following a new anxiety diagnosis, a significant proportion of children experience a mental 
health related hospitalization, inpatient treated self-harm, or an ER visit. The incidence of events in 
children with anxiety varied by age and by the presence of psychiatric co-morbidities and occur more 
often than in children without anxiety. Describing the incidence of these events adds to understanding the 
impact and burden of pediatric anxiety disorders. The information can possibly encourage proper 





Table 5.1. Patient characteristics of children newly diagnosed with anxiety and children in the comparison 
cohort 
 
Children with new 
anxiety diagnosis 
(n=198,450) 
Comparison cohort  
 (n=1,980,082) 
 No. % No. %  
Matching factors     
Male  89,341  45.0%  891,444  45.0% 
Age, Median (IQR) 12 (8-15) 
 
 12 (8-15)  
      3-9 years  65,052  32.8%  648,983  32.8% 
     10-13 years  56,462  28.5%  563,197  28.4% 
     14-17 years  76,936  38.8%  767,902  38.8% 
Year of treatment initiation 
        2005-2006  15,582  7.9%  155,025  7.8% 
    2007-2009  37,197  18.7%  370,582  18.7% 
    2010-2012  78,245  39.4%  781,564  39.5% 
    2013-2014  67,426  34.0%  672,911  34.0% 
Region of first anxiety diagnosis     
    North central  53,987  27.2%  539,754  27.3% 
    Northeast  41,423  20.9%  413,809  20.9% 
    South  61,423  31.0%  614,178  31.0% 
    Unknown  2,313  1.2%  19,512  1.0% 
    West  39,304  19.8%  392,829  19.8% 
Child characteristicsb     
Initial anxiety diagnosis     
    Unspecific anxiety 104,838 52.8% -  
    Generalized anxiety disorder 50,433 25.4% -  
    OCD 9,816 4.9% -  
    PTSD 8,066 4.1% -  
    Panic disorder 6,861 3.5% -  
    Separation anxiety disorder 5,674 2.9% -  
    Other, multiplea 12,762 6.4% -  
Provider type, anxiety diagnosis/match date 
        Psychiatry; Psychologist, therapist  91,539  46.1%  39,781  2.0% 
    Pediatrics  42,633  21.5%  702,458  35.5% 
    Family practice  20,309  10.2%  266,621  13.5% 
    Multi-specialty group  7,615  3.8%  101,543  5.1% 
    Other  26,012  13.1%  621,388  31.4% 
    Unknown, multiple  10,342  5.2%  248,291  12.5% 
Anxiety related symptoms, prior 90 days  28,339  14.3%  140,823  7.1% 
Psychiatric co-morbidities 
        Any other psychiatric diagnosis  53,963  27.2%  174,400  8.8% 
    Depression  12,294  6.2%  16,270  0.8% 
    Adjustment disorder  6,619  3.3%  26,423  1.3% 
    ADHD  23,895  12.0%  95,854  4.8% 
    Developmental delay, learning disability  5,204  2.6%  16,387  0.8% 
    Disruptive behavior, conduct disorder  5,428  2.7%  10,136  0.5% 
    Other episodic mood disorder  1,653  0.8%  2,830  0.1% 
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    Sleep disorder  5,917  3.0%  14,255  0.7% 
    Substance abuse  1,529  0.8%  4,931  0.2% 
Suicidality 
        Self-harm  124  0.1%  144  0.0% 
    Suicide ideation  488  0.2%  708  0.0% 
Medication use in prior year 
        Count, therapeutic subgroups 2 (1-3) 
 
 1 (0-3)  
          0-1  92,765  46.7%  1,034,653  52.3% 
         2-4  82,995  41.8%  793,672  40.1% 
         5+  22,690  11.4%  151,757  7.7% 
    ADHD medication  19,895  10.0%  106,283  5.4% 
    Opioid  16,759  8.4%  164,418  8.3% 
Non-psychiatric co-morbidities 
        Acne  14,870  7.5%  145,646  7.4% 
    Allergic rhinitis  24,822  12.5%  195,983  9.9% 
    Anemia  2,414  1.2%  20,731  1.0% 
    Asthma  18,603  9.4%  154,189  7.8% 
    Cancer diagnosis  486  0.2%  4,533  0.2% 
    Cardiac disorder  3,188  1.6%  17,629  0.9% 
    Dysrhythmia  1,886  1.0%  10,267  0.5% 
    Diabetes  1,067  0.5%  10,345  0.5% 
    Epilepsy, convulsions  2,461  1.2%  15,583  0.8% 
    Fainting, dizziness  6,865  3.5%  33,827  1.7% 
    Gastro-esophageal reflux disease  5,480  2.8%  19,576  1.0% 
    Hearing loss/problems  3,844  1.9%  29,311  1.5% 
    Injury 
            Fracture, sprain  25,280  12.7%  290,402  14.7% 
        Head injury  6,169  3.1%  54,348  2.7% 
        Poisoning  595  0.3%  1,839  0.1% 
        Other  37,935  19.1%  358,908  18.1% 
    Migraine, chronic headache  4,042  2.0%  22,211  1.1% 
    Overweight, obese  3,257  1.6%  23,463  1.2% 
    Spine curvature  3,551  1.8%  32,009  1.6% 
    Visual disturbance/loss  3,527  1.8%  22,959  1.2% 
Well visit   115,380  58.1%  1,221,235  61.7% 
Outpatient, problem oriented visit 3 (1-5) 
 
 2 (1-4)  
      0-1  50,283  25.3%  653,417  33.0% 
     2-5  101,050  50.9%  1,011,636  51.1% 
     6+  47,117  23.7%  315,029  15.9% 
Inpatient admissions 
        Psychiatric diagnosis  546  0.3%  1,519  0.1% 
    No-psychiatric diagnosis  2,733  1.4%  24,063  1.2% 
Emergency room visit 
        None  160,212  80.7%  1,652,013  83.4% 
    1 visit  29,433  14.8%  264,833  13.4% 
    2+ visits  8,805  4.4%  63,236  3.2% 
IQR: interquartile range; PTSD: post-traumatic stress disorder; OCD: obsessive-compulsive disorder; 
ADHD: attention-deficit/hyperactivity disorder 
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aAgoraphobia 0.4%; anxiety due to medical condition 0.5%; social phobia 1.8%; other, specific phobia 
1.5%; other anxiety 1.1%; selective mutism 0.5%; multiple specific anxiety diagnoses 0.7% 






Table 5.2. Cumulative incidence of serious events at 1 month, 6 months, and 1 year in children following a new anxiety diagnosis and in the 
comparison cohort  




Risk (95% CI) 
No. 
events 
Risk (95% CI) No. events Risk (95% CI) 
Mental health related hospitalization       
       Children with anxiety 642 0.33% (0.30-0.35) 2,189 1.20% (1.15-1.25) 3,248 1.95% (1.89-2.02) 
       Comparison cohort  1,168 0.06% (0.06-0.06) 4,827 0.26% (0.26-0.27) 8,318 0.49% (0.48-0.50) 
Inpatient, treated self-harm       
       Children with anxiety 31 0.02% (0.01-0.02) 101 0.06% (0.05-0.07) 131 0.08% (0.06-0.09) 
       Comparison cohort 20 0.00% (0.00-0.00) 126 0.01% (0.01-0.01) 230 0.01% (0.01-0.02) 
Anxiety-related ER visit       
       Children with anxiety 599 0.31% (0.28-0.33) 1,620 0.88% (0.84-0.93) 2,371 1.41% (1.36-1.47) 
       Comparison cohort 590 0.03% (0.03-0.03) 2,645 0.14% (0.14-0.15) 4,657 0.27% (0.27-0.28) 
ER visits (any)       
       Children with anxiety 5,198 2.7% (2.6-2.7) 21,173 11.7% (11.6-11.9) 32,518 19.8% (19.6-20.0) 
       Comparison cohort 34,573 1.8% (1.8-1.8) 145,612 7.9% (7.9-7.9) 233,108 13.5% (13.4-13.5) 
Injury-related ER visits       
       Children with anxiety 1,764 0.9% (0.9-0.9) 9,148 5.1% (5.0-5.2) 15,186 9.4% (9.3-9.5) 
       Comparison cohort 12,932 0.7% (0.6-0.7) 67,485 3.7% (3.7-3.7) 113,483 6.6% (6.6-6.7) 
Recorded suicide ideationa       
       Children with anxiety 312 0.17% (0.15-0.18) 1,080 0.62% (0.58-0.66) 1,626 1.02% (0.97-1.07) 
       Comparison cohort 435 0.02% (0.02-0.03) 2,021 0.11% (0.11-0.12) 3,597 0.22% (0.21-0.23) 








Table 5.3. One-year cumulative incidence of events after a new anxiety diagnosis in children stratified by age at anxiety diagnosis and co-morbid 




Mental health related 
hospitalization 









Risk (95% CI) 
No. 
events 
Risk (95% CI) 
No. 
events 









Age at anxiety 
diagnosis 
         
  
    3-9 years 65,052 229 0.4% (0.4-0.5) * - 233 0.4% (0.4-0.5) 8,988 17% (16-17) 4,198 8% (8-9) 
    10-13 years 56,432 789 1.7% (1.6-1.8) 22 0.04% (0.03-0.07) 621 1.3% (1.2-1.4) 8,388 18% (18-18) 4,348 9% (9-10) 
    14-17 years 76,936 2,230 3.5% (3.3-3.6) 109 0.17% (0.14-0.20) 1,571 2.3% (2.2-2.5) 15,142 24% (23-24) 6,640 11% (10-11) 
Psychiatric co-
morbiditya 
         
  
    Depression  12,294 630 6.3% (5.8-6.8) 46 0.43% (0.32-0.57) 301 3.1% (2.7-3.4) 2,629 27% (26-28) 1,187 13% (12-13) 
       3-9 years  1,056 * - * - * - 159 19% (16-22) 80 10% (8-12) 
       10-13 years 2,903 125 5.3% (4.4-6.3) 10 0.39% (0.20-0.70) 65 2.8% (2.2-3.6) 558 24% (22-26) 275 12% (11-14) 
       14-17 years 8,335 497 7.4% (6.8-8.0) 36 0.50% (0.36-0.69) 230 3.5% (3.0-3.9) 1,912 29% (28-31) 832 13% (12-14) 
    Other  41,669 757 2.2% (2.1-2.4) 20 0.06% (0.04-0.09) 449 1.3% (1.2-1.5) 6,903 21% (20-21) 3,297 10% (10-10) 
       3-9 years  16,691 118 0.9% (0.7-1.0) * - 78 0.6% (0.5-0.7) 2,441 18% (17-19) 1,101 8% (8-9) 
       10-13 years 12,456 186 1.9% (1.6-2.2) * - 123 1.2% (1.0-1.5) 1,838 18% (18-19) 966 10% (9-11) 
       14-17 years 12,522 453 4.4% (4.4-4.8) 19 0.18% (0.11-0.27) 258 2.5% (2.2-2.8) 2,624 26% (25-27) 1,230 12% (12-13) 
    None recorded 144,487 1,861 1.5% (1.5-1.6) 65 0.05% (0.04-0.07) 1,621 1.3% (1.2-1.4) 22,986 19% (19-19) 10,702 9% (9-9) 
       3-9 years  47,305 103 0.3% (0.2-0.3) * - 149 0.4% (0.3-0.4) 6,388 16% (16-16) 3,017 8% (7-8) 
       10-13 years 41,103 478 1.4% (1.3-1.5) 11 0.03% (0.02-0.06) 433 1.2% (1.1-1.3) 5,992 17% (17-18) 3,107 9% (9-10) 
       14-17 years 56,079 1,280 2.7% (2.6-2.9) 58 0.12% (0.09-0.15) 1,039 2.2% (2.0-2.3) 10,606 23% (22-23) 4,578 10% (10-10) 
Reference cohort, no psychiatric co-morbidityb         
       3-9 years  595,329 356 0.1% (0.1-0.1) * - 363 0.1% (0.1-0.1) 60,993 12% (12-12) 27,764 6% (6-6) 
       10-13 years 510,547 1,309 0.3% (0.3-0.3) 21 0.01% (0.00-0.08) 1,008 0.2% (0.2-0.2) 51,710 12% (12-12) 28,496 7% (6-7) 
       14-17 years 703,050 3,626 0.6% (0.6-0.6) 141 0.02% (0.02-0.03) 2,376 0.4% (0.4-0.4) 92,556 15% (14-15) 43,656 7% (7-7) 
*Not displayed due to low event count 
aBaseline psychiatric diagnoses given on the date of anxiety diagnosis or in the prior year 




Table 5.4. Sensitivity analysis: Cumulative incidence in the anxiety cohort restricted to children with a 
second anxiety diagnosisa 





Risk (95% CI) 
No. 
events 
Risk (95% CI) 
No. 
events 
Risk (95% CI) 
Children with a second anxiety 
diagnosis (n=113,437)a 
      
   Mental health related 
hospitalization 
516 0.46% (0.42-0.50) 1,663 1.56% (1.49-1.63) 2,379 
2.42% (2.32 -
2.51) 
   Inpatient, treated self-harm 25 0.02% (0.01-0.03) 80 0.08% (0.06-0.09) 99 0.10% (0.08-0.12) 
   Anxiety-related ER visits 594 0.53% (0.48-0.57) 1,439 1.33% (1.27 -1.40) 1,910 1.90% (1.81-1.98) 
   ER visit, any  3,211 2.8% (2.8-2.9) 12,622 12.0% (11.8-12.2) 19,233 19.8% (19.6-20.1) 
   Injury-related ER visits 1,076 1.0% (0.9-1.0) 5,457 5.2% (5.1-5.4) 9,018 9.5% (9.3-9.7) 
Children without a second 
anxiety diagnosis (n=85,013)a 
      
Mental health related 
hospitalization 
126 0.15% (0.13-0.18) 526 0.71% (0.65-0.77) 869 1.31% (1.22-1.40) 
Inpatient, treated self-harm * - 21 0.03% (0.02-0.04) 32 0.05% (0.03-0.07) 
Anxiety-related ER visits * - 181 0.26% (0.23-0.30) 461 
0.74 % (0.68-
0.82) 
ER visit, any  1,987 2.4% (2.3-2.5) 8,551 11.4% (11.2-11.7) 13,285 19.7% (19.4-20.0) 
Injury-related ER visits 688 0.8% (0.8-0.9) 3,691 5.0% (4.8-5.1) 6,168 9.3% (9.1-9.5) 
*Not displayed due to low event count 














Figure 5.2. Cumulative incidence of mental health related hospitalizations, inpatient treated self-harm, 
and anxiety related ER visits following a new anxiety diagnosis in children and in a comparison cohort  
  
Mental health related hospitalization 
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Figure 5.3. Cumulative incidence of ER visits and injury related ER visits following a new anxiety 






ER visits Injury related ER visits 
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a) Mental health related hospitalizations (Not shown: results for children with a non-depression 
psychiatric co-morbidity)  
 
b) Inpatient, treated self-harm (restricted to children 14-17 years at anxiety diagnosis given low event 
count in younger children)  
 
  
Co-morbid depression, 14-17 yrs 
Anxiety alone, 14-17 yrs 
Co-morbid depression, 10-13 yrs 
Anxiety alone, 10-13 yrs 
Anxiety alone, 3-9 yrs 
Co-morbid depression or anxiety alone, age at anxiety diagnosis (years) 
Years since new anxiety diagnosis 
C-morbid depression, 3-9 yrs 
Other psychiatric co-morbidity 
Co-morbid depression 
Anxiety alone 
Restricted to children age 14-17 years at the new anxiety diagnosis 
Years since new anxiety diagnosis 
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c) Anxiety related ER visits (Not shown: results for children with a non-depression psychiatric co-
morbidity), children aged 3-9 with co-morbid depression excluded due to low event count 
 
 
d) Injury related ER visits and overall ER visits (Not shown: results for children with a non-depression 
psychiatric co-morbidity) 
 
Figure 5.4. Cumulative incidence of a) mental health related hospitalizations, b) treated inpatient self-
harm, c) anxiety-related ER visits, and d) injury-related ER visits and overall ER visits following a new 
anxiety diagnosis by age at anxiety diagnosis and psychiatric comorbidity (diagnosed at baseline) 
 
Co-morbid depression, 14-17  







Anxiety alone, 10-13 
Anxiety alone, 3-9 
Years since new anxiety diagnosis 
Co-morbid depression, 14-17  
Solid purple: co-morbid depression, 10-13 years 
Solid blue: co-morbid depression, 3-9 years 
Dashed green: anxiety alone, 14-17 years 
Dashed purple: anxiety alone, 10-13 years 
Anxiety alone, 3-9 
Co-morbid depression, 14-17  
Anxiety alone, 3-9 
Years since new anxiety diagnosis Years since new anxiety diagnosis 
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CHAPTER 6: OVERALL DISCUSSION 
 6.1. SUMMARY OF FINDINGS 
The aims of this dissertation were to 1) describe the anti-anxiety medication prescribed to 
children with anxiety beginning pharmacotherapy and psychotherapy claims surrounding medication 
initiation, 2) estimate SSRI adherence in children with anxiety and determine if parent adherence can be 
used to predict child adherence, and 3) estimate the incidence of mental health related hospitalizations, 
treated self-harm events, and ER visits following a new anxiety diagnosis. The aims were addressed in a 
commercial claims database covering privately insured children in the US. We included children aged 3-
17 years with an anxiety diagnosis (defined with ICD-9 codes); the specific study cohort varied for each 
aim.  
In our first aim we found that the majority of children (70%) initiated anti-anxiety treatment with 
an SSRI. This included a small, but significant, proportion (7%) of children initiating with an SSRI and 
another anti-anxiety medication. The most common non-SSRI medications used at medication initiation 
included benzodiazepines (8%) followed by non-SSRI antidepressants (7%). The use of benzodiazepines 
as an initial anti-anxiety medication declined in older children from 2004 to 2014. Anxiety disorder, age, 
provider type, and co-morbid psychiatric diagnoses were some of the factors associated with the initial 
anti-anxiety medication class. Benzodiazepines and hydroxyzine were used primarily for short-term use, 
with few children refilling the initial prescription, whereas over half of SSRI initiators continued SSRI 
treatment for 6 months. A third of children were psychotherapy users before anti-anxiety medication 
initiation and most remained users after initiation. Among children who did not have psychotherapy 
claims before medication initiation, only 30% became psychotherapy users after initiation, with little 
change across time.  
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In our second aim we examined SSRI adherence in children with anxiety. In children with anxiety 
initiating an SSRI (n=70,979), 58% were classified as having high adherence (PDC≥0.80). Adherence 
was higher in younger children and in children with an anxiety diagnosis of OCD or social phobia and 
children with panic disorder and PTSD had the lowest adherence. Parent high adherence to SSRIs, statins, 
and antihypertensives independently predicted high child SSRI adherence compared to parent low 
adherence. Findings were consistent across child age groups and when considering parent gender. Parent 
adherence measures and other parent-level variables offered a small improvement in the ability to 
discriminate high vs. low child SSRI adherence at baseline when added to standard child-level variables 
available in claims data. 
In our third aim we identified 198,450 children with a new anxiety diagnosis in an office-based 
setting who were naïve to anti-anxiety treatment prior to their new diagnosis. One-year after a new 
anxiety diagnosis 2.0% of children had a mental health related hospitalization, 0.06% an inpatient, treated 
self-harm event, 1.4% an anxiety-related ER visits, and 20% any ER visit. There was a higher incidence 
in older children with baseline co-morbid depression. In the comparison cohort of a similar population of 
commercially insured children without an anxiety diagnosis, the cumulative incidence of each outcome 
was lower than in children with anxiety. 
6.2. PUBLIC HEALTH IMPLICATIONS 
This dissertation addressed current research gaps in pediatric anxiety. We were able to determine 
that SSRIs were the most commonly used first-line anti-anxiety pharmacotherapy for pediatric anxiety. 
The formal guideline from the American Academy of Child and Adolescent Psychiatry for anxiety 
disorders (excluding PTSD and OCD) was published in 2007.31 Since 2007 additional medications have 
been suggested as possible anxiety treatments; however, SSRIs typically remain the recommended first-
line medication.62,127,128 Aim 1 results revealed that a third of children initiated on a non-SSRI medication 
that has limited or no evidence of effectiveness for pediatric anxiety. Many of these medications have not 
been included in randomized controlled trials for pediatric anxiety; subsequently there is no trial evidence 
for or against these medications in pediatric anxiety. In many situations a non-SSRI first-line 
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pharmacotherapy may be entirely appropriate and we did find that psychiatric co-morbidities were 
associated with the initial mediation received.  
The decreased use of benzodiazepines as an initial pharmacotherapy in older children is a sign 
that practices may have improved in pediatric anxiety, whereas in adults, benzodiazepine use was on the 
rise during that time period.204 Because of dependency concerns, benzodiazepines are usually 
recommended for only short-term treatment.12 We did find evidence that when benzodiazepines are 
prescribed to children they are typically used for short-term treatment. Initiation with two anti-anxiety 
medications was relatively uncommon (7%), but there are concerns surrounding psychotropic poly-
pharmacy. This finding may be particularly concerning since poly-pharmacy typically increases during 
treatment and we saw treatment naïve children beginning pharmacotherapy with two anti-anxiety 
medications.  
Finally, aim 1 findings showed that psychotherapy utilization (based on psychotherapy claims) 
could be substantially improved surrounding anti-anxiety medication initiation in pediatric anxiety. 
Psychotherapy should be considered as a part of the treatment plan when possible. Other forms of 
traditional psychotherapy such as computer/internet-delivered, community/school based, and brief 
behavioral therapy,46,150 suggest that there may be flexibility in the form therapy is provided. This could 
allow more children to be treated with psychotherapy mono-therapy or combination therapy in the future. 
By describing the initial anti-anxiety pharmacotherapy prescribed in children with anxiety and 
psychotherapy utilization, aim 1 can inform efforts to better tailor medication and psychotherapy use in 
pediatric anxiety. 
 Aim 2 focused on SSRI adherence, which was the medication most commonly used at anti-
anxiety medication initiation. Adherence to SSRIs had not been well characterized in children with 
anxiety. We found that adherence can be improved and that it does vary between specific anxiety 
disorders. Given adherence estimates, adherence should be considered before altering medication dosing 
or switching to another anti-anxiety medication.  
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In aim 2 we also identified parent adherence as a predictor of child SSRI adherence. Given the 
role parents play in child adherence, it was important to understand whether parent medication adherence 
could be used as an indicator of future child adherence. The specific mechanism behind parent adherence 
being associated with child adherence likely differs between parent and child pairs, but is a clinically 
relevant indicator that could be integrated into everyday practice to improve the prediction of child 
adherence at baseline. A conversation between providers and parents on the parent’s barriers to adherence 
and if these will translate into barriers for his or her child’s adherence may be the first step to integrating 
parent information into clinical practice. Determining if parent adherence is predictive of child adherence 
outside SSRIs for anxiety and if parent adherence can be used to predict other healthy behaviors in 
children should be highlighted in future research.  
 Aim 3 filled a gap in the literature on the impact and burden of pediatric anxiety disorders after a 
new diagnosis. Results can help inform patients, parents, and providers when a child is diagnosed, a time 
when this information is especially useful. Following a new anxiety diagnosis, a significant proportion of 
children experience a mental health related hospitalization, inpatient treated self-harm, or anxiety-related 
ER visit. While we do not consider treatment type or management of symptoms after a new anxiety 
diagnosis, the incidence of these serious events demonstrate that some children and adolescents need 
improved care. The typical course of pediatric anxiety disorders is thought to be chronic and persistent127 
and the costs of untreated anxiety disorders could be lessened with appropriate mental health care.103 
Better understanding the disorder will hopefully improve the care for children with anxiety disorders, 
especially children at highest risk for one of these serious events.  
6.3. FUTURE RESEARCH  
6.3.1. Medicaid and other populations 
Our research centered on commercially insured children in the US; however results for each aim 
may differ in a Medicaid population or in countries outside the US. Prior work, not related to pediatric 
anxiety, has shown inferior management and treatment utilization in individuals enrolled in Medicaid 
compared to privately insured individuals,116,205,206 including a higher use of antipsychotics that are 
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associated with more side effects.152 It is possible that the initial anti-anxiety medication prescribed and 
psychotherapy claims surrounding medication initiation that we evaluated in aim 1 would differ in 
children covered by Medicaid.  
Additionally, in Canada, adherence to antidepressants was higher in those with private insurance 
compared to public insurance.207 There may be differences in child SSRI adherence in those covered by 
Medicaid and it is unknown if the predictability of parent adherence with child adherence would remain 
across populations. In reference to aim 3, serious events may also differ in non-privately insured children, 
for example, higher ER visits have been reported for children on Medicaid.109 It may be particularly 
useful to describe the management of symptoms in other populations to help interpret any differences in 
serious event incidence between the populations. 
6.3.2. Validation studies  
There is a need for validation studies for psychiatric diagnostic codes used in children in 
administrative data, including the validity of ICD codes for anxiety disorders. There is the possibility that 
recorded anxiety diagnoses are not true diagnoses  i.e. claim entered as rule-out diagnosis, data entry 
error, patient was referred to specialist for further assessment). In a prior study of Veterans Health 
Administration patients with diabetes who participated in the MENtal health-Diabetes (MEND) study, 
algorithms identifying anxiety disorders had a positive predictive value of 0.84 and negative predictive 
value of 0.66.188 However, that is a very different population than the current research and in a different 
datasource. Validations studies of psychiatric diagnoses are further complicated by the fact that a ‘gold 
standard’ would involve diagnostic evaluation or evidence of an evaluation and not a just a recorded 
diagnosis in a medical record. With the switch to ICD-10 diagnostic codes, validating the use of these 
codes will be particularly important to assist in future pediatric anxiety research.    
Describing psychotherapy in administrative claims data is primarily limited by the uncertainty on 
how often psychotherapy use is captured. In 1997, 37% of patients with anxiety were found to have self-
paid for psychotherapy154 and between 2005-2006, 72% of psychiatrists accepted private non-capitated 
insurance which decreased to 55% in 2009-2010.155 However, it is unknown how often psychotherapy use 
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is missing from claims data. An additional consideration for psychotherapy validation is the need to have 
self-report use or access to information from psychiatrists and psychologists.   
6.3.3. Future research related to aim 1 
Additional areas of research stemming from aim 1 findings include further evaluation of follow-
up treatments. Our study focused on the initial anti-anxiety medication and we hinted at subsequent 
medication changes in examining the proportion of non-SSRI initiators that later fill an SSRI prescription. 
However, treatment switches and additions are important to evaluate in closer detail. This will likely vary 
over the life-course and become complicated by the development of psychiatric co-morbidities. Further 
research is needed to determine the extent to which provider availability and costs influence the decision 
on whether a child receives psychotherapy as part of their treatment. Given the amount of children 
diagnosed with anxiety by non-mental health specialists and the low use of psychotherapy after 
medication initiation in children diagnosed by non-mental health providers, attention focused outside 
mental health specialists may be essential to improve care for pediatric anxiety. 
6.3.4. Future research related to aim 2 
In aim 2 we found that parent adherence was predictive of child adherence. However, as 
mentioned in the discussion, self-reported adherence is often overestimated, limiting the clinical utility of 
parent self-reported adherence to inform on the likelihood of high child adherence. More research is 
needed to identify the best and most feasible way parent information could be applied in everyday 
practice to best inform future child adherence. Using this information to improve child adherence will be 
related to the specific mechanism that links both parent and child adherence (ex. pharmacy access vs. 
needing a daily reminder).   
We only evaluated the association of parent adherence to three medication classes. The 
predictability of parent adherence with child adherence may not hold for different parent medications, 
particularly medications in which adherence may not be representative of a healthy behavior (i.e. being 
adherent to opioids or benzodiazepines). Additionally, it would be of interest to determine if parent 
adherence is associated with other child behaviors. This could include whether a child receives 
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vaccinations according to schedule or whether children are more likely to take part in healthy behaviors 
when they have adherence parents. When the healthy user bias is a potential reason for unmeasured 
confounding in pediatric pharmacoepidemiologic studies, it is possible parent adherence (or other parent 
healthy behaviors) may serve as a proxy to aid with adjustment.  
Adherence is likely only one aspect of treatment that is influenced by parents. Caregivers have a 
large say in the treatment type initiated (medication vs. psychotherapy), in managing care during follow-
up (psychotherapy visits, lifestyle changes), and in when to seek care and guidance; all of these are areas 
of interest to explore further. 
6.3.5. Future research related to aim 3 
Aim 3 examined the incidence of selected serious events (mental health related hospitalizations, 
inpatient treated self-harm, ER visits) after a new anxiety diagnosis. We are currently conducting research 
to examine whether the incidence of each event varies based on the initial treatment received following a 
new anxiety diagnosis. However, there is significant unmeasured confounding by anxiety severity 
between the initial treatment received and subsequent events. Therefore, datasources with clinical details 
on anxiety severity will likely be necessary to answer the question of whether initial treatment type is 
associated with a reduction in adverse events.  
Children with a new anxiety diagnosis outside an office setting were excluded from aim 3. 
However, this group should be described in further detail given that these children likely had undiagnosed 
or unrecognized anxiety until their symptoms (or symptoms of a co-morbidity) resulted in a new 
diagnosis in an inpatient, ER, or urgent care setting. Describing these patients could help develop 
interventions to get children into care earlier. 
6.3.6. First recognition of pediatric anxiety 
Future areas of research for pediatric anxiety in general should focus on understanding how 
children first enter the healthcare system. There is a low recognition of anxiety disorders, possibly related 
to the fact that symptoms are often internalized in children and they may be reluctant to share thoughts or 
behaviors.208 During the course of the dissertation, questions were formed around which children get an 
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anxiety diagnosis and how do they first enter the healthcare system to receive that diagnosis. Some 
children may have been referred directly to a mental health provider for evaluation while a general 
practitioner may diagnose and treat other children. In the database used for the current research, we 
cannot identify additional details surrounding how the child first got into care, for example, did the child 
express their symptoms to their parents, were the parents observing the behavior, or did the school refer 
the child. Understanding how children first enter into healthcare for anxiety could help improve efforts to 
get more children into proper care and perhaps reduce visits for somatic symptoms with anxiety going 
unrecognized.  
6.4. CONCLUSIONS  
Given the high prevalence of anxiety disorders in children and adolescents, the impact on daily 
life, and the high costs associated with anxiety,4,178 this dissertation research focused on pediatric anxiety 
to help understand current treatments practices and the burden of anxiety to improve care in the future. 
Many children with mental disorders, including anxiety disorders, never receive the specialty mental 
health care they need.39,201,209 There are ongoing efforts to increase the availability of mental health 
treatments in children210 including the integration of mental health services into primary care.211 This 
research identifies areas of treatment that can be improved so that in the future, as more children enter 
care, children have the best chance to reduce the lasting, negative symptoms of anxiety.  
 In conclusion, through the dissertation aims we found that the majority of children with anxiety 
who start anti-anxiety medication do so with an SSRI, with about half remaining on treatment at 6-months 
and a significant proportion with low adherence. Parent adherence can be used as a baseline indicator to 
help predict child SSRI adherence and aid in the evaluation of distinguishing between non-responders vs. 
non-adherers. Lastly, evaluating the occurrence of serious, high-burden events following a new anxiety 
diagnosis increases awareness for patients, providers, and caregivers and supports the need for 





APPENDIX 1. EVIDENCE OF PHARMACOTHERAPIES USED TO TREAT ANXIETY 
SNRIs: SNRIs included are venlafaxine (Effexor XR), duloxetine (Cymbalta), desvenlafaxine (Pristiq), 
levomilnacipran (fetzima; approved July 2013), and milnacipran (savella). Two RCTs found venlafaxine 
to be effective in treating anxiety in children, both were published after the 2007 AACAP guidelines.212,213 
One trial was in 285 children (8-17 years) with social anxiety disorder212 the other trial in 323 children (6-
17 years) with GAD.213 SNRIs are often seen as an appropriate alternative to SSRIs or recommended if an 
initial SSRI is ineffective.62,63,214,215 All SNRIs were included in the proposal. 
 
Tricyclic antidepressants (TCAs): TCAs included are amitriptyline, clomipramine, desipramine, 
doxepin, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine, and amoxapine 
(dibenzoxazepinederivative TCA). Clomipramine is FDA approved for OCD in adults and children (10+ 
years) and doxepin (Sinequan) is approved for conditions related to anxiety in adults; other TCAs are not 
approved for any anxiety related conditions. Imipramine has shown effectiveness over placebo for 
treating GAD in adults in an RCT.216 Canadian practice guidelines recommend TCAs as a second-line 
antidepressant treatment for adults with certain anxiety disorders.62 For panic disorder in adults, the APA 
cites TCAs as having similar efficacy as SSRIs, SNRIs, and benzodiazepines;139 however, given the side 
effects associated with TCAs and the potential lethality in overdose, TCA use is limited for anxiety.61,63,139 
The AACAP guidelines for pediatric anxiety state that TCAs have been used less since SSRIs were 
introduced as there is the need for close cardiac monitoring and greater medical risk of overdose and that 
controlled trials of TCAs for pediatric anxiety disorders show conflicting results.5 All TCAs were 
included as potential medications for anxiety in children despite the limited evidence in children.  
 
Monoamine Oxidase Inhibitors (MAOIs): MAOIs included are isocarboxazid, phenelzine, selegiline 
transdermal, and tranylcypromine; none of these medications are FDA approved for treating anxiety 
disorders in children and adults. The NIMH lists MAOIs as a potential treatment for anxiety. The APA 
guidelines for panic disorder in adults state that adverse effects are a major concern for MAOIs and that 
MAOIs should be reserved for patients who did not respond to several other treatments,139 as also 
mentioned in recommendations from the British Association for Psychopharmacology.15 MAOIs have not 
been well studied in children;217 however, as MAOIs can be used for anxiety, they were included as 
potential anxiety treatments.59,65 
  
Other antidepressants:  
 Mirtazapine, trazodone, nefazodone: Mirtazapine, trazodone, and nefazodone are antidepressants 
FDA approved for depression but, as with other antidepressants, are sometimes used to treat anxiety. 
There is some limited evidence from small trials of mirtazapine and nefazodone as a treatment for 
PTSD in adults.15,218 There is also limited evidence for trazodone and nefazodone for adults with 
panic disorder,139 and trazodone for GAD.61 However, they are not recommended as first line 
treatments because of tolerability issues, liver toxicity, or common side effects.139,218 
 Atomoxetine: In an RCT of atomoxetine, which is FDA approved for treating ADHD in children, 
atomoxetine was associated with greater symptom improvement in children with ADHD and anxiety 
compared to placebo.219 
 Bupropion: (ex. Wellbutrin) Bupropion is an antidepressant approved for adults in the treatment of 
major depressive disorder (MDD) and is also indicated for the prevention of seasonal affective 
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disorder.220,221 A meta-analysis found no difference in anxiolytic efficacy of Bupropion compared 
with SSRIs when treating patients with MDD222 and preliminary evidence (n=24) showed bupropion 
has similar efficacy to an SSRI in treating GAD in adults.223 Nevertheless, bupropion is used in the 
treatment of anxiety.59,65 This treatment is frequently used for smoking cessation; however, given the 
young age of our population and inclusion requirements, we do not expect observed bupropion to be 
used for smoking cessation.   
 
Buspirone (Buspar): Buspirone is an anti-anxiety medication that is not related pharmacologically to 
other typical anti-anxiety medications and is indicated in adults for anxiety disorders and the short-term 
relief of anxiety symptoms.224 The 2007 AACAP guidelines for the treatment of anxiety disorders, 
suggest buspirone may be an alternative to SSRIs in the treatment of GAD in children.5 However, two 
unpublished 6-week RCTs in children with GAD showed no significant difference between buspirone and 
placebo.14 
 
Benzodiazepines: Benzodiazepines are commonly used for the treatment of anxiety; however, 
prescribing benzodiazepines for long-term use is not recommended because of the risk associated with 
dependency.66-68 Additionally there is insufficient data on efficacy to warrant benzodiazepine use for 
anxiety in children, despite the benefits seen in adult trials.5,12 The AACAP guidelines state that 
benzodiazepines are used in the short-term as adjunct to SSRI treatment when seeking to achieve 
reduction in severe anxiety symptoms.5 There are many benzodiazepines and benzodiazepine derivatives 
available; those included as potential treatments for anxiety were: Alprazolam (Xanax), chlordiazepoxide 
(Librium), clobazam (Onfi, used for seizure control), clonazepam (Klonopin; BZD derivative, 
antiepileptic), clorazepate (Tranxene), diazepam (Valium), lorazepam (Ativan), oxazepam (Serax).  
Halazepam and prazepam have been discontinued in the US but were still included to capture use prior to 
the discontinuation. The hyponitcs and sedative benzodiazepine medications (estazolam, flurazepam, 
triazolam, temazepam, midazolam, quazepam) were not included. A few benzodiazepine agents are 
highlighted below. 
 Clonazepam: Clonazepam is indicated for the treatment of panic disorder, with or without 
agoraphobia in adults and for certain seizure disorders.225 There is not evidence of effectiveness in 
treating pediatric anxiety. In a double-blind crossover trial of 15 children (7-13 years) with anxiety 
(majority with SAD), there was no statistical benefit of clonazepam over placebo with more side 
effects reported during the clonazepam phase included drowsiness and disinhibition.226 
 Alprazolam: Alprazolam is indicated for anxiety disorder, short-term relief of anxiety symptoms, and 
panic disorder with or without agoraphobia in adults.227 In a RCT of 30 children (mean 13 years) with 
overanxious or avoidant disorders there was no statistical difference between alprazolam and 
placebo.228 
 
Beta-blockers: Beta-blockers are an additional medication to treat anxiety.59 Beta-blockers can be 
prescribed for performance related social anxiety, which are taken on an as-needed basis rather than 
regularly.60 An open-label trial of betaxolol in patients with anxiety noted immediate improvements.229 
However, evidence is lacking on the use of beta-blockers for anxiety in children, with some small, open 
label evidence for children with PTSD.230 All agents in the drug class were included: acebutolol, atenolol, 
atenolol/chlorthalidone, bendroflumethiazide/nadolol, betaxolol, bisoprolol fumarate, carteolol, 
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carvedilol, esmolol, metoprolol succinate, metoprolol tartrate, propranolol, timolol maleate, nadolol, 
nebivolol, penbutolol sulfate, pindolol, and sotalol. 
 
Atypical antipsychotics: Atypical antipsychotics have been suggested for possible treatments for anxiety 
or augmentations to treatments for anxiety; however, the long-term use of antipsychotics is associated 
with significant side effects.41,63 Nationally, the prescribing of antipsychotics for the treatment of anxiety 
disorders has risen (source: National Ambulatory Medical Care Survey).80 Given the potential side effects 
and limited RCT evidence, atypical antipsychotics are often recommended as only the second or third-line 
therapy or adjunctive therapy in adults, as in the Canadian clinical practice guidelines for the management 
of anxiety and PTSD.62 The World Federation of Biological Psychiatry guidelines for the 
pharmacological treatment of anxiety disorders suggest that treatment with atypical antipsychotics be 
reserved to specialist settings.63 Given the lack of evidence, guidelines do not recommend atypical 
antipsychotics for treating anxiety disorders in children; 62 31 however, the AACAP guidelines for treating 
children with PTSD cite that novel antipsychotics may be helpful for youth with PTSD.45 The APA 
guidelines for adults with PTSD also suggest second-generation antipsychotic medications may be helpful 
in treatment PTSD.218,231 Rather than including all atypical antipsychotics, only those with evidence (even 
if minimal) or those mentioned in reviews on anxiety treatment were included: 
 Aripiprazole (Abilify): The approved indications for Aripiprazole include schizophrenia, manic and 
mixed episodes associated with bipolar I, adjunctive treatment of MDD, and tourette’s disorder, 
some of which are approved for pediatric use.232 Results from two small, open label trials that 
augmented treatment with aripiprazole in patients with GAD demonstrated promising results.61 A 
review of aripiprazole stated that the use of aripiprazole in anxiety should be explored given the 
existing data, the neurobiology of anxiety, and the pharmacology of aripiprazole.41  
 Ziprasidone (Geodon): The approved indications for ziprasidone include schizophrenia, manic or 
mixed episodes associated with bipolar I disorder, and adjunct to lithium or valproate in bipolar I 
disorder for adults.233 A small, open label trial of ziprasidone in patients with treatment resistant 
GAD was successful in the reduction of symptoms.234 Canadian clinical practice guidelines, cite 
some evidence of the use of ziprasidone for monotherapy in the treatment of GAD in adults.62   
 Quetiapine (Seroquel): The approved indications for quetiapine in the US include schizophrenia, 
bipolar I disorder, depressive episodes associated with bipolar disorder, and MDD adjunctive 
therapy with antidepressants.235 Quetiapine is licensed for GAD in other countries. RCTs, including 
a large (n=873) 8-week trial, found quetiapine to be effective in treating GAD in adults compared to 
placebo but not SSRI antidepressants,236 a finding demonstrated in other studies as detailed in a 
National Institute for Health and Care Excellence off-label review of quetiapine for GAD.237 A RCT 
of adults with GAD stabilized to quetiapine XR (n=432) and subsequently randomized to continue 
quetiapine XR or placebo found quetiapine XR to reduce the risk of anxiety symptom recurrence.238 
 Olanzapine (Zyprexa) and olanzapine/fluoxetine (Symbyax): Approved indications for olanzapine 
in the US include schizophrenia and bipolar disorder in those 13+ years and the combination 
olanzapine/fluoxetine for bipolar disorder and treatment resistant depression.239 Adjunct olanzapine 
to fluoxetine treatment in adults (n=46) with GAD resulted in improved treatment response 
compared to fluoxetine alone.240 Olanzapine is one of the recommended options for acute treatment 
of social anxiety disorder by the British Association for Psychopharmacology.15 
 Risperidone (Risperdal): Indications for risperidone include schizophrenia, bipolar disorder, and 
irritability associated with autistic disorder.241 There is some evidence that risperidone may improve 
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PTSD symptoms, including two open label trials (one in 3 preschool aged children) and case 
reports.230 Another small (n=18) open label trial of risperidone in young males with PTSD, showed 
improvement in symptom remission.242 An RCT of risperidone as adjunctive therapy for GAD in 
adults showed improvement over placebo while another showed no significant difference.243,244  
 Lurasidone (Latuda):  Lurasidone was approved in 2010 and is indicated for schizophrenia (13+ 
years) and bipolar disorder (adults). Since lurasidone was approved in late 2010 we expect to see 
low use in our study population. Along with other atypical antipsychotics, it is recommended in 
adults as a second or third line therapy.62 
 
Antihistamines: The antihistamine hydroxyzine, which was launched in 1956, has been used as an 
anxiety treatment.15,134,245,246 In the US hydroxyzine (Vistaril, Atarax) is indicated for the “symptomatic 
relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in 
which anxiety is manifested” in children and adults.247 The 2005 evidence based guidelines from the 
British Association for Psychopharmacology, include hydroxyzine in their list of pharmacotherapies for 
acute treatment of GAD based on two RCTs in adults with GAD.15,248,249 A 2010 Cochrane review on the 
use of hydroxyzine for GAD in adults concluded that, while hydroxyzine was more effective than 
placebo, there was a lack of evidence to recommend hydroxyzine as the first line treatment for GAD and, 
given the low quality of evidence, they could not conclude on the efficacy of hydroxyzine compared with 
active comparators.250 The World Federation of Biological Psychiatry guidelines for the pharmacological 
treatment of anxiety disorders published in 2012, recommended that hydroxyzine only be considered 
when other medications have been unsuccessful.63 A primary deterrent of hydroxyzine use is 
sleepiness/drowsiness.61,250 
 
Anticonvulsants: There is evidence that anticonvulsants are an effective treatment for anxiety disorders 
in adults.251,252 The AACAP guidelines for anxiety disorders do not mention anticonvulsants as a 
treatment for anxiety disorders. However, the AACAP guidelines for PTSD says anticonvulsants may 
show promise in treating PTSD symptoms.45 Because of the potential side effects, along with the lack of 
research, anticonvulsants are not a recommended treatment option for pediatric anxiety.128 
Anticonvulsants, while not recommended for first-line therapy, are suggested to be useful for 
augmentation in partial responders or among persons who cannot tolerate SSRIs.252 The anticonvulsants 
included as potential treatments for anxiety are listed below with some brief details:  
 Carbamazepine (Tegretol): Carbamazepine is indicated for epilepsy and trigeminal neuralgia.253 A 
small (n=28) open label study254 provided limited evidence that carbamazepine may be useful for 
children with PTSD.255 The Canadian clinical practice guidelines recommend carbamazepine for a 
potential third-line treatment for PTSD in adults.62 
 Gabapentin (Neurontin): In the US gabapentin is approved for postherpetic neuralgia in adults and 
adjunctive therapy in the treatment of partial onset seizures in patients (3+ years) with epilepsy. Off-
label use of gabapentin is high, including for the management of anxiety;256 the drug was even 
associated with illegal marketing, including for psychiatric conditions, resulting in a settlement.257 
There is limited evidence that gabapentin may improve anxiety disorder symptoms.258  
 Pregabalin (Lyrica): In the US approved indications for pregabalin include adjunctive therapy for 
adult patients with partial onset seizures and fibromyalgia.259 In the European Union and other 
countries, however, pregabalin is approved to treat GAD in adults. In controlled trials (4-8 weeks), 
52% of pregabalin treated patients had 50%+ improvement from baseline based on HAM-A total 
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score compared to 38% in patients treated with placebo.260 There is also evidence of pregabalin for 
treating social phobia.252 
 Tiagabine (Gabitril): Tiagabine is indicated for adjunctive therapy in the treatment of partial 
seizures for adults and children (12+ years). Open label trials have shown tiagabine to reduce 
symptoms for social phobia, PTSD, GAD, and panic disorder; however, a larger RCT (n=272) 
showed no statistically significant difference in the reduction of symptoms compared to placebo.252 
The APA guidelines for PTSD do mention tiagabine as a newer medication that has been tested but 
requires larger RCTs.231 
 Valproate/Valproic Acid (Depakote): In the US approved indicators for valproic acid include 
manic episodes associated with bipolar disorder and migraines.261 Some limited evidence exists for 
the use of valproic acid in certain anxiety disorders in adults; however, the evidence is mostly from 
small (n=10-21) open-label studies.252,258,262 APA guidelines for panic disorder suggest more 
controlled studies are needed before it can be recommended.139 
 Lamotrigine (Lamictal): In the US lamotrigine is approved for epilepsy and bipolar disorder.263 
There is limited evidence that lamotrigine is an effective treatment for anxiety. A small RCT (n=15) 
found that patients with PTSD responded better to lamotrigine than placebo.264 
 Topiramate (Topamax): In the US topiramate is indicated for epilepsy (2+ years) and migraines 
(12+ years).265 In open label trials, adults with PTSD or social phobia showed improvement with 
topiramate.252 In a RCT (n=38) of adults with PTSD, topiramate showed improvements over 
placebo.266 
 Levetiracetam (Keppra): In the US levetiracetam is approved for treating seizures in people with 
epilepsy. An open label trial with levetiracetam in social phobia showed symptom improvement, as 
did a case report in patients with GAD. A later RCT did not find levetiracetam to be effective, but in 
another study levetiracetam was effective as augmentation in treatment-resistant PTSD.251,252 
Anticonvulsants not included: Felbarnate, Vigabatrin, Zonisamide, Oxcarbazepine, Phenytoin. 
 
Other medications: The additional medications listed below have been highlighted as potential 
treatments for pediatric anxiety. 
 Riluzole: Riluzole is a medication indicated for patients with amyotrophic lateral sclerosis (ALS or 
Lou Gehrig's disease). Two open label studies in adults showed reduction in anxiety symptoms with 
riluzole 61,64 and it was included in a recent review on novel approaches to treat pediatric anxiety, yet 
an RCT in children with OCD found no significant difference compared to placebo.267 
 D-cycloserine: D-cycloserine (DCS) is approved for the treatment of pediatric tuberculosis. Studies 
have found that DCS used to augment exposure therapy was superior to therapy alone in adults with 
social phobia, panic disorder, specific phobia (heights), and OCD.128,268 A preliminary trial in 
children with OCD did not show any effect; however, a larger trial is underway.128,267 DCS may be 
beneficial for cases when CBT was not successful or there is a need for fast treatment effects.128 
 Memantine (Namenda): Memantine is used in the treatment of Alzheimer’s disease, but has also 
been used in the treatment of anxiety disorders. The majority of research has focused on OCD, 
although memantine has not been formally studied in children with OCD; a small open label in 
adults with GAD showed promising results.64,128 Canadian guidelines for anxiety in adults 
recommended memantine for a second or third line treatment for some disorders, and did not 
recommend it for the treatment of GAD.62 
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 Prazosin, guanfacine, and clonidine (alpha blockers): These medications are listed in the Anxiety 
Disorders Association of America list of medications prescribed for anxiety in adults, specifically for 
PTSD.65 There are case reports of prazosin for youth with PTSD, but no open-label trials or RCTs.230 
A review of treatments for children with anxiety suggests that anti-adrenergics such as guanfacine 
and clonidine may have promise in treating pediatric anxiety.14 
 
Treatments not included: Ondansetron is a serotonin antagonists that was mentioned in a few review 
articles for anxiety treatments in adults61,64 based on RCT (n=54) results. However, follow-up studies 
have not been conducted and as it is not included in treatment guidelines it was not included. Historically 
barbiturates (i.e. phenobarbital, butabarbital) were used to treat anxiety, until the late 1960s when they 
were replaced with benzodiazepines.245 As barbiturates were not included in any treatment 
recommendations, they were not included; also not included are paraldehyde and meprobamate. 
 
Over the counter medications: There are over-the-counter, natural therapies that have been suggested to 
be helpful in treating anxiety. These include valerian, melatonin, kava, tryptophan/hydroxytryptophan, 




APPENDIX 2. ESTIMATES OF PSYCHOTHERAPY USE IN CHILDREN  
The table below contains information on psychotherapy utilization. As the literature is limited on 
psychotherapy use in children with anxiety, the table includes available estimates in children and adults 
with anxiety and with other mental illnesses. 
  
Relevant literature on psychotherapy use in children and adults with anxiety and other mental illnesses  
Datasource Reference; Year Age Psychotherapy 
definition 















what type of care was 
provided during each 
outpatient visit… 
categories included 
mental health counseling 
or psychotherapy 
By treated mental health condition, 
2007: 
 Anxiety: Psychotherapy and 
medication 35% (42% in 1998), 
psychotherapy only 9% (20% in 
1998), medication only 56% (38% in 
1998) 
 Depression: 43% psychotherapy 
+medication, 6% psychotherapy 













Psychotherapy use by mental health 
impairment, 2003-2005 and 2010-
2012 
 More severe = 22.5%, 26.1% 














Four indicators of 
mental health care: 






Population rates: Number of visits 
with psychotherapy per 100 youth (0-
20 years): 
 4.2 (2003-2006) 





to primary care 
providers) 
N/A Receipt of referral for 
psychotherapy  
Psychotherapy referral rates in 
primary care patients  
Patients with anxiety: 
 22% rural vs. 19% nonrural 
Patients with depression: 








18+ Response to the 
question: ‘Was 
psychotherapy provided 
or ordered during the 
visit’ 
Visits with an anxiety disorder 
diagnosis given:  
 In 1985 48% of visits 
psychotherapy offered alone or 
with medication, to 30% of visits in 
1997-1998 
 1997-98: visits to a psychiatrist, 
28% psychotherapy only, 39% 
psychotherapy and medication, and 
30% medication only vs. primary 








Among children and adolescents with 






21+ provided by the 
physician at the visit 
treatment: 











provided by the 
psychiatrics at the visit; 
limited to psychotherapy 
visits to those longer 
than 30 minutes 
Visits to psychiatrist with psychiatric 
diagnosis 
 Percentage of visits involving 
psychotherapy: 44.4% in 1996-
1997, 28.9% in 2004-2005 
 76% of psychiatric visits were by 
patients who had 6+ previous visits 
to the same psychiatrist (2005) 
 With GAD diagnosis: 24.8% of 
visits involved psychotherapy in 
2004-2005, 25.2% panic disorder, 














During the past 12 
months, has child seen 
or talked to a mental 
health professional such 
as a psychiatrist, 
psychologist, psychiatric 
nurse, or clinical social 
worker about child's 
health? 
 All children (nationwide): 7.9% 













Parents were asked yes–
no questions about 
treatment received for 
anxiety, depression, and 
behavioral problems 
during the child’s 
lifetime.  
 35% (n=66) received at least three 
sessions of counseling for various 
reasons at some point 
 Treatment for anxiety received: 9% 
medication, 28% counseling, 31% 
medication or counseling 
 Treatment for depression ever 
received: 20% medication, 40% 












Psychotherapy = if the 
psychiatrist indicated 
that he or she or another 
provider had provided 
psychotherapy in the 
past 30 days 
 66% of patients received some form 
of psychotherapy from the physician 
or another provider in the past 30 

















codes; Receipt of any 
(1) outpatient individual 
therapy 
 Anxiety: 30% received any 
psychotherapy  







CPT codes for 
psychotherapy  
 1.2-1.3% of children received 
psychotherapy 
 0.3%-0.2% of children on 
antidepressant 
 41% of those treated with 







months prior to 
antidepressant start 
 Initiators of an antidepressant with 
MDD: 29% prior psychotherapy  






years during the year 
following diagnosis 
 35% no treatment 
 10% medication only 
 35% Psychotherapy only 
 20% combination  
Average # of visits: 8 






outpatient CPT codes 
Psychotherapy use among people with 
antipsychotic prescription (all 
diagnoses, 2009) 
 13.5% (1-6 years), 20.4% (7-12 
years), 24.8% (13-18 years) 





CPT codes for 
psychotherapy  
Minimally adequate psychotherapy 
(4+ visits in 12 weeks) in depressed 
youth starting treatment 
6-11 years: 66% 







service: 1+ CPT code 
for psychosocial 
services  
Outpatient psychosocial service prior 
to a new start of an antipsychotic 
(prior 90 days, any diagnosis) 
 0-5 years: 39% 
 6-12 years: 50% 
 12-17 years: 52% 
 Patients with anxiety diagnosis = 




APPENDIX 3. ANXIETY DEFINITIONS: ICD-9-CM CODES  
  
Appendix 3 Table. Anxiety disorders: ICD-9-CM codes for cohort 
inclusion 
DSM-5 Anxiety Disorders ICD-9-CM  
     Unspecified anxiety disorder 300.00 
     Panic disorder (without agoraphobia) 300.01 
          Panic disorder with agoraphobia 300.21 
     Generalized anxiety disorder 300.02 
     Other specified anxiety disorder 300.09 
     Specific phobia (ICD-10, specific phobias) 300.29 
          Unspecified phobia 300.20 
     Agoraphobia (without panic attacks) 300.22 
           Agoraphobia with panic attacks 300.21 
     Social anxiety disorder (social phobia) 300.23 
     Separation anxiety disorder 309.21 
     Selective mutism 313.23 
     Anxiety disorder due to a general medical condition 293.84 
Obsessive-compulsive disorder (OCD) * 300.3x 
Post-traumatic stress disorder (PTSD) ** 309.81 
*Under ‘Obsessive-Compulsive and Related Disorders’ 
**Under ‘Trauma- and Stressor-Related Disorders’ 
ICD-9-CM: International Classification of Diseases, Ninth Revision; DSM-5: Diagnostic 
and Statistical Manual of Mental Disorders, Fifth edition  
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Appendix 4 Table. CPT codes for psychotherapy visits with 2013 changes  
Individual psychotherapy 2013 code changes* 
     20 - 30 min. 90804, 90816 30 min. (16 - 37) 90832 
     45 - 50 min. 90806, 90818 45 min. (38 - 52) 90834 
     75 - 80 min.  90808, 90821 60 min. (53+) 90837 
Interactive individual psychotherapy 
     20 - 30 min. 90810, 90823 30 min. (16 - 37) 90832 + 90785 
     45 - 50 min. 90812, 90826 45 min. (38 - 52) 90834 + 90785 
     75 - 80 min. 90814, 90828 60 min. (53+) 90837 + 90785 
Individual with evaluation management 
     20 - 30 min. 90805, 90817 30 min. (16 - 37) E/M code + 90833 
     45 - 50 min. 90807, 90819 45 min. (38 - 52) E/M code + 90836 
     75 - 80 min. 90809, 90822 60 min. (53+) E/M code + 90838 
Interactive individual with evaluation management 
     20 - 30 min. 90811, 90824 30 min. (16 - 37) E/M code + 90833 + 90785 
     45 - 50 min. 90813 90827 45 min. (38 - 52) E/M code + 90836 + 90785 
     75 - 80 min. 90815, 90829 60 min. (53+) E/M code + 90838 + 90785 
Family 90847, 90849 (no changes) 
Group 90853, 90857 90853 (+90785) 
*E/M codes selected based on services provided, not on time; 
Psychiatric diagnostic evaluation: Pre-2013 (90801, 90802), 2013 changes (90791, 90792) 
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APPENDIX 5. DETAILED COVARIATE DEFINITIONS  
Below are the detailed covariate definitions that are used throughout the dissertation aims. Current 
prevalence estimates included are from the 2011/2012 National Survey of Children's Health. 
 
Psychiatric co-morbidities 
Variable ICD-9-CM codes Details/notes 
Any non-anxiety 
psychiatric disorder 
290.x – 319.x (with 
anxiety exclusions) 
Excludes anxiety diagnostic codes as all patients have an 
anxiety diagnosis 






309.89, 309.9x,  
 
 
Adjustment disorder with depressed mood (309.0);  
Adjustment reaction with predominant disturbance of other 
emotions (309.2, except 309.21); Adjustment disorder with 
disturbance of conduct convert (309.3); Adjustment disorder 
with mixed disturbance of emotions and conduct (309.4); 
Adjustment reaction with physical symptoms (309.82), 
Adjustment reaction with withdrawal (309.83), Other 
specified adjustment reactions (309.89), Unspecified 
adjustment reaction (309.9)  
 
Separate indicators for adjustment disorder with and without 
depression  






314 Hyperkinetic syndrome of childhood (314.x); 
 
Specific variable; Attention deficit disorder without mention 
of hyperactivity (314.00), Attention deficit disorder with 
hyperactivity (314.01) 
Depression  296.2x, 296.3x, 
300.4x, 309.1x, 
311.x 
Major depressive disorder (296.2x, 296.3x), Dysthymic 
disorder (300.4x), Depressive disorder, not elsewhere 
classified (311.x), Adjustment reaction: Prolonged depressive 
reaction (309.1) 
 
Estimate of current prevalence in children=2.2% 
Other episodic mood 
disorder 




312.x, 313.81 Disturbance of conduct not elsewhere classified: 
Undersocialized conduct disorder aggressive type (312.0) and 
unaggressive type (312.1), Socialized conduct disorder 
(312.2), Disorders of impulse control not elsewhere classified 
(312.3), Mixed disturbance of conduct and emotions (312.4), 
disturbances of conduct not elsewhere classified (312.8), 
Unspecified disturbance of conduct (312.9); Oppositional 
defiant disorder (313.81) 
 
Estimate of current prevalence in children=3.2% 
Other psychiatric co-morbidities  





Childhood disintegrative disorder (299.1), Other specified 
pervasive developmental disorders (299.8), Unspecified 
pervasive developmental disorders (299.9) 
 
Autistic disorder (299.0) in exclusion criteria  
 
Estimate of current prevalence (Autism, Asperger's, PDD, 





Bipolar disorder 296.0x, 296.4x - 
296.8x, 301.13 
Bipolar i disorder, single manic episode (296.0), Bipolar i 
disorder, most recent episode (or current) manic (296.4), 
Bipolar i disorder, most recent episode (or current) depressed 
(296.5), Bipolar i disorder, most recent episode (or current) 
mixed (296.6), Bipolar I disorder, most recent episode (or 
current) unspecified (296.7), Other and unspecified bipolar 







Developmental reading disorder (315.0); Mathematics 
disorder (315.1); Other specific developmental learning 
difficulties (315.2); Developmental speech or language 
disorder (315.3); Developmental coordination disorder 
(315.4); Mixed development disorder (315.5); Other specified 
delays in development (315.8); Unspecified delay in 
development (315.9);  
 
Alexia, dyslexia (784.61); Mental and behavioral problems 
with learning (V40.0) 
 
Estimate of current prevalence in children=3.6% 
(learning disabilities in children=8.0%) 
Eating disorders 307.1, 307.5 Anorexia nervosa (307.1), Other and unspecified disorders of 
eating (307.5)  
Enuresis, encopresis 307.6, 307.7, 788.36 Enuresis (307.6), encopresis (307.7), nocturnal enuresis 
(788.36) 
Intellectual disabilities 317-319; 758.0x, 
759.83  
Mild intellectual disability (317), Other specified intellectual 
disabilities (318), Unspecified intellectual disabilities (319);  
Down’s syndrome (758.0), Fragile X Syndrome (759.83) 
 
Estimate of current prevalence in children=1.1% 
Personality disorder 301.x  
Schizophrenia 295.x  
Sleep disorders 307.4x, 327.x, 
347.x, 780.5x 
Specific disorders of sleep of nonorganic origin (307.4); 
Organic sleep disorders (327); Cataplexy and narcolepsy 
(347); Sleep disturbances (780.5) 
Substance use disorder 291-292.x, 303-
305.x 
Alcohol-induced mental disorders (291), Drug-induced 
mental disorders (292), Alcohol dependence syndrome (303), 
Drug dependence (304), Nondependent abuse of drugs (305) 
Tics 307.2x   Tic disorder unspecified (307.20), Transient tic disorder 
(307.21), Chronic motor or vocal tic disorder (307.22), 
Tourette’s disorder (307.23) 
 
Estimate of current prevalence (Tourette’s) in children=0.2% 
Neurasthenia  300.5x (removed from DSM) 
Gender identify disorder 302.6x, 302.85 Gender identity disorder in children (302.6x); Gender identity 
disorder in adolescents or adults (302.85) 
Somatoform disorders 300.8x  
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Non-psychiatric co-morbidities  
Variable ICD-9-CM codes Details/notes 
Acne 706.0x, 706.1x Acne varioliformis (706.0), Other acne (706.1) 
Allergic rhinitis 477.x -  
Anemia 280.x - 285.x 
 
 
Iron deficiency anemias (280); Other deficiency anemias (281); 
Hereditary hemolytic anemias (282); Acquired hemolytic anemias 
(283); Aplastic anemia and other bone marrow failure syndromes 
(284); Other and unspecified anemias (285) 
Asthma  493.x -  
Estimate of current prevalence in children=8.8% 
Cancer, malignant 140.x – 209.x -  
Cardiac disorders 
(Elizhauser, 1998) 
See note Congestive heart failure: 398.91, 402.11, 402.91, 404.11, 404.13, 
404.91, 404.93, 428.x 
Cardiac arrhythmias: 426.10, 426.11, 426.13, 426.2-426.53, 426.6-
426.89, 427.0, 427.2, 427.31, 427.60, 427.9, 785.0, V45.0, V53.3 
Vascular disease: 093.2x, 394.0x-397.1x, 424.0x-424.91, 746.3-
746.6, V42.2, V43.3 
Pulmonary circulation disorders: 416.x, 417.9x 
Cerebral palsy 343.x - 
Estimate of current prevalence in children=0.2% 
Diabetes (type I and 
type II) 
249.x, 250.x Diabetes mellitus, type 1 and type 2 (250); Secondary diabetes 
mellitus (249) 
 
Estimate of current prevalence in children=0.3% 
Epilepsy, recurrent 
seizers; convulsions  
345.x, 780.3x Epilepsy and recurrent seizures (345); Convulsions (780.3) 
Fainting, dizziness  780.2x, 780.4x Syncope and collapse (780.2x), Dizziness and giddiness (780.4x) 
Gastroesophageal 
reflux disease 








Noise-induced hearing loss (388.12); Sudden hearing loss, 
unspecified (388.2);  Other abnormal auditory perception (388.4); 
Hearing loss (389.); Congenital anomalies of ear causing 
impairment of hearing (744.0); Problems with hearing (V41.2) 
 
Estimate of current prevalence in children=1.2%  
Hypertension 401.x – 405.x 
 
Hypertensive disease: Essential hypertension (401), Hypertensive 
heart disease (402), Hypertensive chronic kidney disease (403), 
Hypertensive heart and chronic kidney disease (404), Secondary 
hypertension (405) 
Hypothyroidism 243.x, 244.x Congenital hypothyroidism (243), Acquired hypothyroidism (244) 
Injury (800-999)   




805.x – 848.x  Fracture Of Spine And Trunk (805-809), Fracture Of Upper Limb 
(810-819), Fracture Of Lower Limb (820-829), Dislocation (830-




800.x – 804.x, 





Fracture Of Skull (800-804); Intracranial Injury, Excluding Skull 
Fracture (850-854): Concussion (850), Cerebral laceration and 
contusion (851), Subarachnoid subdural and extradural hemorrhage 
following injury (852), Other and unspecified intracranial 
hemorrhage following injury (853), Intracranial injury of other and 
unspecified nature (854); Head injury, unspecified (959.01); Open 
wound of scalp (873.0, 873.1) 
 






drug, biologic  
960.x-979.x Poisoning by drugs, medicinals and biological substances (960-
979)  




Internal injury of chest, abdomen, and pelvis (860-869); Open 
wound of head, neck, and trunk (870-872, 873.2-879); Open wound 
of upper limb (880-887); Open wound of lower limb (890-897); 
Injury to blood vessels (900-904); superficial injury (910-919); 
Contusion with intact skin surface (920-924); crushing injury (925-
929); Effects of foreign body entering through orifice (930-939); 
Injury to nerves and spinal cord (950-957); Certain traumatic 
complications and unspecified injuries (958-959); Toxic effects of 
substances chiefly non-medicinal as to source (980-989); Other and 
unspecified effects of external causes (990-995); Complications of 






Migraine (346); Chronic cluster headache (339.02); Chronic 
paroxysmal hemicrania (339.04); Chronic tension type headache 
(339.12); Chronic post-traumatic headache (339.22) 
Multiple sclerosis  340.x - 
Muscular dystrophy 359.x Muscular dystrophies and other myopathies (359) 
Overweight, Obesity 278.0x 
 
Obesity, unspecified (278.00), Morbid obesity convert (278.01), 




783.22, 783.4x Lack of expected normal physiological development in childhood: 
Lack of normal physiological development, unspecified (783.40), 
Failure to thrive (783.41), Delayed milestones (783.42), Short 
stature (783.43); Underweight (783.22) 
Rheumatoid arthritis, 
inflammatory  










Stuttering, adult onset (307.0); Speech and language deficits, late 
effects of cerebrovascular disease (438.1); Paralysis of Vocal Cords 
(478.3); Aphasia (784.3); Voice disturbance (784.4); Other speech 
disturbance (784.5); Mental and behavioral problems with 
communication including speech (V40.1); Problems with voice 
production (V41.4); Care involving speech-language therapy 
(V57.3) 
 
Developmental speech/language disorder under ‘Development 
delay’ 
 
Estimate of current prevalence (speech disorders) in children=4.8% 
Spine curvature 
(scoliosis, kyphosis) 
737.x Adolescent postural kyphosis (737.0), Kyphosis, acquired (737.1), 
Lordosis, acquired (737.2), Kyphoscoliosis and scoliosis (737.3), 
Curvature of spine associated with other conditions (737.4), Other 
curvatures of spine (737.8), Unspecified curvature of spine (737.9) 
Urinary incontinence 788.3x (no 788.36) Excluding nocturnal enuresis (788.36) 
 




After-cataract, obscuring vision (366.53), Visual disturbances 
(368); Blindness and low vision (369); Visual deprivation 
nystagmus (379.53); Late effects of cerebrovascular disease, 
disturbances of vision (438.7); Corneal opacities, interfering with 
vision, congenital (743.42); Problems with sight (V41.0) 
 
Estimate of current prevalence in children=1.3% 
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Anxiety related measures 
Unspecified anxiety 
diagnosis 
300.00   Diagnosis of unspecified/not otherwise specified 
Inpatient anxiety 
diagnosis 
-  Anxiety diagnosis in an inpatient setting, 
considered more severe 
Physiological symptoms 
related to psychological 
factors 
 
306.x, 307.8x  Physiological malfunction airing from mental 
factors (306.x); Pain disorders related to 
psychological factors (307.8) 
 Note: Codes do not specify the related mental 
disorder 
Additional markers for 
anxiety related diagnoses 
308.x, 313.0x, 313.21, 
313.22 
 Acute reaction to stress (308.x); Overanxious 
disorder specific to childhood and adolescence 
(313.0x); Shyness disorder of childhood (313.21); 
Introverted disorder of childhood (313.22)  
Anxiety-related 
symptoms 3 months 
prior to index date 
780.7x, 783.21, 784.0x, 
785.1x, 786.01, 786.50, 
787.01, 787.02, 789.0x,  
 Abdominal pain (789.0); Chest pain, unspecified 
(786.50); Headache (784.0); Hyperventilation 
(786.01); Malaise and fatigue (780.7); Nausea 
with vomiting (787.01); Nausea alone (787.02); 
Palpitations (785.1); Weight loss (783.21) 
Place of service  Associated with the 
anxiety diagnosis; grouped 
based on available 
MarketScan classification 
 Office (#11) 
 (All others grouped into non-office category)  
 
 









-  Depression diagnosis given in an inpatient setting (considered 
more severe) 
Number of depression 
diagnoses 
-  Count of depression diagnoses during the baseline period 
Recent depression 
diagnosis  
-  Based on whether the most recent depression diagnosis was 
within 30 days of indexdate or not 
Suicidality measures    
Self-harm related 
behaviors 
E950 – E959 
 
 Inpatient and outpatient codes 
 Late effects (E959.x) included for baseline covariate 
 Aim 2 outcome definition more specific, in aim 2 text  
Suicide ideation  V62.84  Inpatient and outpatient codes 
 Code new in late 2005, not included in all analyses  
Injury with an 
undetermined intent  
E980 – E989  Inpatient and outpatient codes 
 Codes represent injury events that may have been accidental or 
purposeful 





Healthcare utilization measures 
Variable Details 
Outpatient, problem oriented 
visits 
 Count of outpatient visits (allowing for 1 visit a day) 
 CPT codes: 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 
99214, 99215  
 
Estimates in children (prior year) office visits to healthcare professional: 0/1 
visit=30%, 2-3 visits=38%, 4+ visits=32% 
Outpatient, well/preventative 
visit 
 CPT codes: 99381, 99382, 99383, 99384, 99385, 99391, 99392, 99393, 
99394, 99395, 99461 
 V-codes: V20.2, V20.3, V70.0, V70.3, V70.5, V70.6, V70.8, V70.9 
Inpatient psychiatric 
hospitalization 
 Inpatient hospitalization with a psychiatric diagnostic code (290.x-319.x) as 
the primary diagnosis (psychiatric diagnosis in the primary/first-listed 
diagnosis) or secondary diagnoses 
Inpatient non-psychiatric 
hospitalizations 
 Inpatient hospitalization without an ICD-9 code of 290-319 as the primary or 
secondary diagnosis  
 
Estimate in children (prior year) hospitalized overnight: 2.3% 
ER visits  Count of ER visits, unique events required to have at least 1 day between date 
of ER services 
 Defined with variable SVCSCAT=Service Sub-Category Code (code 
indicating a detailed category of service, inpatient/outpatient), and for 2004 
defined with the place of service of ER - hospital (STDPLAC=23) 
 Indicator added for ER visits related to anxiety and injury, defined in text 
under aim 3 
 
Estimates in children (prior year) ER visits: 1=12%, 2+=6% 
Psychological evaluation   CPT codes: 90801, 90802, 90791, 90792 
Screened for mental disorder, 
developmental handicap 
 V70.1x, V70.2x, V71.0x, V79.x 
 General psychiatric examination requested by the authority (V70.1); General 
psychiatric examination other and unspecified (V70.2); Observation for 
suspected mental condition (V71.0); Screening for depression (V79.0); 
Screening for alcoholism (V79.1); Screening for mental retardation (V79.2); 
Screening for developmental handicaps in early childhood (V79.3); Screening 
for other specified mental disorders and developmental handicaps (V79.8); 





Medication variables   
Non-SSRI anti-anxiety 
medications 
 Medication list in table under aim 1 
Count of prescriptions 
medications 
 Count of distinct medication classes defined based on MarketScan groupings 
of therapeutic classes (THERCLS) 
 
**Estimate in children: regularly taken prescription medication for at 3+ 
months=13% 
Opioid  Buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, 
hydrocodone, hydromorphone, levorphanol, meperidine, methadone, 
morphine, nalbuphine, opium, oxycodone, oxymorphone, pentazocine, 
propoxyphene, tapentadol, tramadol 
ADHD medication 
(stimulants) 
 Generic names (pre-specific exclusions): Amphetamine-dextroamphetamine, 
amphetamine, dexmethylphenidate, dextroamphetamine, lisdexamfetamine, 
methylphenidate, atomoxetine, clonidine, guanfacine, modafinil, pemoline 
 
Estimates in children: currently have ADD/ADHD and take medication for this 
condition: 5.4% 
Asthma medications   Albuterol, aminophylline, arformoterol, beclomethasone, budesonide, 
budesonide-formoterol, ciclesonide, cromolyn, dyphylline, dyphylline-
guaiFENesin, flunisolide, fluticasone, fluticasone-salmeterol, formoterol, 
formoterol-mometasone, guaiFENesin-theophylline, levalbuterol, 
mometasone, montelukast, omalizumab, pirbuterol, salmeterol, theophylline, 
zafirlukast, zileuton 
Antipsychotics   (Separate from selected atypical antipsychotics listed under aim 1) 
 Generic names (pre-specific exclusions): quetiapine, aripiprazole, 
ziprasidone, olanzapine, risperidone, lurasidone, asenapine, chlorpromazine, 
clozapine, fluphenazine, haloperidol, iloperidone, loxapine, molindone, 
paliperidone, perphenazine, pimozide, prochlorperazine, thioridazine, 
thiothixene, trifluoperazine, acepromazine, droperidol, lithium, 





Additional child covariates  
Variable Details or ICD-9 codes Primary categories or ICD-9 details 
Provider type Associated with the anxiety 
diagnosis; grouped based on 
available MarketScan classifications 
(STDPROV variable) 
 Psychiatry (#365), Child psychiatry (#458) 
 Psychologist (#860) 
 Family practice (#240) 
 Pediatrician (#400)  
 Therapists (Supportive) (#853)  
Exposure to 
psychiatrist 
Diagnosis from a psychiatrist prior 
to the anxiety diagnosis (STDPROV 
variable) 
 365=Psychiatry, 485=Pediatric psychiatry 
Region, division Geographical state of primary 
beneficiary’s residence 
 Grouped by region (4) or division (8) 
Family difficulties 
marker 
V61.0x, V61.20, V61.23-V61.29, 
V61.4x, V61.8x, V61.9x  
Family disruption (V61.0); Counseling for 
parent-child problem unspecified (V61.20): 
parent-biological child (V61.23), parent-adopted 
child (V61.24), parent-foster child (V61.25); 
Other parent-child problems (V61.29); Health 
problems within family (V61.4): Alcoholism 
(V61.41), Substance abuse (V61.42), Other 
health problems (V61.49); Other specified family 
circumstances (V61.8); Unspecified family 
circumstance (V61.9) 
Marker for child 
trauma, neglect   
V15.4x, V61.21, V71.81, 995.5x, 
995.80-995.85, E967.x 
Personal history of psychological trauma 
presenting hazards to health (V15.4); Counseling 
for victim of child abuse (V61.21); Observation 
for suspected abuse and neglect (V71.81); Child 
maltreatment syndrome (995.5); Adult 
maltreatment/abuse (995.80-5); Perpetrator of 
child and adult abuse (E967) 
Housing, economic 
concerns 
V60.0x-V60.2x, V60.8x-V60.9x Lack of housing (V60.0); Inadequate housing 
(V60.1), Inadequate material resources (V60.2); 
Other specified housing or economic 
circumstances (V60.8); Unspecified housing or 
economic circumstance (V60.9) 
Problems related to 
lifestyle  
V69.x Lack of physical exercise (V69.0); Inappropriate 
diet and eating habits (V69.1); High-risk sexual 
behavior (V69.2); Gambling and betting (V69.3); 
Lack of adequate sleep (V69.4); Behavioral 






Variable Details Primary categories 
Psychiatric 
diagnoses 
Covariates defined with 
same ICD-9 or CPT codes 




 Adjustment disorder 
 Substance abuse 
 Other psychiatric diagnosis (ICD-9: 290-319) 
Self-harm event - 
Well-visit - 
Psychotherapy  - 
Medication use Indicators for each 
medication with SSRIs and 
benzodiazepines defined 
same as for children; 
adherence measures 
calculated for SSRIs, 
statins, antihypertensives  
 Benzodiazepine  
 SSRI 
 Statin: Atorvastatin, cerivastatin, fluvastatin, lovastatin, 
pitavastatin, pravastatin, rosuvastatin, simvastatin 
 Antihypertensive: Ace inhibitors and calcium channel 
blockers, aliskiren and hydrochlorothiazide, angiotensin ii 
antagonists and diuretics, azilsartan medoxomil, 
benazepril, bendroflumethiazide, bisoprolol and thiazides, 
candesartan, captopril, chlorothiazide, deserpidine and 
diuretics, enalapril, eprosartan, fosinopril, 
hydrochlorothiazide, hydroflumethiazide, irbesartan, 
lisinopril, losartan, methyclothiazide, methyldopa and 
diuretics, metoprolol and thiazides, moexipril, nadolol and 
thiazides, olmesartan medoxomil, perindopril, 
polythiazide, propranolol and thiazides, quinapril, ramipril, 
rauwolfia alkaloids, reserpine, telmisartan, timolol and 
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